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Antiretroviral therapy, anal high-risk human papillomavirus and anal intraepithelial 
neoplasia: a systematic review and meta-analysis  
 
Supplementary information  
 
The search strategy in MEDLINE and EMBASE on 30 October 2019 
ANAL HPV STUDIES: 
HPV [Title/Abstract] OR Human papillomavirus[Title/Abstract] AND anal OR anal canal [MeSH Terms] OR 
anogenital OR anogenital tract [MeSH Terms] AND Antiretroviral therapy [Title/Abstract] OR ART 
[Title/Abstract] OR Antiretroviral therapy, highly active [MeSH Terms] OR HIV [Title/Abstract] or Human 
immunodeficiency virus [MeSH Terms] 
ANAL LESION STUDIES: 
Intraepithelial neoplasia [Title/Abstract] OR Squamous intraepithelial neoplasia [Title/Abstract] OR Neoplasms 
[MeSH Terms] OR Precancer  [MeSH Terms] OR Cancer [Title/Abstract] OR malignant neoplasm [MeSH 
Terms] OR Intraepithelial lesion [Title/Abstract] OR anus tumor [MeSH Terms] OR anus carcinoma [MeSH 
Terms] OR Precursor lesions [Title/Abstract]  OR Anal intraepithelial lesion [Title/Abstract] OR anus disease 
[MeSH Terms]  OR dysplasia [MeSH Terms] OR anus cancer [MeSH Terms] OR Anal dysplasia 
[Title/Abstract] AND anal [Title/Abstract]  OR anal canal [MeSH Terms] OR anogenital [Title/Abstract]  
OR anogenital tract [Title/Abstract]  AND Antiretroviral therapy [Title/Abstract] OR ART [Title/Abstract] 
OR Antiretroviral therapy, highly active [MeSH Terms] OR HIV [Title/Abstract] or Human immunodeficiency 




This appendix provides full details of all search strings used for bibliographic databases, with dates 
and number of references returned and notes explaining any unusual search techniques or syntax. 
EndNote X9 referencing system was used. We conducted the original search on 1 December 2017 and 
repeated the search at three later dates (25 September 2018, 18 April 2019 and 30 October 2019) 
during the development of the review manuscript to ensure that the review was up to date at time of 
publication.   
Ovid MEDLINE  
Database name Medline 
Database platform OvidSP 
Dates of database coverage 1946 to October 29, 2019 
Date searched 30 October 2017 
25 September 2018 (updated search with limit 
set to yr="2017 -Current") 
18 April 2019 ((updated search with limit set to 
yr="2019 -Current") 
30 October 2019 (updated search with limit set 
to yr="2019 -Current") 
Searched by HK 




Search strategy and number of articles retrieved* on 01 December 2017 
1 HPV (33601) 
2 Human papillomavirus (31061) 
3 Antiretroviral Therapy, Highly Active/ or antiretroviral therapy (20840) 
4 ART (74013) 
5 Antiretroviral therapy (42337) 
6 1 or 2 (40699) 
7 3 or 4 or 5 (106911) 
8 6 and 7 (394) 
9 anal (41873) 
10 anogenital (3806) 
11 anogenital tract (158) 
12 9 or 10 or 11 (44980) 
13 6 and 7 and 12 (141) 
14 human immunodeficiency virus.mp. or HIV/ (100719) 
15 6 and 12 and 14 (246) 
16 13 or 15 (335) 
17 Intraepithelial neoplasia (18013) 
18 squamous intraepithelial neoplasia (160) 
19 Neoplasms/ (2582979) 
20 precancer (1377) 
21 cancer (1362430) 
22 intraepithelial lesion (1931) 
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23 Carcinoma, Squamous Cell/ (128504) 
24 Anus Neoplasms/ or anus carcinoma.mp. (5913) 
25 precursor lesion (2720) 
26 Anal intraepithelial lesion (2) 
27 anal dysplasia (158) 
28 or/17-27 (2830969) 
29 12 and 28 (12050) 
30 7 and 29 (295) 
31 14 and 29 (345) 
32 30 or 31 (555) 
 
*results for 16 and 32 retrieved for screening 
 
Ovid Embase Classic + Embase 
Database name Embase Classic + Embase 
Database platfor OvidSP 
Dates of database coverage 1947 to October 29, 2019 
Date searched 30 October 2017 
25 September 2018 (updated search with limit 
set to yr="2017 -Current") 
18 April 2019 ((updated search with limit set to 
yr="2019 -Current") 
30 October 2019 (updated search with limit set 
to yr="2019 -Current") 
Searched by HK 




Search strategy and number of articles retrieved* on 01 December 2017 
1 HPV (47714) 
2 Human papillomavirus (40860) 
3 highly active antiretroviral therapy/ (36089) 
4 ART (150810) 
5 Antiretroviral therapy/ (3851) 
6 1 or 2 (56877) 
7 3 or 4 or 5 (185004) 
8 6 and 7 (722) 
9 anal.mp. or anal canal/ (54718) 
10 anogenital (5276) 
11 anogenital tract (216) 
12 9 or 10 or 11 (59276) 
13 6 and 7 and 12 (251) 
14 HIV.mp or human immunodeficiency virus/ (370482) 
15 6 and 12 and 14 (1359) 
16 13 or 15 (1383) 
17 Intraepithelial neoplasia (19020) 
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18 squamous cell carcinoma.mp. or squamous cell carcinoma/ (120146) 
19 Neoplasm/ (471117) 
20 precancer (22180) 
21 cancer.mp. or malignant neoplasm/ (3035162) 
22 intraepithelial lesion (3631) 
23 anus tumor/ or anus carcinoma/ (4770) 
24 precursor lesion.mp. (3876) 
25 anal intraepithelial lesion (9) 
26 anus disease/ or dysplasia/ or anus cancer/ or Anal dysplasia (36731) 
27 or/17-26 (3263296) 
28 12 and 27 (17610) 
29 7 and 28 (482) 
30 14 and 28 (2043) 
31 29 or 30 (2127) 
*results for 16 and 31 retrieved for screening 
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Quality assessment using Newcastle-Ottawa assessment scale for cross-sectional and cohort studies (adapted) for paper titled “Effective antiretroviral 
therapy, anal high-risk human papillomavirus, anal intraepithelial neoplasia and anal cancer: a systematic review and meta-analysis” 
 
Description of the adapted grading system 
 For cross-sectional studies (evaluating prevalence of HR-HPV, ASCUS-AIN1+ or HSIL-AIN2+), a study can be awarded a maximum of one star for 
each numbered item within the Selection criteria (total of 3 items) and Outcome category (total of 2 items, in this adapted version of the Newcastle-
Ottawa scale, there is an additional item referring to “independent verification of outcome measure” which is applied to studies evaluating SIL-AIN 
outcomes only). A maximum of two stars can be given for Comparability criteria, allowing for maximum stars=7. For studies evaluating outcome of 
HR-HPV and SIL-AIN, a maximum of two stars can be given for Outcome (ascertainment of outcome); Maximum stars=7 (HR-HPV); 8 (SIL-AIN).  
 
 





 Representativeness of the 
exposed cohort 
Max=1 star 











Max=2 star (HR-HPV) 





(max. of 7 [HR-
HPV]; max of 8 
[SIL-AIN]) 
        
 
 For cohort studies (evaluating anal cancer incidence), a study can be awarded a maximum of one star for each numbered item within the Selection 
(total of 3 items); and Outcome (total of 3 items, 2 items receive 1 star; one item receives max of 2 stars) categories. A maximum of two stars can be 






































Newcastle-Ottawa scale (adapted version)  
 
A. Selection   
 
1) Representativeness of the exposed cohort, details in Table below.  
Analysis Exposed group Outcome Score “1” Score “0” 
ART vs. ART-naive 
(Analysis 1) 





Proportion of ART users with suppressed or undetectable HIV PVL 
is ≥70%  
OR 
If HIV PVL not stratified by ART use, then assume that majority of 
those with undetectable PVL are all on ART 
and therefore allow proportion of all participants enrolled with 
suppressed or undetectable HIV PVL to be ≥60%  
Proportion of ART users with suppressed or undetectable 




Anal cancer incidence  studies conducted in the combination ART era (i.e. 1996 onwards) studies for which duration of follow-up includes the pre-
combination ART era (i.e. includes the period before 1996) 
Undetectable vs. 
detectable HIV PVL 
(Analysis 2) 
Individuals with 




Individuals with undetectable (or suppressed) HIV PVL should be 
representative of effective ART users  
Score “1” if analysis mostly conducted among ART users (% ART 
>80%), with high median CD4+ (>500 cells/ µl ) and with high 
adherence 
Analysis conducted among all participants when % ART 
users is <80%, or  no information given 
Anal cancer incidence  studies conducted in the combination ART era (i.e. 1996 onwards) studies for which duration of follow-up includes the pre-
combination ART era (i.e. includes the period before 1996) 
Nadir CD4+  
≥200 vs. <200 cells/µl 
(Analysis 3) 
Individuals with nadir 
CD4+ ≥200  
All  Studies included in this analysis were more likely to be conducted 
when guidelines for initiation recommended initiation at <=350, so 
that individuals with nadir <200 were representative of general 
population of PLHIV initiating ART at that time in that setting 
Score “1” if recruitment in recent ART era (>2008) 
Recruitment in early ART era when nadir CD4 might be 
lower (earlier than 2008) 
Current CD4+  
≥500 vs. <500 cells/µl 
(Analysis 3) 
Individuals with 
current CD4+ ≥500  
All The majority of studies in this analysis included a high 
proportion of ART users (>90%) and with undetectable PVL 
(>80%).  
score 1 if controlling HIV, i.e. most ART users with undetectable 
PVL 
Participants with current CD4+ <500 could therefore by mix of ART 
users and ART-naïve, few studies provide this data  
High proportion ART users but low proportion with 
undetectable PVL 
Or mostly ART naïve with low proportion undetectable 












2) Selection of the non-exposed cohort 
Analysis Non-exposed groups Outcome Score “1” Score “0” 
ART vs. ART-naive 
(Analysis 1) 




Drawn from same source as ART users,  
And /or 
 if median CD4+ not stratified by ART status and there is a high 
proportion of ART users, then median CD4+ among all participants 
should be ≥400 cells/µl 
If study includes a large proportion of ART naïve (>70%), then 
median CD4 >500 is acceptable 
Drawn from different source as ART users, or  
Median CD4+ count of ART-naïve individuals is <500 
cells/µl,  
or no information given 
Undetectable vs. 
detectable HIV PVL 
(Analysis 2) 
Individuals with 





This analysis is mostly conducted among individuals taking ART; 
therefore individuals taking ART but with detectable HIV PVL 
should report low adherence, and have lower median CD4+ count. 
This information is unavailable in the included studies, so the 
following applies:  
The unexposed should come from same pool as exposed  
no information given 
Nadir CD4+ ≥200 vs. 
<200 cells/µl 
Individuals with nadir 





Median nadir is <350 cells/ µl  among ART users as most studies 
were conducted in period when guidelines recommended ART 
initiation at <350 cells/ µl 
or 
The unexposed should come from same pool as exposed  
No information given  
Current CD4+ ≥500 vs. 
<500 cells/µl 
Individuals with 





The unexposed should come from same pool as exposed  
 
No information given 
Note: this item is not used to assess risk of bias for anal cancer incidence studies 
 
 
3) Ascertainment of exposure 
Analysis Exposure Score “1” Score “0” 
ART vs. ART-naive 
(Analysis 1) 
ART use Clinic records  Self-report, no information, or unclear information (i.e participants 
completed questionnaire without clarifying if HIV related information was 
extracted from clinic records or through self report) 
Undetectable vs. detectable 
HIV PVL (Analysis 2) 
Undetectable HIV 
PVL  
Lab test at time of outcome measure (at least one visit with HIV PVL <400 
copies/ml), or clinic records in previous 6 months, or ‘most recent’ 
If authors state that data on HIV PVL obtained from national/regional HIV 
monitoring database, it is assumed that HIV PVL is biannual and measured in 
previous 6 months.  
Obtained from clinic records >6 months prior to outcome measure, or does 
not indicate time obtained from clinic records, self reported or no 
information.  
Nadir CD4+ ≥200 vs. <200 
cells/µl 
Nadir CD4+ count Clinic records No information  
Current CD4+ ≥500 vs. 
<500 cells/µl 
Current CD4+ count Lab test at time of outcome measure, or clinic records in previous 6 months, or 
‘most recent’.  
If authors state that data on CD4+ count obtained from national/regional HIV 
monitoring database, it is assumed that CD4+ count is measured in previous 12 
months. 
Obtained from clinic records >6 months prior to outcome measure, or does 






4) Outcome of interest was not present at start of study (for anal cancer incidence studies only) 
- Score of “1” if study reports exclusion of prevalent cancer cases identified at enrolment or before or within first 6 months of HIV diagnosis, or in the 
first 6 months of ART initiation  
- Score of “0” if no information  
 
B. Comparability  
1) Study controls for factors strongly predictive of prevalence of anal HR-HPV, ASCUS-AIN1+ and HSIL-AIN2+ :  
- score of “2” if study adjusts for any of: receptive anal intercourse, ART use, ART duration, HIV PVL, nadir or current CD4+ count 
- score of “1” if adjusts for sociodemographic or behavioural factors, but not receptive anal intercourse, ART use, ART duration, HIV PVL, nadir or 
current CD4+ count 
- score of “0” if estimate is unadjusted for potential confounders (i.e. raw data used to estimate crude effect estimate, or original authors present crude 
effect estimate in univariate risk factor analysis) 
 
2) Study controls for factors strongly predictive of anal cancer incidence:  
- score of “2” if study adjusts for any of: ART use, ART duration, HIV PVL, nadir or current CD4+ count AND duration of HIV infection  
- score of “1” if study adjusts for any of: ART use, ART duration, HIV PVL, nadir or current CD4+ count  
- score of “0” if estimate is adjusted for sociodemographic or behavioural factors, or is unadjusted for potential confounders (i.e. raw data used to 
estimate crude effect estimate, or original authors present crude effect estimate in univariate risk factor analysis) 
 
 
C. Outcome (adapted)  
1) Ascertainment of outcome 
Outcome Score “2” Score “1” Score “0” 
HR-HPV prevalence, 
incidence or persistence 
Validated/commercial PCR or genotyping method; high risk 
defined using the current International Agency for Research on 
Cancer (IARC) classification(1): ‘carcinogenic to humans’ 
(HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59). The 
definition of HR can include ‘probable carcinogenic’ (HPV68), 
and HPV66 (targeted by some next generation HPV tests) 
Definition of high risk includes “possible” carcinogenic types 
(26, 53, 66, 67, 70, 73, 82) or low risk types, or definition 
includes fewer than the 12 “carcinogenic” types  
 




recurrence or regression  
Directed biopsy indicated by HRA and/or following positive 
screen test in addition to random biopsy of normal looking 
quadrants (considered highest quality) 
Or 
Biopsy indicated by HRA/cytology abnormality and biopsy rate 
≥75% 
Histological verification of tissue obtained through directed 
biopsy indicated by HRA following abnormal cytology or HR-
HPV positive screen test; OR  
A composite diagnosis of cytology + histology following HRA 
guided biopsy (with or without knowledge of cytology); OR  
Histological verification of tissue obtained through directed 
Biopsy indicated by HRA without knowledge of cytology or 
HR-HPV test when biopsy rate ≥50% 
Cytology or HRA only without histological verification 
(irrespective of whether there was independent verification 
of cytology or HRA) 
OR 
Histological verification of tissue obtained through 
directed Biopsy indicated by high resolution anoscopy 
(HRA) without knowledge of cytology or HR-HPV test 
when proportion of participants with biopsy <50% as this 
represents a very limited number of verified endpoints 
Anal cancer incidence Histology confirmed, or ICD10 clinic records verified by 
histology 




2) Independent verification of outcome; Relevant for outcomes of ASCUS-AIN1+ or HSIL-AIN2+ prevalence, incidence, recurrence or regression only :  
- score “1” if outcome classification is independently verified by a second, or series of, pathologist(s) by consensus review (for histology measures 
only), or if p16 staining was used for grading of biopsies.  
- score “o” if outcome classification is not independently verified, or no information given  
 
3) Duration of follow-up was long enough for outcomes to occur  
- Score “1” if median duration of follow-up was ≥3 months (HR-HPV incidence or persistence); ≥12 months (ASCUS-AIN1+ and HSIL-AIN2+ 
outcomes); ≥5 years (anal cancer incidence).  
- Score “0” if less than above, or if retrospective or case-control study 
-  
4) Adequacy of follow up of cohorts (anal cancer incidence studies only)  
- score “1” if loss to follow up is ≤20% and full description of participants lost to follow-up, either in flowchart, or in table of descriptive characteristics 
- score “0” if loss to follow up is >20% or case-control study/retrospective study and/or no information given 
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Supplementary Table 1. Summary characteristics of studies included for each outcome 
  
























N PLHIV N  
pop. 




All  130 417 006 13 2 968 29 7 750 9 2 539 37 8 790 23 8 400 17 380 231 
Gender and sexual 
orientation  
Women 25 5 221 4 550 5 732 2 354 10 2 813 5 1 177 0 - 
MSM 57 33 888 4 1 373 15 4 197 6 1 962 12 3 112 13 4 733 3 11 388 
MSW 7 1 084 2 400 0 - 0 - 4 636 0 - 0 - 
Combination men  16 82 164 1 119 6 1 944 0 - 7 1 542 1 147 3 78 623 
Combination women and men  25 294 649 2 526 3 877 1 223 4 687 4 2 343 11 290 220 
Geographic region  Africa 4 930 2 426 1 200 0 - 1 304 1 200 0 - 
Asia 20 4 000 3 517 9 1 681 3 539 6 1 527 1 148 0 - 
Latin America 10 2 838 2 433 4 1 170 3 993 4 1 235 0 - 0 - 
Europe 41 224 135 0 - 9 3 219 3 1 007 14 3 502 9 3 718 6 212 593 
North America 53 184 799 6 1 592 6 1 480 0 - 12 2 222 11 4 182 11 167 638 
Australia 2 304 0 - 0 - 0 - 0 - 1 152 0 - 
Study design  Randomised controlled trial2 3 851 0 - 0 - 0 - 0 - 1 575 
 
- 
Prospective cohort 25 289 783 0 - 0 - 0 - 0 - 0 - 11 287 055 
Cross-sectional3 84 23 077 11 2 455 27 7 283 8 2 493 34 7 717 19 7 122 
 
- 
Record linkage 2 15 901 0 - 0 - 0 - 0 - 0 - 2 15 901 
Retrospective cohort or chart review 11 86 060 0 - 0 - 0 - 3 1 073 3 703 3 76 921 
Case-control or convenience  5 1 334 2 513 2 467 1 46 0 - 0 - 1 354 
           











spontaneous regression   
N 
pop. 














N PLHIV N  
pop. 




All 2 1 345 4 1 444 5 562 5 898 3 7 487 1 100 2 261 
Gender and sexual 
orientation  
Women 0 - 0 - 2 149 0 - 0 - 0 - 0 - 
MSM 1 612 3 1 140 1 132 5 898 2 7 367 1 100 1 152 
MSW 0 - 1 304 1 48 0 - 0 - 0 - 0 - 
Combination men  1 733 0 - 0 - 0 - 0 - 0 - 0 - 
Combination women and men  0 - 0 - 1 233 0 - 1 120 0 - 1 109 
Geographic region  Africa 0 - 1 304 0 - 0 - 0 - 0 - 0 - 
Asia 0 - 1 123 0 - 1 123 0 - 0 - 0 - 
Latin America 0 - 0 - 0 - 0 - 0 - 0 - 0 - 
Europe 2 1 345 2 1 017 1 233 1 310 1 156 1 100 0 - 
North America 0 - 0 - 4 329 2 313 2 7 331 0 - 1 109 
Australia 0 - 0 - 0 - 1 152 0 - 0 - 1 152 
Study design  Randomised controlled trial2 0 - 0 - 0 - 0 - 2 276 0 - 0 - 
Prospective cohort 2 1 345 4 1444 5 562 4 746 0 - 1 100 1 109 
Cross-sectional3 0 - 0 - 0 - 0 - 0 - 0 - 0 - 




















1 152 1 7211 0 
 
1 152 














1all study populations combined – of a total of 122 studies included, there were 130 discrete populations; 2three randomised controlled trials designed to evaluate the efficacy of: the quadrivalent HPV vaccine (baseline HSIL status in total cohort in the study) in(2);  efficacy of imiquimod, 
topical fluorouracil, and electrocautery for the treatment of AIN (estimate used in this meta-analysis is among total cohort and adjusted for treatment type in(3) and  efficacy of ablation with infrared coagulation (treatment) or no treatment (active monitoring)(4); 3can include point prevalence 
estimate from prospective cohort studies; Studies in the category “combination men” included men only but did not provide effect estimates stratified by sexual orientation; studies in the category “combination women and men” included a combination of women and men but did not 
provide effect estimates stratified by gender or sexual orientation; N. pop=Number of populations studied; HR=high-risk; ASCUS-AIN1+=atypical squamous cells of undetermined significance or anal intraepithelial neoplasia, grade 1 or greater; HSIL-AIN2+=high-grade squamous 
intraepithelial lesions or anal intraepithelial neoplasia, grade 2 or greater; MSM=men who have sex with men; MSW=men who have sex with women, PLHIV=people living with HIV 
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Supplementary Table 2. Pooled prevalence of ART, undetectable HIV PVL, HR-HPV and anal lesion outcomes, by gender and sexual orientation1 
 
All Africa Asia Latin America Europe North America Australia 






N2  Pooled estimate 
(%, 95%CI) 
N2  Pooled estimate 
(%, 95%CI) 
N2  Pooled estimate 
(%, 95%CI) 






Women                 
Taking ART 19 77.9 (72.6-83.2) 1 96.5 (92.9-98.6) 4 74.7 (57.7-91.7) 3 69.7 (43.9-95.4) 5 88.8 (82.1-95.5) 6 70.3 (60.3-80.3) 0 - 
Undetectable HIV PVL3 13 71.2 (63.0-79.4) 1 83.0 (77.1-87.9) 0 - 2 54.4 (51.3-57.5) 4 73.7 (59.8-87.6) 6 72.0 (63.9-80.1) 0 - 
Ever practiced RAI 17 34.6 (21.9-47.3) 0 - 3 2.8 (-0.4-6.0)     3 56.9 (38.2-75.7) 3 28.0 (16.5-39.6) 8 40.5 (30.7-50.4)   0 - 
HR-HPV prevalence 7 43.8 (38.2-49.4) 1 41.2 (34.2-48.4) 3 37.4 (21.3-53.6) 1 49.0 (40.5-57.4) 2 48.0 (43.1-52.9) 0 - 0  
ASCUS-AIN1+ prevalence 13 18.3 (11.4-25.2) 0 - 2 2.7 (1.6-3.7) 2 26.4 (23.8-29.1) 3 15.2 (4.4-26.1) 6 25.5 (18.1-33.0) 0  
HSIL-AIN2+ prevalence 5 13.7 (9.1-18.4) 1 15.6 (10.8-21.4) 0 - 0 - 1 12.9 (8.2-19.0) 3 13.6 (6.6-20.6) 0 - 
               
Men who have sex with men               
Taking ART  45 74.7 (70.4-78.9) 0 - 10 53.3 (30.3-76.2) 3 88.1 (74.9-1.01) 21 78.4 (69.1-87.7) 10 81.6 (70.3-92.8) 1 93.6 (89.6-96.5) 
Undetectable HIV PVL3 38 67.0 (60.1-73.9) 0 - 8 46.1 (15.4-76.8) 2 73.0 (69.9-76.0) 16
1 
76.0 (70.9-81.0) 10 65.5 (52.6-78.3) 2 84.8 (82.0-87.6) 
Reported recent RAI (≤12 months) 18 60.4 (51.5-69.0) 0 - 6 64.4 (55.6-73.1) 1 49.3 (44.6-54.1) 6 72.2 (67.6-76.9)  5 43.8 (35.8-51.8) 0 - 
HR-HPV prevalence 23 69.0 (63.7-74.4) 0 - 7 63.5 (47.9-79.1) 4 69.3 (54.5-84.1) 6 74.9 (68.9-80.9) 6 68.9 (60.3-77.6) 0 - 
ASCUS-AIN1+ prevalence 14 38.0 (29.4-46.6) 0 - 3 32.7 (27.9-37.5) 0 - 9 37.0 (24.7-49.2) 2 47.3 (44.3-50.4) 0  
HSIL-AIN2+ prevalence 12 30.5 (22.8-38.2) 0 - 1 57.3 (48.3-65.9) 0 - 6 21.7 (13.6-29.8) 4 33.5 (13.0-54.0) 1 47.3 (40.5-54.1) 
                 
Men who have sex with women               
Taking ART  6 79.7 (71.8-87.5) 1 64.8 (59.1-70.2) 0 - 0 - 1 80.1 (74.1-86.0) 3 84.2 (79.6-88.8) 0 - 
Undetectable HIV PVL3 6 62.5 (47.0-77.9) 1 54.3 (47.1-61.4)  0 - 0 - 2 48.2 (41.2-55.1) 3 78.1 (66.6-89.7) 0 - 
Ever practiced RAI 5 6.8 (2.2-11.4) 1 4.9 (2.8-8.0) 0 - 0 - 1 0.0 (-) 3 11.0 (7.0-15.0) 0 - 
HR-HPV prevalence 8 28.6 (19.6-37.7) 0 - 3 27.9 (18.3-37.5) 2 13.0 (7.0-19.0) 1 33.3 (26.8-40.4)  2 38.8 (25.1-52.5) 0  
ASCUS-AIN1+ prevalence 6 23.6 (7.6-39.6) 1 49.0 (43.3-54.8) 1 2.1 (0.1-11.1) 0 - 3 23.5 (5.4-41.6) 1 19.6 (12.0-29.1) 0  
HSIL-AIN2+ prevalence 1 4.1 (1.9-7.7) 0 - 0 - 0 - 0 - 1 4.1 (1.9-7.7) 0 - 
1Pooled (unadjusted) prevalence calculated using metaprop in Stata version 16; 2number of individual populations studied; 3calculated among all participants irrespective of ART use (few studies calculate among ART users only); AIN=anal 




Supplementary Table 3. Summary of studies reporting the association of ART use, HIV viral load and CD4+ count with HR-HPV, anal lesion 
outcomes and invasive anal cancer incidence  
Study, Year Study 
no.  




Mean or Median 
age, years [IQR] 






Definition Prevalence Diagnostic method 
HPV prevalence 




Women NK 200 38 (33-44) 97.0% 89.0% 430 (311–600)  HR-HPV (13 HR 
types)2 
43.0% Hybrid Capture II 
 
Heard et al, 2016 (6) A2 France-Paris, Marseille, 
Colombes 
Women 2007-2012 308 45 (40-50) 96.8% 84.1% 612 (450, 802) HR-HPV (13 HR types) 46.6% Linear Array  
Menezes et al, 
2016(7) 
A3 India-Chennai Women 2011 50 33 (20–45) 48.0% NR 425 (range: 
106–1229 
HR-HPV (13 HR types) 47.8% PCR  
Sohn et al, 2018(8) A43 Thailand & Vietnam Perinatally infected females 2013-2015 93 19 (17-20) 94% 62% 593 (392-808) HR-HPV (13 HR types) 41.9% Linear Array 
Hidalgo-Tenorio et 
al, 2018(9) 
A46 Spain-Granada Women 2012-2016 85 44 (±8) 93.7% 82.4% 646 (±372) HR-HPV (13 HR types) 
+ HPV26, 53, 66, 73, 82 
49.4% Linear Array 
Godbole et al, 
2014(10) 
A4 India-Pune Women 2012-2013 98 35 (30, 38) 64.3% NR 488 (365, 617) 
among ART 
users 
Any HPV (37 types) 14.3% Linear Array 
Kojic et al, 2011(11) A5 USA- 4 cities Women 2004-2006 120 38 (31-44) 77% 87% 445 (323-598) Any HPV (37 types) 90.0% Linear Array 
Palefsky et al, 
2001(12) 
A7 USA-San Francisco  Women 1995-1997 223 40 (20-61) NR (monotherapy 
only)  
42.1% 44% with CD4+ 
2001-500 
Any HPV (29 types: 6, 
11, 16, 18, 26, 31, 32, 
33, 35, 39, 40, 45, 51, 
52, 53, 54, 55, 56, 58, 
59, 61, 66, 68, 69, 70, 
73, AE2, Pap 155, and 
Pap 291, HPV 2, 13, 34, 
42, 57, 62, 64, 67, 72, 
and W13B).  
76.2% PCR  
Volpini et al, 2017(13) A8 Brazil-Vitória Women 2013-2015 109 41 (±10) 81.6% 64.2% NR Any HPV (16, 18, 31, 
33, 35, 39, 45, 51, 52, 
56, 58 and 59, 6, 11, 40, 
42, 43, 44, 54, 61, 70, 
72, 81, 89, HPV 2a, 3, 7, 
10, 27, 28, 29, 30, 32, 
34, 55, 57, 62, 67, 69, 
71, 74, 77, 83, 84, 85, 
86, 87, 90, 91, 26, 53, 
66, 68, 73, 82) 
60.3% PCR (56 types) 
Combes et al, 
2018(14)  
A10 France-6 cities MSM 2014-2016 452 51 (IQR:45-56) 95.6% 89.6%3 685 (507-892) HR-HPV (13 HR types) 
+ HPV66 
70.0% Cobas4800 and 
PapilloCheck  
Del Amo et al, 
2013(15) 
A11 Spain-8 cities MSM 2007-2013 586 34.9 (30.1-40.8) 25% NK 532 (IQR, 403–
701) 
HR-HPV (13 HR types) 83.4% Linear Array 
Gianella et al, 
2016(16) 
A12 USA-California MSM NK 120 47 (39-52) 100% 84.0%  HR-HPV (13 HR types) 
+ HPV66 
45.0% Aptima HPV Assay 
(mRNA  from E6/E7) 
Hidalgo-Tenorio et 
al, 2017(17) 
A13 Spain Granada MSM 2010-2016 311 36.7  86.2% 73.7% 699 (±508) HR-HPV (13 HR types) 
+ HPV26, 53, 66, 73, 82 
81.3% Linear Array 
Lee et al, 2016(18) A14 Korea_Busan MSM 2014-2015 133 46 (37-56) 100% 88% 605 (486-851) HR-HPV (13 HR types) 
+ HPV26, 66, 73, 82 
47.4% HPV Genotyping 
Chip™ Kit 
Li et al, 2015(19) A15 China-Xi’an MSM 2014 193 34 (±9) 86.2% NR 394 (259-517) HR-HPV (13 HR types) 
+ HPV26, 34, 53, 55, 
66, 69, 82, 83 
94.8% Hybribio HPV DNA test 
(21 HR types) 
Limia et al, 2017(20) A45 Cuba-Havana MSM 2012 56 35 (range, 20–61 
years 
79% NR 54% with CD4+ 
200-500 
6 HR types (16, 18, 31, 
33, 45, and 58) 
89.3% PCR (6 HR types) 
Wiley et al, 2013(21) A21 USA-Baltimore MSM 2010-2011 579 55 (±9.4) NR NR 609 (±282) HR-HPV (12 HR types: 
HPV16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 
59) 
68.4% Linear array 
Nyitray et al, 2018(22) A16 USA-Houston MSM 2014-2016 68 Range: 18-29 yrs NR NR NR HR-HPV (13 HR types) 79.4% PCR (36 types) 
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Schwartz et al, 
2013(23) 
A17 USA-San Francisco MSM 2009-2010 305 53 (47-60) 93.8% 91% 81% with CD4+ 
≥350cells/mm3 
HR-HPV (13 HR types) 
+ HPV66 
79.1% Cobas 4800 




MSM 2013-2015 245 36.9 (±9.2) 79.0% 69.4% 433 (317-595) HR-HPV (13 HR types) 76.6% Linear array 
Torres-Ibarra et al, 
2014(25) 
A19 Mexico-Mexico City MSM 2009-2011 446 33 (18-68) 83.4% 58.7% 65% with CD4+ 
>350 cells/µl 
HR-HPV (13 HR types) 72.2% Linear Array 
Van Aar et al, 
2013(26) 
A20 The Netherlands- 
Amsterdam 
MSM 2010-2011 264 46 (39-53) 86.7% 77.3% 530 (410-700) HR-HPV (12 HR types: 
HPV16, 18, 31, 33, 35, 








MSM 2007-2009 247 47 (40-53) 80.4% 66.8% 490 (358-640) HR-HPV (13 HR types) 
+ HPV73, 82 
76.3% INNO-LiPA 
Cranston et al, 
2015(28) 
A44 Thailand-Bangkok MSM 2006-2010 192 25.8 ± 5.9 47.9% 30.2% 409.8 ± 177.1 HPV6,11,16,18,31,33,45
, 52, 58 
50.0% GP5+/GP6+ PCR 
Hernandez et al, 
2016(29) 
A24 India- Vellore & 
Mumbai 
MSM 2009-2010 300 42% aged 26-35 
years 
44.4% 35.3% NR Any HPV (37 types + 
90/106, 86/87) 
95% PCR  
Mendez-Martínez et 
al, 2014(30) 
A25 Mexico-Mexico City MSM 2008 324 39.1 (±9.4) 92.4% 75% 442 Any HPV (28 types: 16, 
18, 26, 31, 33, 35, 39, 
45, 51, 52, 53, 56, 58, 
59, 66, 68, 73, 82, 6, 11, 
40, 43, 44, 54, 70, 69, 
71,74) 
86.1% PCR+INNO-LiPA 
Palefsky et al, 
1998(31)  
A26 USA-San Francisco MSM 1991-1994 346 42 (24-64) NR NR 38% with CD4+ 
between 201-
500 
Any HPV (29 types: 6, 
11, 16, 18, 26, 31, 32, 
33, 35, 39, 40, 45, 51, 
52, 53, 54, 55, 56, 58, 
59, 61, 66, 68, 69, 70, 
73, AE2, Pap 155, and 
Pap 291, HPV 2, 13, 34, 
42, 57, 62, 64, 67, 72, 
and W13B). 
92.8% PCR  
Patel et al, 2018(32) A27 USA-4 cities MSM 2004-2012 403  42 (36-48) 78%  74%   454 (312-655) Any HPV (37 types) 95%  
 
Linear array 
Patel et al, 2018(32) A27 USA-4 cities MSW  2004-2012 96 42 (36-48) 81% 75% 379 (237-555) Any HPV (37 types) 59% Linear array 






2012-2013 304 38 (±8) 65% 54% 445 (328-567) Any HPV (37 types) 73.7% Linear Array  
Liu et al, 2019(34)  A47 China-Taizhou Combination men (50% MSM) 2016-2017 160 43 (±13) NR NR 43% with CD4+ 
≥500 cells/µl 
HR-HPV (13 HR types) 
+ HPV53, 66 
65.0% (MSM); 
27.8% (MSW) 
HPV GenoArray  
Cranston et al, 
2012(35) 
A30 USA – Los Angeles Combination men (80% MSM) 2005-2007 316 50% between 40-
49 yrs 
NR 52.6% NR HR-HPV (13 HR types) 
+ HPV73 
64.4% PCR  
Guimaraes et al, 
2011(36) 
A31 Brazil-Rio de Janeiro & 
Minas Gerais 
Combination men (18% MSM 
only; 59% MSW&M;23% 
MSW only) 
2007 445 78.2% >35 years 89.6% 59.6% 39% with CD4+ 
≥500 cells/µl 
HR-HPV (12 HR types: 
HPV16, 18, 31, 33, 39, 
45, 51, 52, 56, 58, 59, 
66) 





Wilkin et al, 2004(37) A32 USA-New York City Men 61% MSM, 39% MSW) 2001-2002 92 NR 82% 50% NR HR-HPV (13 HR types) 61% HC-II & PCR 
Yu et al, 2013(38) A33 Taiwan-Tainan Combination men (66% MSM) 2010-2011 198 73% ≥30 yrs 82.8% 21.8% 507.8 ± 258.3 HR-HPV (11 types: 16, 
18, 31, 33, 39, 45, 51, 
56, 58, 59, and 66 
39.7% PCR  
Tosato-Boldrini et al, 
2018(39) 
A36 Brazil-Vitoria Combination (64% Women, 
26% MSM, 9% MSW)   
2013-2016 223 Women: 41.0 
[±10.2];  
Men: 40.0 [±12.6] 
81.2% 60.1% 80% with CD4+ 
>350 cells/µl 
HR-HPV (13 HR types) 
+ HPV26,53,66,73,82 





Nagata et al, 2015(40) A37 Japan-Tokyo Combination (7% women, 86% 
MSM, 7% MSW) 
2009-2015 421 44 (39, 55) 75.1% 62.5% 369 (179, 582) HR-HPV (13 HR types) 
+ HPV67 
19.2% (women);  
20.6% (MSW): 
75.9% (MSM) 
PCR-Invader assay  
Borghetti et al, 
2014(41) 
A38 Italy-Rome Combination (81% men, 56% 
MSM) 
NR 233 44 (39-48) 84% NR 558 (405-718) HR-HPV (13 HR types) 61.8% Hybrid Capture II 
Videla et al, 2013(42) A34 Spain-Badalona Combination men (73% MSM, 
27% MSW) 
2005-2009 733 MSM:  
40 (35-46) 
MSW:  
79% (MSM); 95% 
MSW 





HR-HPV (13 HR types+ 
HPV6 and 11) 
84% (MSM); 
42% MSW 
IVD-CE F-HPV typing  
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44 (40-48) 
Beachler et al, 
2013(43) 
A35 USA-Baltimore Combination (39% women, 
18% MSM, 43% MSW) 
2006 – 
2009 
404 46 (42–51) 67.8% 34.1% 304 (183-502) Any HPV (37 types: 16, 
18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 68, 
73, 6, 11, 26, 40, 42, 53, 
54, 55, 61, 62, 64, 66, 
67, 69, 70, 71, 72, 81, 
82, 83, 84, 89, and IS39) 
84.0% PCR  
Chinyowa et al, 
2018(44) 
A41 Zimbabwe-Harare Combination (60% female, 1% 
MSM) 
2014-2015 122 40 (range: 18-69) 95.1% NR 375 (235-557) Any HPV (29 types: 16, 
18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 66, 
68, 6, 11, 26, 32, 40, 53, 
54, 55, 61, 69, 70, 73, 
82,83,84) 
44.3% PCR  
Gautam et al, 2018(45) A42 India-Varanasi Combination men (38% 
reported RAI) 
2014-2015 119 35 (±8) 41.3% NR 253 Any HPV (29 types: 16, 
18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 68, 
73, 82, 26, 53, 66, 6, 11, 
40, 42, 43, 44, 54, 61, 
70, 72, 81) 
27.7% PCR  
HPV incidence  
Geskus et al, 2016(46) A39 Spain-multicentre MSM 2007-2013 612 33 (28-39) 38.9% NR 569 (444-741) HR-HPV (12 types: (16, 
18, 31, 33, 35, 39, 45, 
51, 52, 56, 58 and 59) 
11 per 100 p-y 
(HPV59) to 19 per 
p-y (HPV51) 
Linear Array 
HPV persistence  
Geskus et al, 2016(46) A39 Spain-multicentre MSM 2007-2013 612 33 (28-39) 38.9% NR 569 (444-741) HR-HPV (12 types: (16, 
18, 31, 33, 35, 39, 45, 
51, 52, 56, 58 and 59) 
NR Linear Array 
Phanuphak et al , 
2013(47) 




al, 2019(48)  
A48 Spain-Granada MSM 2010-2018 279 36 (±10) 87.7% 85.9% 690 (±475) HR-HPV (13 HR types) 
+ HPV26, 53, 66, 73, 82 
65.1% over 49 
months 
Linear Array  





MSW 2012-2013 304 38 (±8) 65% 54% 445 (328-567) Any HPV (37 types) 26% over 18 
months 
Linear array 
SIL-AIN prevalence  
Baranoski et al, 
2012(50) 
B1 USA-Boston Women 2006-2010 99 40 (range: 22-57) 79% 62% NR ASCUS-AIN1+ 
 
33.3% (cumulative 
prevalence over 3 
years) 
Cytology+, 
HRA+directed Bx  
(Bx =36%) 
Cambou et al, 
2015(51) 
B2 Brazil-Rio de Janeiro Women 2011-2013 863 42 (35-49) 86%6 53.1% NR ASCUS+ 31% Cytology 
Chaves et al, 2012(52) B3 Brazil-Porto Alegre Women 2006-2008 184 36 (±9) 41.0% NR NR ASCUS+ 14.1% Cytology 
Conley et al, 2010(53) B4 US-4 cities Women 2004-2006 150 39 (32-45) 73.3% 67.3% 36% ≥500 
cells/mm3 
ASCUS+ 35.3% Cytology 
Gingelmaier et al, 
2010(54) 
B5 Germany-Munich Women 2007-2008 104 36 (±12) 99.0% 64.4% 421 (58-1020) ASCUS-AIN1+ 13.5% Cytology+, 
HRA+directed Bx  
(Bx =13%) 
Holly et al, 2001(55) B6 USA-San Francisco Women 1995-1997 196 40 (20-61) NR (pre cART 
era) 
42.9% NR ASCUS-AIN1+ 26.0% Cytology+, 
HRA+directed Bx  
(Bx =20%) 
Pittyanont et al, 
2014(56) 
B7 Thailand -Chanthaburi Women 2013-2014 574 55% aged 30-49 
yrs 
94.2% NR NR ASCUS+ 2.2% Cytology 
Sananpanichkul et al, 
2015(57) 
B8 Thailand -Chanthaburi Women 2013-2014 393 41 ± 9 NR NR 40% ≥500 
cells/mm3 
ASCUS+ 3.6% Cytology 
Tandon et al, 2010(58) B9 USA-Boston Women 2006-2007 100 41 (±8) 78.8% 62.0% NR ASCUS-AIN1+ 17.2% Cytology+, 
HRA+directed Bx  
(Bx =14%) 
Abramowitz et al, 
2007(59) 
B10 France-Paris Women 2003-2004 150 37 (33-42)  
 
 
67% 55% 410 (288-584) 
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Women NK 200 38 (33-44) 97.0% 89.0% NR HSIL-AIN2+ 17.5% Cytology+, 
HRA+directed Bx  
(Bx =75%) 
Gaisa et al, 2017(60) B12 USA-New York Women 2009-2014 208 47 (41-52) NR 71.6% 522 (335-773) HSIL-AIN2+ 6.6% Cytology+, 
HRA+directed Bx  
(Bx =80%) 
Heard et al, 2015(61) B13 France-Paris, Marseille, 
Colombes 
Women 2012 171 47 (37-51) 98.0% 89.0% 655 (476-844) HSIL-AIN2+ 12.9% HRA+directed Bx  
(Bx =41%); composite 
cyto-histology  
Hessol et al, 2009(62) B14 USA-San Francisco, 
Chicago, and Brooklyn 
Women 2001-2003 342 NR (38% between 
31-40 years) 
NR NR NR HSIL-AIN2+ 10.8% Cytology+, 
HRA+directed Bx  
(Bx =9%) 
Stier et al, 2019 (63) B49 USA-12 sites Women 2014-2016 256 49.4 (±8.5) 94.5% 85.2% 664 (444– 881) HSIL-AIN2+ 27.0% HRA, directed + random 
biopsy  
(Bx =100%) 






2012-2013 304 38 (±8) 65% 54% 445 (328-567) ASCUS+ 49.0% Cytology 
Conley et al, 2010(53) B4 US-4 cities MSW 2004-2006 92 42 (38-48) 84.8% 70.7% 34% ≥500 
cells/mm3 
ASCUS+ 19.6% Cytology 
Conley et al, 2010(53) B4 US-4 cities MSM 2004-2006 379 42 (36-48) 78.9% 71.5% 45% ≥500 
cells/mm3 
ASCUS+ 56.5% Cytology 
D´Souza et al, 
2016(64) 
B15 USA-4 cities MSM 2010-2011 622 55 (49-61) 91% 78% 595 (431-796)  ASCUS+ 42.2% Cytology  
Dona et al, 2015(65) B16 Italy-Rome MSM 2009-2017 388 41 (33-49) 90% 87% 607 (433-800) ASCUS+ 53.2% Cytology  
Goodall et al, 
2012(66) 
B17 UK-Edinburgh MSM 2006-2007 130 39 (17-68) 80% NR 503 (87-1201) Mild dyskaryosis or 
greater  
21.5% Cytology 
Gonzalez et al, 2013 
(67) 
B23 Spain – 7 Autonomous 
Communities 
MSM 2007-2011 450 33 (28-39) 16% at study entry NR 51% >500 
cells/µL 
LSIL+ 54.7% Cytology 
Lacey, 1999(68) B18 UK-Manchester MSM 1994-1996 57 35 (range 19–62) 0% NR 273 (range 10–
588) 
ASCUS+ 10.5% Cytology  
Li et al, 2009(69) B19 Thailand-Bangkok MSM 2007-2008  118 33 (±8)  34.2% 27.8% 342 (216-437) ASCUS+ 33.9% Cytology  
Yang et al, 2012(70) B21 China-Beijing MSM 2011 93 40% aged 30-39 
years 
30.5% NR 73% <500 
cells/µl 
ASCUS+ 37.9% Cytology 
Yaegashi et al, 
2017(71) 
A23 Japan-Kanazawa MSM 2013-2014 148 39 (±8) 100% 98.6% 593 ±185 ASC-H+ 34.4% Cytology  
Abramowitz et al, 
2007(59) 
B10 France-Paris MSM  2003-2004 200 41 (36-46) 
 
83% 63% 533 (365-707) 
 
AIN1+ 21.0% HRA-directed Bx 
(Bx =11%) 
Richel 
 et al, 2013(72) 
B22 The Netherlands-
Amsteram 
MSM 2008-2010 311 47 (41-55) 89% 86% 550 (430-718) AIN1+ 56.3% HRA-directed Bx 
(Bx=56%) 




MSM 2007-2009 247 47 (40-53) 80.4% 66.8% 490 (358-640) AIN1+ 16.0% HRA+directed Bx 
(Bx=49%) 
Clifford et al, 
2019(73) 
B46 France-6 cities MSM 2014-2016 502 51 (45-56) 95.8% 92.1% 682 (506-881) HSIL-AIN2+ 10.4% HRA directed Bx  
(Bx =45%) 
Dalla-Pria et al, 
2014(74) 
B25 UK- London MSM NR 368 42 (range: 22-77) 84% 85% 441 (range: 10-
1476) 




B26 Spain-Granada MSM 2010-2013 140 37 (±9) 77.1% 95.0% 653 (±262)  HSIL-AIN2+ 20.0% Cytology+, 
HRA+directed & 




B27 Spain-Granada MSM 2010-2014 201 37 (±9) 86.6% 71.1% 725 (±604)  HSIL-AIN2+ 18.4% Cytology+, 
HRA+directed & 
random Bx  
(Bx =100%) 
Libois et al, 2017(77) B28 Belgium-Brussels MSM 2011-2013 320 44 (36-51) 87% 74% <50c/ml; 
54% sustained 
PVL<50 c/ml 
over 2 yrs) 
638 (480-800) HSIL-AIN2+  19.7% Cytology+, 
HRA+directed  
(Bx=38%) 
Machalek et al, 
2016(78) 
B29 Australia-Sydney MSM 2010-2015  152 49 (43-56)  93.6% 89.5% 65% >500 
cells/µl 
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Masia et al, 2019 (79) B47 Spain-Alicante MSM 2013-2017 145 45 (36–53) 100% 86.2% 4 557-638 HGAIN 24.1% HRA + directed biopsy 
Marra et al, 2019 (80) B48 The Netherlands-
Amsterdam 
MSM 2010-2011 193 50 (±10) 97.4% 94.3% 681 (±250) HSIL-AIN2+ 25.9% HRA + directed biopsy 
(Bx =78%) 
Palefsky et al, 
2005(81) 
B30 USA-San Francisco MSM 1998-2000 357  42 (±7)  74.8% 34.3% 47% between 
200-500 cells/µl 
HSIL-AIN2+  51.9% HRA-directed Bx 
(Bx=81%); Composite 
cyto-histology 
Salit et al, 2009(82) B31 Canada-Toronto MSM 2001-2005 224 44 (38-50) 63.4% 53.1% 381 (231-590) AIN2-3 33.0% HRA-directed Bx  
(Bx =95%) 
Schwartz et al, 
2013(23) 
A17 USA-San Francisco MSM 2009-2010 305 53 (47-60) 93.8% 91% 81% with CD4+ 
≥350cells/mm3 








MSM 2008-2015 1678 49 (±10) 96% 89.3% 620 (480-790) HSIL-AIN2+ 29.6% HRA-directed Bx  
(Bx =>53%) 
Abramowitz et al, 
2007(59) 
B10 France-Paris MSW 2003-2004 123 42 (37-48) 78% 61%  380 (220-553) AIN1+ 7.3% HRA-directed Bx 
(Bx =11%) 
Borghetti et al, 
2014(41) 
A38 Italy-Rome Combination (81% men, 56% 
MSM) 
NR 233 44 (39-48) 84% NR 558 (405-718) ASCUS+ 11.1% Cytology  
Cheng et al, 2014(84) B33 Taiwan -Taoyuan Combination men (79% MSM, 
21% MSW) 
2011 230 33 ±8 NR 36.9% NR ASCUS+ 23% Cytology 
Gautam et al, 2018(45) A42 India-Varanasi Combination men (38% 
reported RAI) 
2014-2015 95 35 (±8) 41.3% NR 253 ASCUS+ 63.2% Cytology 
Piketty et al, 2003(85) B20 France-Paris Combination men (51% MSM, 
49% IDU)  
1999-2000 117 MSM: 39 (27-73)  









ASCUS-AIN1+ MSM: 71.6% 
IDU: 36.0% 
Cytology+, 
HRA+directed Bx  
(Bx =39%); Composite 
cyto-histology 
Rosa-Cunha et al, 
2011(86) 
B34 USA-Florida Combination men (40% 
reporting anal sex) 
2006 98 51 (±9)  75.6% 46.6% 404 (241-673) ASCUS+ 53.1% Cytology  
Pereira et al, 2008(87) B35 Brazil –Pernambuco Combination men (58% MSM, 
42% MSW) 
2006 60 42 88.3% 75.0% 43% with CD4+ 
>500 cells/µL 
SIL-AIN1+ MSM: 34.3% 
MSW: 8.0% 
HRA-directed Bx  
(Bx =28%) 
Rovelli et al, 2017(88) B36 Italy-Milan Combination men (80% MSM) NR 875 43 (36-50)  98.3% 81.2% 675 (522-874) ASCUS+ 29.0% Cytology  
Chuang et al, 2016(89) B38 USA-Hawaii Combination (82% male; no 
stratification by sexual 
orientation) 
NR 61 50 (±8) 100% 82% NR ASCUS+ Women : 9.1% 
Men : 58.0% 
Cytology 
Payam et al, 2011(90) B39 USA-Hawaii Combination (94% men) NR 68  49 (43-56) 91.2% 88.2% 465 (314-665) ASCUS-AIN1+ 54.4% Cytology+, 
HRA+directed Bx  
(Bx =44%) 
Gimenez et al, 
2011(91) 
B41 Brazil-Manaus Combination (no stratification 
given) 
NR 128 NR 44.5% NR NR AIN1+ 39.1%  HRA directed biopsy + 
1Q if no visible lesions 
Frank et al, 2018(92) B37 USA-Atlanta Combination men (77% MSM) 2013-2015 147 39 (32–48) 96.6% NR 325 (203–473) HSIL-AIN2+ 61.2% HRA-directed Bx; 
(Bx=97%) 
Scott et al, 2008(93) B40 USA-Connecticut  Combination (27% MSM, 28% 
IDU, 18&MSW, 21% women, 
6% unkown) 
2002-2004 265 44 (26-77)  75.0% 57.0% 458 (±323) ASCUS-AIN1+ 27.9% Cytology+, 
HRA+directed Bx  
(Bx =2%; composite 
cyto-histology) 
Cranston et al, 
2018(2) 
B42 USA & Brazil Combination (18% female, 
82% male)  
2012-2013 575 Women: 48 (42, 
55) 





Men: 599 (437, 
767) 
HSIL-AIN2+ 32.5% HRA-directed; 
Composite cytology-
histology 
Gaisa et al, 2014(94) B43 USA-New York Combination:  
Women (23%), MSM (71%), 
MSW (6%) 
2009-2012 728 Women: 48 (43-
52)  
MSM:  42 (33-49) 





78% (MSM); 78% 
MSW 
Women:  514 
MSM: 521 
MSW: 449 
HSIL-AIN2+ 8.1% (Women) 
12.5% (MSM);  
4.1% MSW 
Cytology+, 
HRA+directed Bx  
(Bx =82%) 
Wilkin et al, 2004(37) A32 USA-New York City Men (61% MSM, 39% MSW) 2001-2002 92 NR 82% 50% NR LGAIN 
+HGAIN 
40.2% HRA+directed Bx 
(Bx=40%) 
Willeford et al, 
2016(95) 
B44 USA-North Carolina Combination men (91% MSM, 
9% MSW) 
2008-2013 348 42 (18-75) NR NR NR HSIL+ 30.1% Cytology+, 
HRA+directed Bx  
Weis et al, 2011(96)  B50 USA-Texas Combination (30% women, 
47% MSM, 23% MSW) 
 
 
2006-2008 692 41 (14–79) NR NR 48% ≥400 
cells/µL 
HSIL-AIN2+ 27.8% Cytology+, HRA 




Study, Year Study 
no.  




Mean or Median 
age, years [IQR] 






Definition Prevalence Diagnostic method 
SIL-AIN incidence  








Normal to ASCUS+ 9.4 per 100 PY Cytology 
Durante et al, 
2003(98) 
C2 USA- Connecticut and 
Massachusetts 
Women 1995-1998 86 47% aged 30-39 
years 
40.7% NR 26% with CD4+ 
<200 
Normal to ASCUS+ 22 per 100 PY Cytology 








Normal to ASCUS+ 17.9 per 100 PY Cytology 
Borghetti et al, 
2014(41) 
A38 Italy-Rome Combination (81% men, 56% 
MSM) 
NR 233 44 (39-48) 84% NR 558 (405-718) Normal to ASCUS+ 15.4 per 100 PY Cytology 
Conley et al, 2016(97) C1 USA- 4 cities MSW 2004-2012 48 44 (39-49) 89% 90% 482 (353-608) Normal to ASCUS+ 8.9 per 10 PY Cytology 
Burgos et al, 2015(99) C4 Spain-Barcelona MSM 2009-2014 310 41 (34-47) 85.0% 73.0% 550 (434-754) <HGAIN to HGAIN 10.5 per 100 PY HRA directed, random 
if ASCUS+ on cytology 
(Bx =26%) 
De Pokomandy et al, 
2011(100) 
C5 Canada-Montreal MSM 2002-2005 147 43 (range: 21-66) 90.0% 56.0% 380 (range: 0-
1440) 
≤AIN1 to AIN2-3 12.8 per 1000 
person months 
HRA directed Bx  
(Bx =89%) 
Palefsky et al, 1998 
(101) 
C3 USA-California MSM NR 166 NR NR NR 47% with CD4+ 
<200 cells/µl 
≤ASCUS to HSIL+  20% over 2 years HRA directed Bx; 
Composite cytology-
histology 
Phanuphak et al, 
2013 (102) 
 
C6 Thailand-Bangkok MSM 2009-2010 123 28 (24-33) 13.0% 9.8% (69% of 
ART users) 
343 (248-455) <HSIL-AIN2/3 
to ≥HSIL-AIN2/3 
2.61 per 100 PY HRA directed Bx  
(Bx =67%) 
Tong et al, 2013(103) C7 Australia-Sydney MSM 2004-2011 152 47 (42-53) NR but considered 
100% 
83.5% 500 (357-662) <HSIL-AIN2/3 
(HGAIN) to HSIL-
AIN2/3 (HGAIN) 
7.4 per 100 PY HRA directed Bx  
(Bx =44%) 
Anal cancer 
D’Souza et al, 
2008(104) 
D1 USA - Baltimore, 
Chicago, Los Angeles 
and Pittsburgh (MACS) 
MSM 1984-2007 6,972 47.4  NR NR NR Anal & rectal cancers5 69.0 per 100,000 
P-Y 
Histology report or 
cancer registry 




MSM 1988-2008 1,691 47 (41-54) 100% NR NR Anal cancer 196 per 100,000 
P-Y 
British Colombia 
Cancer and HIV/AIDS 
Drug Treatment 
Program registries and 
Anal Dysplasia Clinic 
database 




MSM 1984-2014 2,725 34 (30-40) 51.6% 47.3% NR Anal cancer 38 (HBV-); 186 
(HBV+) per 
100,000 P-Y 
MACS public dataset 
(ICD-0-3), includes 
histological verification 
Barnell et al, 2019 D18 USA-California (KPNC) Combination (10% women, 
20% MW and 70% MSM) 
1998-2012 13,552 66% ≤44 years 49.7% 39.1% 55% with CD4+ 
≥350 
Anal cancer 101 per 100,000 
P-Y 
KPNC cancer registry 
histologically confirmed 
Chiao et al, 2013(107) D3 USA – nationwide 
registry of military 
veterans (VA-CCR) 
Combination men (no 
stratification by sexual 
orientation) 
1985-2009 45,231 37% aged 40-50 
years 
63.7% NR NR Squamous cell cancer of 
the anus 
134.4 per 100,000 
P-Y 
Veterans Affairs Clinica 
Case registry; ICD-9 
codes 154.2 and 154.3. 
Crum-Cianflone et al, 
2010(108) 
D4 USA – nationwide 
military veterans (US 
HIV Natural History 
study) 
Combination men (no 
stratification by sexual 
orientation) 
1985-2008 4,506 42 (33-47) 45.5% Median log10 
copies/ml: 3.0 
(1.4-4.4) 
432 (282-509) Anal cancer 61.9 per 100,000 
P-Y 
Histology confirmed 
Mbang et al, 2015(109) D5 USA – nationwide 
registry of military 
veterans (VA-CCR) 
Men (no stratification by 
sexual orientation) 
1985-2010 28,886 44 (37–51) 100% 58% with 
PVL<500 c/ml 
more than 40% of 
the time 
56% with CD4+ 
>350 cells/ul 
Squamous cell 
carcinoma of the anus 
138.0 per 100,000 
P-Y 
Veterans Affairs HIV 
registry; ICD-9 
codes154.2 and 154.3 
Bertisch et al, 
2013(110) 
D6 Switzerland (Swiss HIV 
cohort study) 
Women (15%), MSM (73%), 
MSW (12%) 
1988-2011 354 NR 88.1% NR NR Anal cancer 59 anal cancer 
cases 
Swiss HIV Cohort 
Study/Swiss cantonal 
cancer registries 
Bruyand et al, 
2015(111) 
D7 Europe,  Australia & 
USA -11 cohorts 
(D:A:D study) 
Women (27%), MSM (44%), 
Other, including MSW&IDU 
(29%) 
2004-2012 41,762 39 (33-46) 89.7% Median log10 
copies/ml: 2.3 
(1.7-4.3) 
433 (281-620) Anal cancer 50.0 per 100,000 
P-Y 
D:A:D study records 
Cachay et al, 
2014(112) 
D8 USA-San Diego Women (11%),  MSM (78%), 
MSW (11%) 
2001-2012 2,804 40 (34-46) 74.2% 47.3% 384 (217-572) Anal cancer 23 anal cancer 
cases (1.7% over 5 
years) 
Linkage of cytology 
database and UCSD 




Study, Year Study 
no.  




Mean or Median 
age, years [IQR] 






Definition Prevalence Diagnostic method 
Chao et al, 2012(113) D9 USA-California (KPSC 
& KPNC) 
Combination (90% male, 62% 
MSM) 
1996-2008 12,872 40 (±9.8) 21.1% Median: 50,927 
(±103,656) 
364 (±279) Anal cancer 90.3 per 100,000 
P-Y 
KPNC and KPSC HIV 
and cancerregistries; 
ICD-9  
Guiguet et al, 
2009(114) 
D10 France-62 University 
Hospitals (FHDH-
ANRS CO4) 
Combination (32% MSM, 14% 
IDU, 27% other men, 28% 
women) 
1998-2006 52,278 45% aged 30-39 
years 
16.8% at study 
entry, 73% during 
whole study 
period 
16.9% at study 
entry, 50% during 
whole study 
period 
325 (177-491) Anal cancer 30.0 per 100,000 
P-Y 
ICD10 clinic records 
Hessol et al, 2007(115) D11 USA -California Combination -persons with 
AIDS (95% male, 88% MSM, 
9% IDU) 
1990-2000 14,210 44% aged 35-45 
years 
2.8% taking 
HAART prior to 
AIDS diagnosis 
NR 65% <200 
cells/ul at AIDS 
diagnosis 
Anal cancer  134 per 100,000 
P-Y 
San Francisco AIDS 
surveillance registry 
matched with California 
Cancer Registry; ICD10 
clinic records 
Piketty et al, 2008(116) D12 France-62 University 
Hospitals (FHDH-
ANRS CO4) 
Combination (28% women, 
35% MSM, 37% other men) 
1992-2004 86,322 34.2 (29.3-41.0) 60.6% NR NR Anal cancer 28.3 per 100,000 
P-Y 
ICD10 clinic records 
validated with histology  
Powles et al, 
2008(117) 
D13 UK-London (Chelsea 
and Westminster HIV 
cohort) 
Combination (90% male) 1983-2007 11,112 33 (±9) 45.7% NR Nadir: 157 
(IQR: 33-315) 
Anal cancer 122 per 100,000  
P-Y 
Cancer registries 
(checked by HIV 
oncologist) 
Richel et al, 2015 D17 The Netherlands (AIDS 
Therapy Evaluation in 
the Netherlands cohort)  
Combination (80% male) 1995-2012 20,765 NR 85% NR Nadir: 200 (80-
314) 





HIV cohort + verified 
histopathology  
Silverberg et al, 
2012(118) 
D15 USA and Canada (NA-
ACCORD) 
Combination (26% women, 
55% MSM, 19% other men) 
1996-2007 34,189 Women: 36 (30-
43)  
MSM:  38 (33-44) 
MSW: 40 (35-46) 






Anal cancer Women: 30 per 
100,000 P-Y 
MSM: 131 per 
100,000 P-Y 
MSW: 46 per 
100,000 P-Y 
Medical records, patient 
interviews, cancer 
linkage 
Response to treatment             
Burgos et al, 
2017(119) 
C9 Spain-Barcelona MSM 2009-2016 100 43 (36-49) 84.0% 69.8% 629 (418-801) HGAIN recurrence 
following electrocautery 
23.5% per year HRA directed, random 
if ASCUS+ on cytology  
Cranston et al, 
2014(120) 
C10 USA-Pittsburgh MSM 2009-2013 7211 48 (25-70) NR 79.2% 573 (±264) Clearance:  
AIN2+ to <AIN2 
following trichloroacetic 
acid 7 
78.6% HRA + directed Bx 
Richel et al, 2013(3) C11 The Netherlands-
Amsterdam 





treatment:  HGAIN to 
≤LGAIN 8 
38.5% HRA (Bx=100%)  
Goldstone et al, 2019 
(4) 
C13 USA-7 sites Combination (93% male) 2011-2014 120 49 (25–78) IRC 
arm; 51 (27–67) 
AM arm 
90.0% 64.2% IRC: 669 (501–
816; AM: 620 
(514–736) 
Clearance: complete 
index lesion clearance 
following treatment 
(IRC) or regression of 
all index HSILs to 
≤LSILs at month 12 
(AM) 
45.8% (62% in 
IRC arm and 30% 
in AM arm) 
HRA (Bx=100%) 
Spontaneous regression             
Liu et al 2018(121) C12 USA-New York Combination (92% men) 2009-2016 109 47 (24-73) NR NR NR Regression from LSIL to 
<LSIL 
22.0% HRA + directed Bx 
Tong et al, 2013(103) C7 Australia-Sydney MSM 2004-2011 101 47 (42-53) NR but considered 
100% 
83.5% 500 (357-662) AIN3 to <AIN3 69.9 per 100 
person years 
HRA directed Bx  
1Undetectable PVL, irrespective of ART use (<50 copies/ml where available, some studies report undetectable PVL as <400 copies/ml); 2HR-HPV defined according to the 2009 International Agency Research on Cancer classification(1), as those at least “probably carcinogenic to humans” and include HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59 (carcinogenic) and 68 (probable carcinogenic); “any HPV” includes combination of high-risk and low-risk types; Linear Array targets  37 different HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, 82, IS39, 6, 11, 40, 42, 54, 55, 61, 62, 64, 71, 72, 81, 83, 84, 89); 3In the meta-analysis, ART defined as 
effective ART (ART user with undetectable HIV PVL vs. ART users with detectable PVL/ART naïve combined); 4Maisa et al presents suppressed HIV PVL (<1000 copies/ml) 514% of all cancers were rectal cancer; 6thymidine analogue exposure (no data given for combination ART exposure); 7Among 72 men, there were 98 HSIL lesions; the 
number of lesions was used as denominator in the analyses; 8primary outcome was histological resolution of AIN at 4 weeks after end of treatment with either imiquimod, fluorouracil or electrocautery. Complete response was defined as resolution of AIN and partial response defined as regression from HG to LG AIN. Where authors present median 
values stratified by diseased and non-diseases groups, median value from non-diseased groups is given. MSM=men who have sex with men; MSW=men who have sex with women; NK=not known; PCR=polymerase chain reaction; ASCUS-AIN1+=atypical squamous cells of undetermined significance or anal intraepithelial neoplasia, grade 1 or 
greater; LSIL=low-grade squamous intraepithelial lesion; HSIL-AIN2+=high-grade squamous intraepithelial lesions or anal intraepithelial neoplasia, grade 2 or greater; HGAIN=high-grade anal intraepithelial lesion; ASC-H=atypical squamous cells-cannot exclude high grade squamous intraepithelial lesion; HRA=high resolution anoscopy; 
HBV=Hepatitis B virus; LBC=liquid based cytology; Bx=biopsy -indicates proportion of participants with a biopsy taken; Q=quadrant; IDU=injecting drug users; FHDH-ANRS CO4- French Hospital Database on HIV; p-m=person months; PY=person years; MACS=Multicenter AIDS Cohort Study; KPNC=Kaiser Permanente Northern California; 
KPSC=Kaiser Permanente Southern California; UCSD=University of San Diego, California; D:A:D study=the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) - a prospective multi-cohort study that focused on the association between antiretroviral drugs and cardiovascular disease, liver and renal disease, and non-AIDS-defining 
malignancies; VA-CCR=Veterans Administration Clinical Case Registry; ATHENA=AIDS Therapy Evaluation in the Netherlands national observational HIV cohort; NA-ACCORD=North American AIDS Cohort Collaboration on Research and Design; IR=infrared coagulation; AM=active monitoring 
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Supplementary Table 4. Meta-analysis of association of HIV-related factors and anal HR-HPV 
prevalence, stratified by gender and sexual orientation and geographic region 
    ART vs. ART-naïve Undetectable vs 
detectable HIV PVL 
Nadir CD4+  
≥200 vs. <200 cells/µl 
Current CD4+  
≥500 vs. <500 cells/µl 
All N studies 18 17 6 8 
 Effect estimate 
(95%CI) 
0.65 (0.54-0.79) 0.67 (0.57-0.78) 0.68 (0.40-1.14)  0.72 (0.607-0.87)  
 I2 12.1% 4.0% 58.9% 5.1% 
 p for heterogeneity 0.31 0.407 0.033 0.391 
By gender and sexual orientation         
Women N studies 2 4 4 1 
 Effect estimate 
(95%CI) 
0.38 (0.14-1.02) 0.71 (0.45-1.11) 0.62 (0.43-0.90) 0.61 (0.38-0.99) 
 I2 0.0% 19.40% 0.0% - 
 p for heterogeneity 0.781 0.293 0.738 - 
Men who have sex with men N studies 10 9 2 3 
Effect estimate 
(95%CI) 
0.79 (0.60-1.05) 0.72 (0.58-0.90) 0.71 (0.13-3.77) 0.79 (0.58-1.06) 
I2 21.9% 0.0% 84.0% 0.00% 
p for heterogeneity 0.242 0.613 0.013 0.749 
Men who have sex with 
women 
N studies 0 0 0 0 
Effect estimate 
(95%CI) 
- - - - 
I2 - - - - 
p for heterogeneity - - - - 
Combination men N studies 3 3 0 3 
 Effect estimate 
(95%CI) 
0.51 (0.35-0.74) 0.64 (0.48-0.84) - 0.82 (0.54-1.26)  
 I2 0.0% 12.50% - 0.00% 
 p for heterogeneity 0.991 0.319 - 0.899 
Combination women and men N studies 3 1 0 1 
Effect estimate 
(95%CI) 
0.54 (0.37-0.79) 0.39 (0.22-0.68) - 0.50 (0.29-0.86) 
I2 0.0% - - - 
p for heterogeneity 0.784 - - - 
By geographic region           




- 0.56 (0.27-1.18)  - - 
 I
2 - - - - 
 p for heterogeneity - - - - 




0.58 (0.40-0.84)     0.78 0.53-1.13)      0.40 (0.16-0.99)  0.86 (0.53-1.38) 
 I
2 16.1% 0.00% 0.0% 41.4% 
 p for heterogeneity 0.312 0.893 0.939 0.181 




0.65 (0.43-0.98)  0.55 (0.42-0.71)  - 0.61 (0.44-0.85)  
 I
2 20.9% 1.10% - 0.00% 
 p for heterogeneity 0.285 0.364 - 0.352 




0.69 (0.48-0.98) 0.71 (0.50-1.02) 0.78 (0.422-1.43)  0.74 (0.56-0.97)  
 I
2 35.9% 35.00% 69.0% 0.00% 
 p for heterogeneity 0.154 0.188 0.022 0.52 




0.75 (0.31-1.82)  0.80 (0.49-1.29)  - - 
 I
2 0.0% 21.40% - - 
 p for heterogeneity 0.422 0.282 - - 




- - - - 
 I
2 - - - - 
 p for heterogeneity - - - - 
By Study Design            
Cross-sectional N studies 16 17 5 8 
 Effect estimate 
(95%CI) 
0.68 (0.55-0.84) 0.67 (0.57-0.78) 0.71 (0.41-1.24) 0.72 (0.60-0.87) 
 I2 14.4% 4.0% 64.4% 5.1% 
 p for heterogeneity 0.288 0.407 0.024 0.391 
Convenience N studies 2 0 1 0 
 Effect estimate 
(95%CI) 
0.51 (0.32-0.82)     - 0.38 (0.08-1.76) - 
 I2 0.0% - - - 




Supplementary Figure 1. Funnel plot of publication bias using data from studies on the association of HIV 
related factors and HR-HPV prevalence  
(A) ART vs. ART-naive (B) Undetectable vs. detectable HIV PVL   
       




Supplementary Table 5. Risk of bias assessment of studies evaluating the association of HIV-related factors and anal HR-HPV prevalence 




of the exposed  







ART vs. ART-naïve 
       
 
Menezes, 2016 A3 Women - - * - ** 3 Low 
Hidalgo-Tenorio, 2018 A46 Women * * * - * 4 Mid-high 
Combes, 2018 A10 MSM * * * - ** 5 High 
Del Amo, 2013 A11 MSM - * - - ** 3 Low 
Cranston, 2015 A44 MSM - - - - * 1 Low 
Hidalgo-Tenorio, 2017 A13 MSM * * * - * 4 Mid-high 
Li, 2015 A15 MSM - - - ** * 3 Low 
Schwartz, 2013 A17 MSM * - * - ** 4 Mid-high 
Somia, 2018 A18 MSM * * - - ** 4 Mid-high 
Limia, 2016 A45 MSM - - - - * 1 Low 
Torres-Ibarra, 2014 A19 MSM * - * - ** 4 Mid-high 
van der Snoek, 2012 A22 MSM * * * - * 4 Mid-high 
Guimares, 2011 A31 cMen * * * - ** 5 High 
Wilkin, 2004 A32 cMen - - * ** ** 5 High 
Videla, 2013 A34 cMen * * * - * 4 Mid-high 
Boldrini, 2018 A36 Combination * * - - * 3 Low 
Nagata, 2015 A37 Combination * - - - * 2 Low 
Borghetti, 2014 A38 Combination - * * ** * 5 High 
Undetectable vs. detectable HIV PVL 
     
 
Boldrini, 2018 A36 Combination * * - - * 3 Low 
Cranston, 2012 A30 cMen - * * - * 3 Low 
Gianella, 2016 A12 MSM * * * - ** 5 High 
Goeieman, 2017 A1 Women * * - - ** 4 Mid-high 
Guimares, 2011 A31 cMen * * - - ** 4 Mid-high 
Heard, 2016 A2 Women * * * - ** 5 High 
HidalgoTenorio, 2018 A46 Women * * * - * 4 Mid-high 
Cranston, 2015 A44 MSM 0 * - - * 2 Low 
Hidalgo-Tenorio, 2017 A13 MSM * * * ** * 6 High 
Lee, 2011 A14 MSM * * - - * 3 Low 
Nyitray, 2018 A16 MSM 0 * * - ** 4 Mid-high 
Schwartz, 2013 A17 MSM * * - - ** 4 Mid-high 
Sohn, 2018 A43 Women * * * - * 4 Mid-high 
Somia, 2018 A18 MSM * * * - ** 5 High 
Torres-Ibarra, 2014 A19 MSM * * * - ** 5 High 
van Aar, 2013 A20 MSM * * * ** ** 7 High 
Videla, 2013 A34 cMen * * * - * 4 Mid-high 
Nadir CD4+ count ≥200 vs. <200 cells/µl 
     
 
Heard, 2016 A2 Women * * * - ** 5 High 
Menezes, 2016 A3 Women * * * - ** 5 High 
Sohn, 2018 A43 Women * * * - * 4 Mid-high 
Hidalgo-Tenorio, 2018 A46 Women * * * - * 4 Mid-high 
Hidalgo-Tenorio, 2017 A13 MSM * * * ** * 6 High 
van Aar, 2013 A20 MSM * * * - ** 5 High 
Current CD4+ count ≥500 vs. <500 cells/µl 
    
 
Heard, 2016 A2 Women * * * - ** 5 High 
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of the exposed  







Combes, 2018 A10 MSM * * - - ** 4 Mid-high 
Del Amo, 2013 A11 MSM - * * - ** 4 Mid-high 
Lee, 2011 A14 MSM * * - - * 3 Low 
Guimaraes, 2011 A31 cMen * * - - ** 4 Mid-high 
Yu, 2013 A33 cMen - * - - * 2 Low 
Liu, 2019 A47 cMen - * * - * 3 Low 
Boldrini, 2018 A36 Combination * * - - * 3 Low 
Refer to page 5 for description of grading system 
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Supplementary Table 6. Meta-analysis of HIV-related factors and HR-HPV prevalence, ASCUS-AIN1+ and HSIL-AIN2+ prevalence and anal 
cancer incidence, stratified according to Newcastle-Ottawa quality scoring  
 All studies Studies of mid-high quality Studies of high quality 












I2 P  
HR-HPV prevalence             
ART vs. ART naïve  18 0.65 (0.54-0.79) 12.1% 0.310 11 0.62 (0.49-0.78) 0.0% 0.944 4 0.57 (0.38-0.86) 0.0% 0.953 
Undetectable vs. detectable HIV PVL 17 0.67 (0.57-0.78)      4.0% 0.407 13 0.66 (0.56-0.79) 0.0% 0.473 6 0.73 (0.58-0.92) 0.0% 0.417 
Nadir CD4+ ≥200 vs. <200 cells/µl 6 0.68 (0.40-1.14)  58.9% 0.033 6 0.68 (0.40-1.14) 58.9% 0.033 4 0.68 (0.33-1.40) 71.9% 0.014 
Current CD4+ ≥500 vs. <500 cells/µl 8 0.72 (0.60-0.87) 5.1% 0.391 4 0.72 (0.58-0.91) 0.0% 0.707 1 0.61 (0.38-0.99)  - - 
ASCUS-AIN1+ prevalence             
ART vs. ART naïve  28 0.96 (0.74-1.26) 55.4% <0.001 8 0.92 (0.50-1.71) 73.7% <0.001 2 0.35 (0.16-0.75) 9.4% 0.293 
Undetectable vs. detectable HIV PVL 20 0.73 (0.64-0.83) 0.0% 0.50 9 0.72 (0.53-0.98) 34.2% 0.144 0 - - - 
Nadir CD4+ ≥200 vs. <200 cells/µl 10 0.52 (0.40-0.67) 0.0% 0.534 1 0.43 (0.18-1.01) - - 0 - - - 
Current CD4+ ≥500 vs. <500 cells/µl(7, 15, 16, 19, 37, 
39, 40) 
11 0.67 (0.48-0.91)   43.4% 0.061 2 0.97 (0.29-3.26) 72.8% 0.055 1 0.59 (0.37-0.92) - - 
HSIL-AIN2+ prevalence             
ART vs. ART naïve  15 1.18 (0.81-1.73) 48.0% 0.020 12 1.06 (0.70 (1.61) 38.3% 0.085 8 0.83 (0.53-1.28) 30.6% 0.184 
Undetectable vs. detectable HIV PVL 16 0.84 (0.72-0.98) 0.0% 0.801 11 0.79 (0.65-0.95) 38.3% 0.085 8 0.78 (0.61-1.00) 30.6% 0.184 
(7-9, 27, 123)Sustained undetectable HIV PVL 4 0.62 (0.41-0.81) 0.0% 0.506 4 0.62 (0.41-0.81) 0.0% 0.506 4 0.62 (0.41-0.81) 0.0% 0.506 
Nadir CD4+ ≥200 vs. <200 cells/µl(7, 15, 16, 19, 37, 39, 
40) 
6 0.60 (0.41-0.89) 67.6% 0.009 6 0.60 (0.41-0.89) 67.6% 0.009 3 0.69 (0.42-1.15) 74.2% 0.021 
Current CD4+ ≥500 vs. <500 cells/µl 5 0.72 (0.46-1.13)  79.2% 0.001 3 0.71 (0.33-1.52) 75.5% 0.017 2 1.00 (0.57-1.76) 43.4% 0.184 
Anal cancer incidence             
ART vs. ART naïve 9 1.34 (0.99-1.81) 0.0% 0.876 8 1.30 (0.96-1.77) 0.0% 0.941 5 1.42 (0.98-2.06) 0.0% 0.895 
Per year on ART 2 1.06 (1.01-1.11) 0.0% 0.798 2 1.06 (1.01-1.11) 0.0% 0.798 2 1.06 (1.01-1.11) 0.0% 0.798 
Undetectable vs. detectable HIV PVL 3 0.84 (0.56-1.27) 0.0% 0.587 3 0.84 (0.56-1.27) 0.0% 0.587 2 0.90 (0.57-1.42) 0.0% 0.442 
Sustained undetectable HIV PVL  2 0.56 (0.44-0.70) 0.0% 0.938 2 0.56 (0.44-0.70) 0.0% 0.938 2 0.56 (0.44-0.70) 0.0% 0.938 
Nadir CD4+ ≥200 vs. <200 cells/µl 3 0.33 (0.18-0.60) 0.0% 0.794 2 0.34 (0.16-0.71) 0.0% 0.507 1 0.44 (0.15-1.26) - - 
Nadir CD4+ per 100 cells/µl increase 2 0.60 (0.46-0.78) 21.7% 0.259         
P for heterogeneity 
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Supplementary Table 7. Meta-analysis of anal HPV and related-disease outcomes according to HIV-related factors, where number of studies are low 














HPV (any) prevalence                 
ART vs. ART naïve(10, 29, 33, 44, 45) 5 0.80 (0.54-1.91) 0.0% 0.705 1 1.10 (0.20-5.90) - - 
HIV-1 PVL undetectable vs. detectable(13, 29, 30, 32) 5 0.52 (0.30-0.90) 31.1% 0.214 - - - - 
Current CD4+ ≥500 vs. <500 cells/µl(11-13, 29, 31) 5 0.39 (0.18-0.84) 65.5% 0.021 - - - - 
Current CD4+ ≥500 vs. <200 cells/µl(43) - - - - 1 0.63 (0.48-0.77) - - 
         
HR-HPV prevalence                 
Adherence 100% vs. <100% (21) 1 0.86 (0.76-0.97) - -     
         
HPV16 prevalence         
ART vs. ART-naïve (7, 14, 25, 27, 29, 122) 6 0.90 (0.64-1.26) 0.0% 0.96 - - - - 
Undetectable vs. detectable HIV PVL(6, 29, 30, 122) 4 0.64 (0.43-0.97) 17.9% 0.301 - - - - 
Nadir CD4+ ≥200 vs. <200 cells/µl(6, 7, 63) 2 0.56 (0.17-1.83) 53.0% 0.145 - - - - 
Current CD4+ ≥500 vs. <500 cells/µl(6, 14, 29, 122) 4 0.93 (0.68-1.27) 0.0% 0.538 - - - - 
         
HR-HPV incidence         
ART vs. ART-naïve (42, 46) 2 0.59 (0.19-1.88)     84.2% 0.012     
         
HR-HPV persistence 5         
ART vs. ART-naïve  (46, 47) 2 0.82 (0.65-1.02) 0.0% 0.900     
ART >5 years vs. ≤5 years(48)     1 0.98 (0.97-0.997)   
Per log10 increase HIV PVL(47) 1 1.05 (0.75-1.47) - - - - - - 
Nadir CD4 per 50 cells/µl increase(47) - - - - 1 0.85 (0.71-1.03) - - 
         
Any HPV persistence 4         
ART >12 months vs. <6 months(49)     1 0.49 (0.13-1.75) - - 
Sustained viral suppression(49)     1 0.73 (0.30-1.75) - - 
         
ASCUS-AIN1+ prevalence         
Per year on ART(72) - - - - 1 0.92 (0.87-0.97) - - 
         
ASCUS-AIN1+ incidence         
ART vs. ART-naive(41, 97, 98) 4 1.15 (0.69-1.92) 0.0% 0.787 1 1.07 (0.40–2.85) - - 
HIV PVL undetectable vs. detectable(97) 3 0.69 (0.40-1.17) 0.0% 0.485 - - - - 
Nadir CD4+ ≥200 vs. <200 cells/µl (97) 3 0.73 (0.48-1.10) 0.0% 0.406 - - - - 
Current CD4+ ≥500 vs. <500 cells/µl (97, 98) 4 0.42 (0.14-1.27)  78.1% 0.003 1 0.24 (0.07-0.85)   - - 
         
HSIL-AIN2+ prevalence         
≥2 years vs. <2 years/ART-naïve (77) 1 0.32 (0.16-0.63) - - - - - - 
≥5 years vs. < 5 years(73) 1 0.73 (0.39-1.38)   - - - - - - 
         
HSIL-AIN2+ incidence                 
ART vs. ART-naïve(99) - - - - 1 0.39 (0.21-0.73) - - 
≥4 years vs. <4 years ART (100) - - - - 1 0.30 (0.10–0.89) - - 
HIV PVL undetectable vs. detectable (100, 103) 2 0.99 (0.48-2.03)  0.0% 0.745 - - - - 
Nadir CD4+ ≥50 vs. <50 cells/µl(100)     1 0.09 (0.01-0.84) - - 
Nadir CD4+ ≥350 vs. <200 cells/µl(102) 1 0.14 (0.05-0.40) - - 0 - - - 
Current CD4+ ≥500 vs. <500 cells/µl (31, 99, 100) 3 0.69 (0.34-1.43) 80.8% 0.006 - - - - 
         
HSIL-AIN2+ clearance following management         
ART vs. ART-naïve 5  (4) - - - - 1 4.95 (0.77-31.60) - - 
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Per year on ART6 (3) - - - - 1 1.07 (1.01-1.13) - - 
HIV viral undetectable vs. detectable(120) 2 1.17 (0.62-2.21) 0.0% 0.842 - - - - 







HSIL-AIN2+ recurrence following management         
ART vs. naive(119) 1 1.02 (0.96-1.08) - - - - - - 
HIV viral undetectable vs. detectable(119) 1 0.84 (0.35-2.05) - - - - - - 
Nadir CD4+ ≥200 vs. <200 cells/µl(119) - - - - 1 0.38 (0.16-0.94) - - 
Current CD4+ ≥500 vs. <500 cells/µl(119) 1 1.41 (0.74-2.70) - - - - - - 
         
HSIL-AIN2+ spontaneous regression among those not treated                 
HIV viral undetectable vs. detectable(103, 121) 2 2.17 (0.84-5.57) 0.0% 0.543 - - - - 
         
Anal cancer incidence                 
Per year with HIV RNA <100,000 c/ml(114) - - - - 1 0.83 (0.71-0.91) - - 
Nadir CD4+ ≥110 vs. <100 cells/µl(123)     1 0.41 (0.26-0.67)   
Per year with current CD4+ >200 cells/µl(114) - - - - 1 0.77 (0.67-0.83) - - 
Baseline CD4+ ≥350 vs. <350 cells/µl(124)     1 0.46 (0.27-0.79)   
ART started post-1996 vs. pre-1996(105) - - - - 1 0.33 (0.16-0.68) - - 
1includes studies with either 1.) no adjustment and 2.) studies that adjust for sociodemographic factors only but no adjustment for HIV related factors; 2adjusted for at least one of the following: ART status or duration, HIV PVL,  current CD4+ cell count; nadir CD4+ cell count, years living 
with HIV,  receptive anal intercourse (RAI); 3Odds Ratio (OR) used for prevalent outcomes, Hazard Ratio (HR) or Rate Ratio (RR) used for prospective outcomes (incidence, progression and regression/recurrence); 4 HR-HPV persistence defined as as having the same specific HPV (HPV16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) type at 2 consecutive visits (baseline, month 6 (for the first 120 participants), and month 12 visits) in(47); HR-HPV clearance estimated as time-dependent variable in (46); i.e. the definition of HR-HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 
and 59) clearance includes clearance after an HPV positive visit at study entry (prevalent positive cases) and clearance after an observed new infection (incident positive cases). The authors report that “not using ART was associated with increased clearance rates (AOR=1.23, 95%CI: 0,98-
1.55). We thus interpreted the estimate as similar to an increase in HR-HPV persistence among ART users; In (48), HR-HPV (16, 18, 26, 31, 33, 35, 39, 45, 51–53, 56, 58, 59, 66, 68, 73, and 82) clearance defined as the disappearance of all HR-HPV genotypes from anal canal mucosa in the 
latest examination, with negative HPV PCR. We inversed the estimate reported (“In the multivariate analysis, ART duration of >5 years was the sole factor favoring oncogenic HPV genotype clearance (OR: 1.016, 95% CI 1.003–1.030))”; i.e ART duration of >5 years was associated with a 
reduction in HR-HPV persistence (OR=0.98, 95%CI: 0.97-0.997); In (49), any HPV persistence defined as detection of the same HPV DNA type (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 66, 68, 69, 70, 71, 72, 73, 81, 83, 84) that was detected at 
enrolment; 5adjusted for treatment arm (infrared coagulation vs. no treatment but active monitoring) , clinic site of recruitment and number of index; 6 including ART-naïve participants as 0 years
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Supplementary Table 8. Meta-analysis of association of HIV-related factors and ASCUS-AIN1+ 
prevalence, stratified by gender and sexual orientation and geographic region 
    ART vs. ART-
naïve 
Undetectable vs detectable 
HIV PVL 
Nadir CD4+  
≥200 vs. <200 cells/µl 
Current CD4+  
≥500 vs. <500 
cells/µl 
All N studies 28 20 10 11 
 Effect estimate 
(95%CI) 
0.96 (0.74-1.26) 0.73 (0.64-0.83) 0.52 (0.40-0.67)  0.67 (0.48-0.91) 
 I2 55.40% 0.00% 0.00% 43.4% 
 p for heterogeneity <0.001 0.495 0.534 0.061 
By gender and sexual orientation         
Women N studies 7 5 4 3 
 Effect estimate 
(95%CI) 
1.47 (0.76-2.84) 0.70 (0.58-0.85) 0.46 (0.27-0.79) 0.47 (0.28-0.77) 
 I2 57.90% 0.00% 0.00% 6.50% 
  p for heterogeneity 0.027 0.75 0.937 0.343 
Men who have sex with men N studies 9 6 2 4 
 Effect estimate 
(95%CI) 
0.75 (0.50-1.14) 0.79 (0.62-0.998) 0.80 (0.47-1.38) 0.73 (0.47-1.14) 
 I2 53.10% 0.00% 34.80% 41.0% 
  p for heterogeneity 0.029 0.56 0.216 0.165 
Men who have sex with women N studies 2 3 1 1 
 Effect estimate 
(95%CI) 
2.05 (1.18-3.57) 0.52 (0.27-0.99) 0.50 (0.10-2.53) 0.69 (0.22-2.22) 
 I2 0.00% 15.70% - - 
  p for heterogeneity 0.347 0.306 - - 
Combination men N studies 6 3 1 3 
 Effect estimate 
(95%CI) 
0.90 (0.52-1.56) 0.73 (0.51-1.05) 0.40 (0.21-0.75)     0.82 (0.31-2.17) 
 I2 20.80% 1.70% - 71.70% 
  p for heterogeneity 0.277 0.36 - 0.029 
Combination women and men N studies 4 3 2 0 
 Effect estimate 
(95%CI) 
0.77 (0.29-2.01) 0.53 (0.14-2.00) 0.37 (0.22-0.63) - 
 I2 72.90% 61.40% 0.00% - 
 p for heterogeneity 0.011 0.08 0.739 - 
By geographic region           




2.26 (1.25-4.07) 0.63 (0.36-1.10)  - - 
 I
2 - - - - 
  p for heterogeneity - - - - 




1.32 (0.80-2.18)  1.07 (0.56-2.02)  0.40 (0.21-0.75)  0.79 (0.45-1.39)  
 I
2 0.00% - - 10.60% 
  p for heterogeneity 0.783 - - 0.327 




1.07 (0.71-1.62)  0.70 (0.57-0.86)  - 2.07 (0.62-6.98)  
 I
2 37.70% - - - 
  p for heterogeneity 0.186 - - - 




0.60 (0.42-0.84)  0.71 (0.55-0.93)  0.72 (0.50-1.05)  0.95 (0.66-1.38)    
 I
2 13.00% 5.30% 0.00% 0.0% 
  p for heterogeneity 0.32 0.392 0.682 0.390 




1.13 (0.56-2.72)  0.77 (0.57-1.04)  0.39 (0.26-0.58)  0.49 (0.36-0.66)  
 I
2 68.70% 11.90% 0.00% 0.00% 
  p for heterogeneity 0.002 0.339 0.98 0.507 




- - - - 
 I
2 - - - - 
  p for heterogeneity - - - - 
By study design            
Cross-sectional N studies 25 18 10 11 
 Effect estimate 
(95%CI) 
1.06 (0.82-1.37) 0.74 (0.65-0.85) 0.52 (0.40-0.67)  0.67 (0.48-0.91) 
 I2 49.8% 0.0% 0.00% 43.4% 
  p for heterogeneity 0.003 0.538 0.534 0.061 
Retrospective cohort or chart review 
  
N studies 3 2 0 0 
Effect estimate 
(95%CI) 
0.36 (0.13-0.96) 0.44 (0.13-1.51) - - 
I2 44.0% 41.4% - - 
p for heterogeneity 0.168 0.191 - - 
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Supplementary Figure 2. Funnel plot of publication bias using data from studies on the association of HIV 
related factors and ASCUS-AIN1+ prevalence  
(A) ART vs. ART-naive (B) Undetectable vs. detectable HIV PVL   
      
(C) Nadir CD4+ count ≥200 vs. <200 cells/µl (D) Current CD4+ count ≥500 vs. <500 
cells/µl 
 
     
There was some evidence to suggest publication bias among studies evaluating the association of 
undetectable PVL and ASCUS-AIN1+ prevalence (Beggs rank correlation test p=0.01 for the crude 
analysis). There was variation in the study size [range: 50-875] and when excluding one study among 
50 male IDU,(85) the pooled OR among 19 studies was similar (cOR=0.74, 95%CI: 0.65-0.84) with no 
evidence of publication bias (p=0.14).  
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Supplementary Table 9. Risk of bias assessment of studies evaluating the association of HIV related factors and ASCUS-AIN1+ prevalence 
Study Study 
ID 
Population Selection  Comparability  Outcome Total 
(max=8) 
Quality 










ART vs. ART-naïve   
Abramowitz, 2007 B10 Women * - * - - * 3 Low 
Baronoski, 2012 B1 Women * - * - * - 3 Low 
Cambou, 2015 B2 Women - - - - - - 0 Low 
Chaves, 2012 B3 Women - - - - - - 0 Low 
Gingelmaier, 2011 B5 Women - * - - * - 2 Low 
Pittyanont, 2014 B7 Women - - - - - - 0 Low 
Tandon, 2010 B9 Women * - * - * - 3 Low 
Abramowitz, 2007 B10 MSM * * * - - * 4 Mid-high 
D´Souza, 2016 B15 MSM * * * - - - 3 Low 
Dona, 2018 B16 MSM * * * - - - 3 Low 
Goodall, 2012 B17 MSM * * * - - - 3 Low 
Li, 2009 B19 MSM * - * ** - - 4 Mid-high 
Piketty, 2003 B20 MSM - - * - * * 3 Low 
Richel, 2013 B22 MSM * * * - * - 4 Mid-high 
van der Snoek, 2012 A22 MSM * * * ** * - 6 High 
Yang, 2012 B21 MSM - - - - - - 0 Low 
iAbramowitz, 2007 B10 MSW * - * - - * 3 Low 
Chikandiwa, 2018 A29 MSW * * * * - - 4 Mid-high 
Pereira, 2008 B35 cMen * * * - * - 4 Mid-high 
Piketty, 2003 B20 cMen - - * - * * 3 Low 
Rosa-Cunha, 2011 B34 cMen - * - - - - 1 Low 
Rovelli, 2017 B36 cMen * * * - - - 3 Low 
Wilkin, 2004 A32 cMen * - * ** * * 6 High 
Gautam, 2018 A42 cMen * - * - - - 2 Low 
Gimenez, 2011 B41 Combination - - - - ** - 2 Low 
Payam, 2011 B39 Combination * * - - * - 3 Low 
Scott, 2008 B40 Combination * * * - * - 4 Mid-high 
Borghetti, 2014 A38 Combination * * * - - - 3 Low 
Undetectable vs. detectable HIV PVL  
Abramowitz, 2007 B10 Women * * * - - * 4 Mid-high 
Baronoski, 2012 B1 Women - * * - * - 3 Low 
Cambou, 2015 B2 Women - * - ** - - 3 Low 
Gingelmaier, 2011 B5 Women - * - - * - 2 Low 
Tandon, 2010 B9 Women - * * - * - 3 Low 
Abramowitz, 2007 B10 MSM * * * - - * 4 Mid-high 
D´Souza, 2016 B15 MSM * * * - - - 3 Low 
Dona, 2018 B16 MSM * * - - - - 2 Low 
Piketty, 2003 B20 MSM - * * - * * 4 Mid-high 
Richel, 2013 B22 MSM * * * - * - 4 Mid-high 
van der Snoek, 2012 A22 MSM * * * - * - 4 Mid-high 
Abramowitz, 2007 B10 MSW - * * - - * 3 Low 
Chikandiwa, 2018 A29 MSW * * * * - - 4 Mid-high 





Population Selection  Comparability  Outcome Total 
(max=8) 
Quality 










Cheng, 2014 B33 cMen - * * - - - 2 Low 
Rosa-Cunha, 2011 B34 cMen - * - - - - 1 Low 
Rovelli, 2017 B36 cMen * * - ** - - 4 Mid-high 
Chuang, 2016 B38 Combination  * * - - - - 2 Low 
Payam, 2011 B39 Combination  * * - - * - 3 Low 
Scott, 2008 B40 Combination  * * * - * - 4 Mid-high 
Nadir CD4+ count ≥200 vs. <200 cells/µl  
Abramowitz, 2007 B10 Women - * * - - * 3 Low 
Baronoski, 2012 B1 Women * * * - * - 4 Mid-high 
Gingelmaier, 2011 B5 Women - * - - * - 2 Low 
Tandon, 2010 B9 Women - * * - * - 3 Low 
Abramowitz, 2007 B10 MSM - * * - - * 3 Low 
Dona, 2018 B16 MSM * * * - - - 3 Low 
Abramowitz, 2007 B10 MSW - * * - - * 3 Low 
Cheng, 2014 B33 cMen * * * - - - 3 Low 
Chuang, 2016 B38 Combination - * - - - - 1 Low 
Scott, 2008 B40 Combination - * * - * - 3 Low 
Current CD4+ count ≥500 vs. <500 cells/µl  
Conley, 2010 B4 Women - * * - - - 2 Low 
Holly, 2001 B6 Women - * * - * - 3 Low 
Sananpanichkul, 2015 B8 Women - * - - - - 1 Low 
Conley, 2010 B4 MSM * * * ** - - 5 High 
Lacey, 1999 B18 MSM - * * - - - 2 Low 
Yang, 2012 B21 MSM - * - - - - 1 Low 
Gonzalez, 2013 B23 MSM * * * - - - 3 Low 
Conley, 2010 B4 MSW - * * - - - 2 Low 
Cheng, 2014 B33 cMen - * * - - - 2 Low 
Pereira, 2008 B35 cMen * * * - * - 4 Mid-high 
Rosa-Cunha, 2011 B34 cMen * * - - - - 2 Low 
Refer to page 5 for description of grading system  
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Supplementary Table 10. Meta-analysis of association of HIV-related factors and HSIL-AIN2+ 
prevalence, stratified by gender and sexual orientation and geographic region 
    
ART vs. ART-naïve Undetectable vs detectable 
HIV PVL 
Nadir CD4+  
≥200 vs. <200 cells/µl 
Current CD4+  
≥500 vs. <500 
cells/µl 
All N studies 15 16 6 5 
 Effect estimate 
(95%CI) 
1.18 (0.81-1.73) 0.84 (0.72-0.98) 0.60 (0.41-0.89)  0.72 (0.46-1.13)  
 I2 48.0% 0.00% 67.6% 79.2% 
 p for heterogeneity 0.020 0.801 0.009 0.001 
By gender and sexual orientation         
Women N studies 2 3 1 1 
 Effect estimate 
(95%CI) 
2.37 (1.00-5.61) 0.73 (0.46-1.15)   0.44 (0.25-0.78) 0.61 (0.23-1.56) 
 I2 0.0% 0.00% - - 
  p for heterogeneity 0.714 0.954 - - 
Men who have sex with men N studies 11 11 5 3 
 Effect estimate 
(95%CI) 
1.11 (0.68-1.83) 0.94 (0.77-1.14)   0.65 (0.43-0.97)   0.87 (0.53-1.41)        
 I2 57.3% 0.00% 63.6% 71.7% 
  p for heterogeneity 0.009 0.741 0.027 0.029 
Men who have sex with women N studies 0 0 0 0 
 Effect estimate 
(95%CI) 
- - - - 
 I2 - - - - 
  p for heterogeneity - - -  -  
Combination men N studies 0 0 0 0 
 Effect estimate 
(95%CI) 
- - - - 
 I2 - - - - 
  p for heterogeneity - - - - 
Combination women and men N studies 2 2 0 1 
 Effect estimate 
(95%CI) 
1.02 (0.56-1.88) 0.69 (0.51-0.92) - 0.51 (0.35-0.74)   
 I2 0.00% 0.00% - - 
 p for heterogeneity 0.889 0.877 - - 
By geographic region           




- 0.83 (0.31-2.21)  - - 
 I
2 - - - - 
  p for heterogeneity - - - - 




- - 0.29 (0.12-0.67)  - 
 I
2 - - - - 
  p for heterogeneity - - - - 




- - - - 
 I
2 - - - - 
  p for heterogeneity - - - - 




0.88 (0.58-1.33) 0.83 (0.64-1.06)   0.87 (0.67-1.13)  1.00 (0.57-1.76)   
 I
2 36.7% 0.00% 20.70% 43.3% 
  p for heterogeneity 0.136 0.709 0.283 0.184 




2.19 (1.08-4.43)        0.85 (0.69-1.05) 0.44 (0.25-0.78) 0.69 (0.37-1.28) 
 I
2 49.3% 7.3% - 78.6% 
  p for heterogeneity 0.079 0.373 - -0.031 




0.74 (0.12-4.64)  0.71 (0.15-3.35)  0.54 (0.27-1.09)  0.39 (0.17-0.86)  
 I
2 - - - - 
  p for heterogeneity - - - - 
By study design           
Randomised controlled trials N studies 0 1 0 0 
 Effect estimate 
(95%CI) 
- 0.67 (0.42-1.05) - - 
 I2 - - - - 
  p for heterogeneity - - - - 
Cross-sectional N studies 14 14 6 5 
 Effect estimate 
(95%CI) 
1.12 (0.80-1.79) 0.87 (0.74-1.03) 0.60 (0.41-0.89) 0.72 (0.46-1.13) 
 I2 51.7% 0.0% 67.6% 79.2 
  p for heterogeneity 0.013 0.780 0.009 0.001 
Retrospective cohort or chart 
review 
  
N studies 1 1 0 0 
Effect estimate 
(95%CI) 
1.11 (0.31-4.01)   0.71 (0.34-1.46)         - - 
I2 - - - - 





Supplementary Figure 3. Funnel plot of publication bias using data from studies on the association of HIV 
related factors and HSIL-AIN2+ prevalence  
 
(A) ART vs. ART-naive (B) Undetectable vs. detectable HIV PVL   
         
Publication bias was not assessed when number of studies was lower than 10.  
 
 
There was some evidence to suggest publication bias among studies evaluating the association of nadir 
CD4+ count (≥200 cells/µl) and HSIL-AIN2+ prevalence (Beggs rank correlation test p=0.09 for the 
crude analysis). One study(71) found a significantly decreased risk of atypical squamous cells cannot 
exclude HSIL (ASC-H) prevalence with high nadir CD4+ cell count. Removing this study from the 
analysis resulted in a non-significant association of high nadir CD4+ cell count and HSIL-AIN2+ 





Supplementary Table 11. Risk of bias assessment of studies evaluating the association of HIV related factors and HSIL-AIN1+ prevalence 
Study Study ID Selection  Comparability  Outcome Total (max. 
=8) 
Quality 










ART vs. ART-naïve   
Hessol, 2009 B14 - - * ** * - 4 Mid-high 
Dalla Pria, 2014 B25 * * - - * - 3 Low 
Hidalgo-Tenorio, 2014 B26 * * * * ** - 6 High 
Hidalgo-Tenorio, 2015 B27 * * * - ** - 5 High 
Libois, 2017 B28 * * * - * * 5 High 
Machalek, 2016 B29 * * - * * * 5 High 
Palefsky, 2005 B30 - - - ** * - 3 Low 
Salit, 2009 B31 - - - - ** * 3 Low 
Schwartz, 2013 A17 * * * - * - 4 Mid-high 
Siegenbeek van Heukelom, 2017 B32 * * * - * * 5 High 
Clifford, 2018 B46 * * * - - * 4 Mid-high 
Gaisa, 2014 B43 * * - ** ** - 6 High 
Willeford, 2016 B44 - - - ** * * 4 Mid-high 
Stier, 2019 B49 * * * 0 ** * 6 High  
Marra, 2019 B48 * * * - * * 5 High 
Undetectable vs. detectable HIV PVL  
Clifford, 2018 B46 * * * * - * 5 High 
Cranston, 2018 B42 * * - - - - 2 Low 
Goeieman, 2017 A1 * * - - ** * 5 High 
Schwartz, 2013 A17 * * - - * - 3 Low 
Siegenbeek van Heukelom, 2017 B32 * * * - * * 5 High 
Gaisa, 2017 B12 * * - - ** - 4 Mid-high 
Dalla Pria, 2014 B25 * * - - * - 3 Low 
Hidalgo-Tenorio, 2015 B27 * * * * ** - 6 High 
Libois, 2017 B28 * * * - * * 5 High 
Machalek, 2016 B29 * * - * * * 5 High 
Palefsky, 2005 B30 - * * - * - 3 Low 
Salit, 2009 B31 - * - - ** * 4 Mid-high 
Gaisa, 2014 B43 * * - - ** - 4 Mid-high 
Masia, 2019 B47 * * - - - - 2 Low 
Stier, 2019 B49 * * * 0 ** * 6 High  
Marra, 2019 B48 * * * - * * 5 High 
Sustained viral suppression          
Clifford, 2018 B46 * * * * - * 5 High 
Libois, 2017 B28 * * * - * * 5 High 
Siegenbeek van Heukelom, 2017 B32 * * * ** * * 7 High 
Marra, 2019 B48 * * * - * * 5 High 
Nadir CD4+ count ≥200 vs. <200 cells/µl  
Libois, 2017 B28 * * * - * * 5 High 
Machalek, 2016 B29 * * - - * * 4 Mid-high 
Siegenbeek van Heukelom, 2017 B32 * * * - * * 5 High 
Yaegashi, 2017 A23 * * * * - - 4 Mid-high 
Clifford, 2018 B46 * * * - - * 4 Mid-high 
Stier, 2019 B49 * * * 0 ** * 6 High  
Current CD4+ count ≥500 vs. <500 cells/µl  
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Study Study ID Selection  Comparability  Outcome Total (max. 
=8) 
Quality 










Heard, 2015 B13 * * * - * * 5 High 
Machalek, 2016 B29 * * - - * * 4 Mid-high 
Palefsky, 2005 B30 - * * - * - 3 Low 
Siegenbeek van Heukelom, 2017 B32 * * * - * * 5 High 
Weis, 2011 B50 * * - * - - 3 Low 




Supplementary Table 12. Meta-analysis of association of HIV-related factors and anal cancer 
incidence, stratified by gender and sexual orientation and geographic region 








Nadir CD4+  
≥200 vs. <200 
cells/µl 
Current CD4+  
≥500 vs. <500 
cells/µl 
All N studies 9 3 2 3 0 
 Effect estimate 
(95%CI) 
1.40 (1.03-1.89) 0.84 (0.56-1.27) 0.56 (0.44-0.70)  0.33 (0.18-0.60)  - 
 I2 0.00% 0.0% 0.00% 0.00% - 
 p for heterogeneity 0.883 0.587 0.938 0.794 - 
By gender and sexual orientation     -     
Women N studies 0 0 0 0 0 
 Effect estimate 
(95%CI) 
- - - - - 
 I2 - - - - - 
  p for heterogeneity - - - - - 
Men who have sex with men N studies 2 0 0 2 0 
 Effect estimate 
(95%CI) 
1.41 (0.61-3.27)       - - 0.36 (0.17-0.77) - 
 I2 0.00% - - 0.00% - 
  p for heterogeneity 0.874 - - 0.648 - 
Men who have sex with women N studies 0 0 0 0 0 
 Effect estimate 
(95%CI) 
- - - - - 
 I2 - - - - - 
  p for heterogeneity - - - - - 
Combination men N studies 1 1 1 0 0 
 Effect estimate 
(95%CI) 
2.10 (0.55-8.02) 0.64 (0.24-1.71) 0.56 (0.41-0.77) - - 
 I2 - - - - - 
  p for heterogeneity - - - - - 
Combination women and men N studies 6 2 1 1 0 
 Effect estimate 
(95%CI) 
1.36 (0.97-1.90)        0.89 (0.57-1.41)    0.55 (0.40-0.76) 0.26 (0.09-0.75) - 
 I2 0.00% 0.0% - - - 
 p for heterogeneity 0.654 0.401 - - - 
By geographic region            




- - - - - 
 I
2 - - - - - 
  p for heterogeneity - - - - - 




- - - - - 
 I
2 - - - - - 
  p for heterogeneity - - - - - 




- - - - - 
 I
2 - - - - - 
  p for heterogeneity - - - - - 




1.41 (0.77-2.61)   - - 0.26 (0.09-0.75)  - 
 I
2 35.50% - - - - 
  p for heterogeneity 0.212 - - - - 




1.43 (0.94-2.17)  0.84 (0.56-1.27) 0.56 (0.44-0.70)  0.36 (0.17-0.77)  - 
 I
2 0.00% 0.0% 0.00% 0.00% - 
  p for heterogeneity 0.989 0.587 0.938 0.648 - 




- - - - - 
 I
2 - - - - - 
  p for heterogeneity - - - - - 
By study design            
Prospective cohort N studies 6 2 0 2 0 
 Effect estimate 
(95%CI) 
1.32 (0.93-1.87) 0.90 (0.57-1.42)      - 0.34 (0.16-0.71) - 
 I2 0.0% 0.0% - 0.0% - 
  p for heterogeneity 0.810 0.442 - 0.507 - 
Record linkage N studies 1 0 0 1 0 
 Effect estimate 
(95%CI) 
1.23 (0.62-2.45)   - - 0.31 (0.11-0.87)      - 
 I2 - - - - - 
  p for heterogeneity - - - - - 
Retrospective cohort or chart 
review 
  
N studies 1 1 2 0 0 
Effect estimate 
(95%CI) 
1.39 (0.20-9.81)       0.62 (0.24-1.62) 0.56 (0.44-0.70)  - - 
I2 - - 0.00% - - 
p for heterogeneity - - 0.938 - - 
Case-control N studies 1 0 0 0 0 
Effect estimate 
(95%CI) 
4.75 (0.60-37.50) - - - - 
I2 - - - - - 
  p for heterogeneity - - - - - 
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Supplementary Table 13. Risk of bias assessment of studies evaluating the association of HIV related factors and anal cancer incidence 
Study Study 
ID 
Population Selection  Comparability  Outcome Total 
(max=9) 
Quality 













ART vs. ART-naïve  
         
 
Aldersley, 2019 D16 MSM - - - * ** * * 5 Mid-high 
D´Souza, 2008 D1 MSM * - - * ** * * 6 High 
Crum-Cianflone, 
2010 
D4 cMen - * * ** ** * - 7 High 
Powles, 2008 D13 Combination - * - ** * * - 5 Mid-high 
Bertisch, 2013 D6 Combination - * * * * - - 4 Low 
Hessol, 2007 D11 Combination - * * * * * * 6 High 
Chao, 2012 D9 Combination * * * ** * * - 7 High 
Piketty, 2008 D12 Combination * * * * ** * - 7 High 
Cachey, 2015 D8 Combination * - * - ** * - 5 Mid-high 
Per year on ART          
Bruyand  D7 Combination * - * - ** * * 6 High 
Chao, 2012 D9 Combination * * * ** * * - 7 High 
Undetectable vs. detectable HIV PVL          
Cachey, 2015 D8 Combination * - * - ** * - 5 Mid-high 
Crum-Cianflone, 
2010 
D4 cMen - * * ** ** * - 7 High 
Barnell, 2019 D18 Combination * - * ** ** * - 7 High 
Sustained undetectable HIV PVL 
        
 
Mbang, 2015 D5 cMen - * * ** * * * 7 High 
Chiao, 2013 D3 Combination  - * * ** * * * 7 High 
Nadir CD4+ count ≥200 vs. <200 cells/µl 
       
 
D´Souza, 2008 D1 MSM * * - * ** * * 7 High 
Duncan, 2015 D2 MSM - * - - * * - 3 Low 
Powles, 2008 D13 Combination - * - ** * * - 5 Mid-high 








Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 




Convenience sample of 404 HIV-infected men and women recruited from a clinic at the Johns 
Hopkins Hospital (JHH) in Baltimore, Maryland, in 2006. Participants were followed 
semiannually for up to 2 and a half years. Women had higher risk of anal HPV compared to MSM 
– bias toward high risk women?  
Medium risk  
A physician collected anal samples. Purified DNA was evaluated for the 
presence of 37 HPV types by use of PGYM09/11 PCR primer pools 
and reverse line-blot hybridization (Roche Molecular Systems) 
Low risk 
Adjusted for sex, sexual orientation, smoking, 
number lifetime anal sex partners, number 
recent receptive anal sex partners, condom use 
and current and nadir CD4+ 
Low risk  
Anal HPV prevalence associated 
with younger age, being female, 
higher number of lifetime anal sex 
partners and lower current CD4+; 
Similar for incident HPV infection.  
Boldrini et 
al, 2018 
A cross-sectional study of HIV-positive men and women (18±69 years of age) attending a public 
STI/HIV screening and treatment center in Vitoria, Brazil, from March 2013 to February 2016. 
Low risk 
PGMY09/11, RFLP, RLB.  
Low risk 
None.  High risk (no adjustment for sexual 
behaviour or HIV related factors) 
ART use and undetectable PVL 
associated with decreased risk of 
HR-HPV prevalence among men 
and women combined. No data 




Longitudinal, observational study on a cohort of consecutively enrolled, HIV-seropositive patients 
followed at a single Italian center including HIV-1 infected patients aged 18 years or older. 
Recruitment procedure unclear. Medium risk  
Hybrid Capture II. Low risk  adjusted for CDC stage, AGW and current 
CD4+. Low risk  
Non nucleoside reverse transciptase 
inihibitors (NNRTI) users has lower 
HR-HPV compared to users of 
Protease Inhibitors.  
Chinyowa et 
al, 2018 
Cross-sectional study performed on 152 consecutive patients (88 females; 64 males) attending 
OIC at Parirenyatwa Group of Hospitals and Harare Central Hospital between November 2014 
and June 2015. Eleven patients opted not to be included in this study with the main reason given 
for refusal being lack of time. 85% of patients enrolled at the centre are on HAART. Low risk 
PCR (29 types)  
Low risk 
No adjustment. High risk  
Chikandiwa 
et al, 2017 
Baseline data from men living with HIV enrolled in a prospective cohort study to evaluate the 
natural history of HPV infection and disease in HIV-infected men in South Africa between 
October 2012 and August 2013, men in the community or attending HIV clinics were approached 
and asked to volunteer for the study. Potential participants were screened for eligibility and 
enrolled if they were willing to provide informed consent, 18 years or older, reported at least one 
episode of sexual intercourse in the past 3 months and were HIV positive on rapid testing. Low 
risk 
 
HPV determined by Linear Array. Crude estimate only  
Chikandiwa, 
2019 
As for Chikandiwa, 2017 
Low risk 
 
HPV determined by Linear Array. Any HPV persistence defined as 
detection of the same HPV DNA type (6, 11, 16, 18, 26, 31, 33, 35, 39, 
40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 66, 68, 69, 70, 71, 72, 
73, 81, 83, 84=32 types) that was detected at enrolment. Medium risk 
(any HPV only)  
Adjusted for marital status, smoking, alcohol 
use, age at sexual debut, number of sexual 
partners 
Persistent anal HPV infection was 
associated with persistent SILs 
(aOR=2.95; 95%CI: 1.08-10.89). 
Combes et 
al, 2018 
HIV-positive MSM aged ≥35 years attending infectious disease units in 6 University Hospitals 
across France (Dijon, Lyon, Marseille, Montpellier, Paris and Rennes) from December 2014 to 
June 2016, as part of APACHES study. Subjects were ineligible if they had any of the following: 
history of anal cancer or pelvic radiotherapy; anal intraepithelial neoplasia (AIN) grades 2/3 
treated during the last 12 months; any anticancer chemotherapy during the last 24 months; 
nonaffiliation with the French social insurance system. Out of 738 participants screened, 575 were 
enrolled and randomized between March 2012 and August 2013.  Low risk  
Cobas4800 and PapilloCheck (genotyping), performed at the HPV 
National Reference Centre at the Pasteur Institute, Paris, France. 
Detection of non-HR types by PapilloCheck were ignored.  
Low risk 
No adjustment (re-calculated for review).  
High risk (no adjustment for sexual behaviour 
or HIV related factors).  
 
 
ART use was not associated with a 
reduction in HR-HPV prevalence. 
Cranston et 
al, 2012 
Men participating in one of the two waves of data collection (2005– 2007) at the Los Angeles site 
for National Institute on Drug Abuse’s Sexual Acquisition and Transmission of HIV - Cooperative 
Agreement Program (SATH-CAP). The sample for each wave was recruited using Respondent 
Driven Sampling (RDS). An initial set of ‘seeds’ who were MSM or drug users were passively 
recruited via advertisements posted on walls and online, others recruited to the study were either 
an MSM and/or drug user or was their sexual partner. Low risk 
Clinician or self taken internal anal swab, HPV DNA detected using 
(AmpliTaq Gold (Applied Biosystems, Foster City, CA) PCR was 
performed on purified HPV DNA using MY09/MY11 consensus HPV 
L1 primers as well as primers for amplification of the human beta-
globin.  
Low risk 
Crude estimate only. High risk having a sex partner who injected 




The Bangkok MSM Cohort study was established in 2006 as part of the US Centers for Disease 
Control and Prevention (CDC) collaboration with the Thailand Department of Disease Control of 
the Ministry of Public Health. For the HPV substudy, convenience sample of frozen  
anal swab specimens obtained between 2006 and 2010 from 200 HIV-infected and 200 HIV-
uninfected participants to the University of Pittsburgh for HPV testing. High risk  
PCR. Low risk  Crude estimate only. High risk   
Critchlow et 
al, 1998 
Between October 1989 and February 1997, men attending the AIDS Prevention Project of the 
Seattle King County Department of Public Health, Washington, DC, USA, were recruited into a 
longitudinal study of HIV infection and anal HPV infection. Of the 910 men enrolled, 287 HIV-
seronegative and 322 HIV-seropositive men were seen for at least two visits at which specimens 
adequate for the detection of anal HPV DNA were obtained. Medium risk (35% loss to follow 
up) 
Anal specimens for assessment of HPV DNA were collected using a dry 
Dacron swab (Medical Packaging Corp., Camarillo, California, USA), 
with sampling of both the anal canal and lower rectal mucosa.  
Low risk 






Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
Del Amo et 
al, 2013 
MSM recruited in to the CoRIS study– an open and multicenter cohort established in January 
2004 that consists of adult patients with confirmed HIV infection who were naive to cART at 
study entry. Patients are followed periodically according to routine clinical practice, usually every 
4 months at following sites; Granada, Madrid, Seville, Alicante, La Rioja, San Sebastien, Tenerife 
and Barcelona). Median time since HIV diagnosis was 5 months (IQR: 1-13) and median CD4+ 
was 532 (403-701) and HIV PVL (15672, 3020-46697). Men were only recently diagnosed with 
HIV and those not taking ART still have high CD4+. Medium risk (bias towards well controlled 
HIV/recently HIV infected)  
Linear Array Genotyping test at the Retroviruses and Papillomavirus 
Unit of the National Center for Microbiology in Madrid 
Low risk  
Crude estimate only. High risk.  No association of ART nor CD4+ 




Cross-sectional exploratory study was conducted between 2014 and 2015 in HIV positive men 
attending the ART Center of Banaras Hindu University (BHU) with approximately 15,000 PLHIV 
registered in it. All HIV positive men above the age of 18, attending the ART centers were eligible 
for the study. Low risk 
PCR (29 types); Low risk Crude estimate only. High risk.  
Geskus et al, 
2016 
MSM recruited in to the CoRIS study (as in Del Amo, 2013). Of 1476 HIV-positive MSM within 
CoRIS-HPV, 612 had at least two visits; characteristics of these 612 men did 
not differ substantially from the other 864. Low risk  
Anal HR-HPV determined through the Linear Array HPV Genotyping 
test. HR-HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59=12 
types) clearance defined as time-dependent variable; i.e. the definition 
of HR-HPV clearance includes clearance after an HPV positive visit at 
study entry (prevalent positive cases) and clearance after an observed 
new infection (incident positive cases). The authors report that “not 
using ART was associated with increased clearance rates (AOR=1.23, 
95%CI: 0,98-1.55). We thus interpreted the estimate as similar to an 
increase in HR-HPV persistence among ART users.  
Incidence and clearance rates estimated using a two-stage Markov 
model that allowed for interval censored event data. Authors report 
associations of HIV related factors and HPV clearance; in the review the 
estimates are inversed for outcome of persistence. Low risk  
Age, HIV viral load, university education and 
asymptomatic CDC stage  
Age and HIV-RNA viral load had a 
statistically significant 
effect on HR-HPV clearance 
Gianella et 
al, 2016 
Participants prospectively enrolled and followed as part of the California Collaborative Treatment 
Group (CCTG) 592 study, which was an internet-based behavioral intervention study of HIV 
infected MSM at high-risk for sexually transmitted infections. Selection criteria for inclusion 
unclear.  High risk.  
Aptima HPV Assay (mRNA  from E6/E7) – may explain the lower 
prevalence of HR-HPV compared to other studies 
High risk  
Crude estimate only. High risk. Decreased risk of HR-HPV among 
those with undetectable vs. 
detectable PVL but not significant 
Godbole et 
al, 2014 
Cross-sectional study conducted between December 2012 and October 2013 with a planned 
sample size of 100. HIVinfected women older than 18 years, attending the HIV care and research 
clinics run by National AIDS Research Institute (NARI), Pune, India, were assessed for eligibility. 
Women were recruited regardless of CD4+ counts and antiretroviral therapy (ART) status. 
Women who were pregnant, had conditions that could preclude pelvic and/or anal examination, 
had a hysterectomy or history of screening/treatment for anal neoplasia, and history of HPV 
vaccination were excluded. 
Of 178 women attending the NARI clinics during the study period, 124 were found eligible and 
offered informed consent. Of these, 24 (19.3%) women refused participation.Medium risk (small 
sample size) 
PCR-based amplification of target DNA using the Linear Array HPV 
genotyping assay. Low risk 
Adjusted for sexual abstinence, menopausal, 
bowel hygiene (front to back wiping), rectal 
insertion, anal sex, education, cervical HPV 
and cervical cytology, number of lifetime sex 
partners. Low risk 




HIV-infected women aged 25–65 years recruited from Themba Lethu Clinic (TLC), the HIV unit 
at Helen Joseph Hospital, Johannesburg, South Africa. The inclusion criteria were documented 
HIV infection, age 25–65, and ability to give consent and participate in study-related activities. 
Exclusion criteria were pregnancy, clinically active sexually transmitted infection (participation 
was allowed after the sexually transmitted infection treatment was completed), previous 
hysterectomy with removal of the cervix, and significant medical/mental illness that would 
prevent the participant from completing the study.Low risk 
Hybrid Capture II. Low risk Adjusted for HIV related factors where 
associations found in MVA. No data or 
adjustment for receptive anal intercourse.  
Low/medium risk 
Weak evidence that longer duration 
ART and higher current CD4+ 
count associated with decreased 
risk of HR-HPV 
Guimaraes 
et al, 2011 
A multicenter cross-sectional study of HIVseropositive male patients attending 6 public AIDS 
referral clinics in urban Brazil (4 in Rio de Janeiro and 2 in Belo Horizonte, Minas Gerais), from 
May through November 2007 (PAPBRASIL). All participants were required to have 
a confirmed HIV diagnosis and be 18 years of age or older 
at the time of the study. 
Low risk 
PCR (39 HPV types). Unclear methods. High risk Unadjusted (ART and PVL detection). 
Published data reports significant association 
of HR-HPV with low (<200 cells-mm3) 
current CD4+ count, adjusted for sexual 
orientation and receptive anal intercourse. Data 
used in meta-analysis are unadjusted because 
different CD4+ count thresholds are used (500 
cell/mm3 used as cut-off).  Associations not 
stratified by sexual orientation. High risk 
Low contemporary CD4+ count  
Heard et al, 
2016 
Cross-sectional and screening study nested within the VIHGY cohort, a multicenter study of HIV-
infected women conducted in 5 sites within France. Women were recruited during their first 
VIHGY visit in 2012 at 3 of the VIHGY hospital sites: Paris-Pitié-Salpétrière, Colombes-Louis-
Mourier, and Marseille-Sainte Marguerite, 43% of the women originated from Sub Saharan 
Africa. Women were eligible if they had no history of anal cancer, and were invited to participate 
Linear Array. Low risk 
 
Crude estimate only. High risk. HR-HPV prevalence lower among 
women current CD4+ >500, and 
nadir CD4+ <200.  







Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
in a 2-step study: (1) anal HPV specimen collection during the gynecological visit and (2) to 
undergo an HRA at specialized anal dysplasia clinics.Low risk 
Hernandez 
et al, 2016 
HIV-positive MSM recruited from 2 study sites, Christian Medical College (CMC), Vellore (a 
large research and teaching institution) and Humsafar Trust (HT), Mumbai [a male sexual health 
nongovernmental organization]. Men were recruited through outreach workers and local HIV/ 
AIDS support groups and were also referred from other NGOs. Enrollment occurred from 
September 2009 to August 2010. Men were eligible for the study if they had had sexual contact 
with another man in the preceding 6 months and were HIV-positive. Low risk 
PCR (39 HPV types); the outcome was any HPV (39 types), so few 
HPV negative participants and low power to observe a difference 
between exposure groups. Medium risk 
 
Crude estimate only. High risk. Higher HPV prevalence among 
men reporting RAI and among men 
with low/no vaginal sex partners. 
No associations observed with any 
of ART use, undetectable VL or 




A screening, diagnosis and treatment and follow-up program for dysplastic anal muscosa lesions 
in the Infectious Diseases Department of 3rd level hospital in Southern Spain. Inclusion criteria 
were: age ≥18 years, self-reported MSM, HIV positivity, and signing of informed consent to study 
participation. Exclusion criteria were: female sex, self-reported heterosexuality, and history of 
anal canal neoplasm. 
Low risk  
Linear Array. Low risk Unadjusted for associations with ART and 
PVL; associations with nadir CD4+ adjusted 
for age, employment, number sex partners in 
last 12 months, condom use, AGW, syphilis/ 
other STI, smoking, current and nadir CD4+, 
VL, time since HIV diagnosis.Medium risk 
Nadir CD4= <200 cells/ul 





A single-centre, longitudinal, prospective study among WLHIV who were consecutively enrolled 
in a programme for screening, diagnosis,treatment and follow-up of dysplastic lesions of the anal 
mucosa(May 2012–December 2016). The patients were recruited from the infectious disease unit 








A longitudinal, prospective, single-center study of 405 HIV+ MSM patients consecutively 
enrolled between May 2010 and December 2018 in a program for the screening, diagnosis, 
treatment, and follow-up of dysplastic anal mucosa lesions conducted by the Infectious Disease 
Department at  “Virgen de las Nieves” University Hospital, Granada, Spain. The inclusion 
criterion was being an HIV+ MSM aged >18 years with no history of ASCC. Unclear recruitment 
method and numbers of men lost to follow-up.  
At V0 and all subsequent visits, genotyping by qualitative PCR (Linear 
Array HPV Genotyping Test). HR-HPV (16, 18, 26, 31, 33, 35, 39, 45, 
51–53, 56, 58, 59, 66, 68, 73, and 82=18 types) clearance defined as the 
disappearance of all HR-HPV genotypes from anal canal mucosa in the 
latest examination, with negative HPV PCR. We reversed the estimate 
reported (“In the multivariate analysis, ART duration of >5 years was 
the sole factor favoring oncogenic HPV genotype clearance (OR: 1.016, 
95% CI 1.003–1.030))”; i.e ART duration of >5 years was associated 
with a reduction in HR-HPV persistence (OR=0.98, 95%CI: 0.97-
0.997).  
Follow-up visits: The timing of the next follow-up visit depended on the 
results of HRA and cytology conducted at baseline. Patients with normal 
anoscopy and LSIL (AIN1) were evaluated one year later with cytology, 
HPV PCR, and anoscopy studies.  
Once their treatment was completed, these patients underwent another 
anoscopy, and those with normal histology or LSIL were given an 
appointment one year later, while those with HSIL were re-treated. 
When ASCC was detected, patients were referred to the oncology 
department for treatment. (Unclear if anal swabs for HPV were taken 
during these visits).  
Adjusted for age, Charlson co-morbidity index, 
number sex partners in the last month or since 
last visit, condom use, infection with LR-HPV 
HR-HPV persistence associated 
with shorter time on ART, and 
multiple sex partners 
Kojic. 2011 Women enrolled in Study to Understand the Natural History of HIV/AIDS in the Era of Effective 
Therapy (the SUN Study), a prospective observational cohort study, from March 2004 to June 
2006 from 7 clinics in 4 US cities. A total of 167 women were enrolled of total cohort of 700 
women; of these, 120 women had data on HPV and cytology. Participants were generally healthy 
patients with HIV receiving routine outpatient care. Patient data was extracted from medical 
records. Unclear how the 167 women were chosen (given the especially high prevalence of anal 
HPV at 90%). High risk  
Clinician collected swabs, Linear Array. Low risk Crude estimate only. High risk Current low CD4 (<500) associated 
with higher risk of anal HPV 
Lee et al, 
2016 
Cross sectional study conducted at the Pusan National University Hospital, a university-affiliated 
teaching hospital providing HIV care for HIV-infected patients in southeastern region of Korea. 
HIV-infected men who attended the HIV outpatient clinic of the study hospital were enrolled 
between July 2014 and January 2015, who were aged >18 years, and who had not received a 
diagnosis of anal cancer prior to enrollment. Relatively small sample, may not be representative of 
wider MSM HIV+ community.Medium-high risk 
HPV Genotyping Chip™ Kit. Low risk  Crude estimate only. High risk. 
 No associations found with sexual preference 
(vaginal, anal sex), no of female or male sex 
partners or history of STI. RAI and anal sex 
history not measured.   
Younger age only significant factor 
associated with HR-HPV 
Li et al, 
2015 
The study was conducted in the Eighth People’s Hospital in Xi’an from April to July 2014. Study 
participants were recruited through a local nongovernment organization (Xi’an Tongkang 
Volunteers Workstation). Multiple methods were used for recruitment including website 
advertisements, distributing flyers with study-related information at MSM frequented venues (e.g., 
MSM clubs, bars, parks and bathhouses), and eligible study participants were also encouraged to 
refer their peers to attend the study. Those eligible participants were HIV-seropositive males, at 
Hybribio HPV DNA test (21 HR types). Low risk A priori adjustment for age, ART status and 
CD4+ count. Adjusted for RAI in MVA.  
No data on HIV-1 PVL or nadir CD4+ to 
assess how well the men were controlled HIV 
disease (86% were taking ART yet median 
CD4+ count was 394 cells/ul). No data on STI.  
Low risk 
ART use associated with decrease 
in HR-HPV prevalence. RAI 
associated with increase HR-HPV 
prevalence. Higher HR-HPV 
among men with higher current 
CD4 count (but unadjusted for RAI 






Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
least 18 years old, ever had homosexual behaviors, willing to provide anal swabs and blood for the 
test, and physically able and willing to provide written informed consent. Low risk 
Liu et al, 
2019 
A cross-sectional study conducted in Taizhou City, Zhejiang Province from August 2016 to 
October 2017. Participants were recruited by Taizhou City Center for Disease Control and 
Prevention (CDC) and three county-level CDCs. Convenient sampling was used to enrol HIV-
positive men who were routinely followed-up by the four CDCs and HIV-negative men attending 
HIV Voluntary Counselling and Testing (VCT) clinics in the same CDCs. A total of 1286 HIV 
infected men had been routinely followed-up and 473 men had visited the VCT clinics during the 
study period.  
HPV genotyping using the HPV GenoArray Test Kit (Hybribio Ltd., 
Guangdong, China) detecting 21 HPV genotypes, 15 are HR-HPV 
including 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68.   
Crude estimate only  “Ever had homo-sexual behaviour “ 





Anal samples from HIV+ MSM patients attending the HIV Clinic at the Instituto Nacional de 
Ciencias Médicas y Nutrición “Salvador Zubirán” (INCMNSZ) in Mexico City were used for this 
study. Patients over 18 years old, who presented to care between August and December 2008, 
were invited to participate.  
Medium -high risk. Unclear selection method. 
INNO-LiPA. Low risk Crude estimate only. High risk No MVA conducted 
Menezes et 
al, 2016 
Consecutive women receiving care at Y.R. Gaitonde Center for AIDS Education and Research in 
Chennai, India. Low sample number (n=50). Medium risk 





Adolescent girls (13 to 18 yrs) recruited in the REACH project (Reaching for Excellence in 
Adolescent Care and Health) of the Adolescent Medicine HIV/AIDS Research Network across 15 
different clinical sites in 13 cities in US, The study enrolled participants who were in care and 
acquired HIV through sexual activity of injecting drug use. Low risk 
Anal samples taken by clinician for cytology and HPV DNA testing 
using single dacron swab. Low risk 
Adjusted for AGW. High risk Low CD4 count associated with 
higher prevalence of any HPV 
Nagata, 
2015 
Convenience sample of HIV+ participants attending the Department of Gastroenterology and 
Hepatology at the National Center for Global Health and Medicine (NCGM), Tokyo, Japan 
between September 2009 and March 2015. Eligible patients were HIV-positive patients, at least 
18 years old, who were willing to receive gastrointestinal (GI) tract cancer screening, provide anal 
swabs and blood for tests, and physically able and willing to provide written informed consent.  
Convenience sampling of participants may not be generalizable to wider HIV+ population despite 
high sample size.  Medium risk  
PCR-Invader assay. Low risk A priori adjusted for age, sexual orientation, 
CD4+ count, HIV PVL, presence of other 
STIs. No data on RAI, number sexual partners, 
condom use. Analysis not stratified by gender 
or sexual orientation (although the majority of 
participants identified as MSM and 
associations of HR-HPV with ART adjusted 
for sexual orientation). Medium/low risk.  
 
HR-HPV higher among those with 
younger age, MSM, CD4+ count 
<100 cells/ul, and having ≥2 STIs  
Nyitray et al, 
2018 
Men were recruited from 2014 to 2016 for the parent study, the Young Men’s Affiliation Project 
(YMAP), which examined their attendance history at risk and health venues and the HIV 
infection/sexually transmitted disease risk and prevention among young MSM in Houston and 
Chicago, Illinois. Participants were recruited using a respondent-driven sampling (RDS) 
method, where young MSM “seed” participants were identified first from health-promoting and 
social venues. Each seed and successive waves of respondents were asked to refer up to 4 peers 
into the study by offering them vouchers. Low risk  
PCR genotyping. Low risk  Crude estimate only. High risk  
Palefsky et 
al, 1998  
Homosexual and bisexual men recruited in the San Francisco Men’s Health (SFMHS), in the San 
Francisco General Hospital Co- hort Study (SFGH), and at the University of California, San 
Francisco (UCSF), responding to newspaper advertisements. Small sample and early HAART era. 
High risk 
PCR and HC-II. Low risk  Adjusted for anogenital warts  
Palefsky, 
2001 
Participants in this study were recruited between November 1995 and January 1997 from women 
who were participating at the San Francisco Bay Area site of the multicenter WIHS, a natural-
history cohort study of HIV disease in women.Low risk 
Hybrid Capture II. Low risk Crude estimate only. High risk Anal HPV associated with 
detectable PVL and low CD4 
Patel, 2018 The SUN study enrolled 700 HIV-infected adults from 7 clinics in 4 US cities into a prospective 
observational cohort study. Participants were generally healthy HIV-infected patients receiving 
routine outpatient care and whose entire antiretroviral experience consisted only of highly active 
combination antiretroviral therapy (cART). Participants were classified as MSM or MSW 
according to self-report. Study follow up period ended in 2012. Low risk 
Linear Array. Low risk Associations of ART and HPV stratified 
according to sexual orientation but associations 
are unadjusted for confounding despite 
measures of sexual behaviour (including RAI, 
number of sex partners and rectal STI 
measured). High risk  
Among MSW, smoking was 
associated with HPV prevalence 
(unadjusted estimate)  
 
Phanuphak 
et al, 2013 
Thai men aged 18 years or older who reported a history of anal sex with men were recruited in the 
study at the Thai Red Cross AIDS Research Centre in Bangkok, Thailand. Men were excluded if 
they had prior treatment for anal cancer, anal cytology,high-resolution anoscopy, or infrared 
coagulation within 12 months before enrollment; trichloroacetic acid or podophyllin application to 
the intra-anal area in the month before enrollment; or evidence of active concurrent intra-anal or 
perianal bacterial or herpes simplex virus infection at the time of enrolment.  
Low risk  
Anal samples were collected from participants at the baseline, month 6 
(for the first 120 participants), and month 12 visits by 1 study physician. 
Linear Array. HR-HPV (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, and 68=13 types) persistence defined as having the same specific HPV 
type at 2 consecutive visits. Anal samples were collected from 
participants at the baseline, month 6 (for the first 120 participants), and 
month 12 visits. . Low risk 
Crude estimates for ART and PVL (no 
significance on univariate analysis); nadir 
CD4+ adjusted for sex acts per week, age, 
smoking. High risk  
Smoking was the only factor with 
significant association with any 
high-risk HPV persistence in the 
multivariate model (OR: 2.3, 95% 
CI: 1.17 to 4.5, P = 0.015). 
Schwartz, 
2013 
Using the Kaiser HIV registry at San Francisco KPNC anal cancer screening clinic, men aged ≥18 
years, not diagnosed with anal cancer prior to enrolment were identified and enrolled between 
2009-2010.  
Low risk  






Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
Sohn, 2019 Perinatally infected (PHIV) and HIV uninfected (HU) female adolescents and young adults aged 
12–24 years with a history of vaginal intercourse were recruited at 5 study sites as part of The 
HPV in Adolescents Study: Thailand—HIV-NAT-Thai Red Cross AIDS Research Centre, and 
Siriraj Hospital Mahidol University both in Bangkok, and Chiang Rai Prachanukroh Hospital in 
Chiang Rai, and Vietnam—Children’s Hospital 1 and Hung Vuong Hospital, both in Ho Chi Minh 
City; all Thai sites and Children’s Hospital 1 were providing routine HIV care to the PHIV youth 
invited to participate in the study. Participants excluded if they were pregnant at the screening 
visit, if they had an untreated symptomatic STI (except genital warts), or had received prior doses 
of HPV vaccine and if they were unable to independently complete the study’s audio computer-
assisted self-interview. Individuals were excluded if they were behaviourally HIV infected or if 
they were HIV uninfected with other chronic diseases or were using medications associated with 
compromised immune function. Low-medium risk (small sample)   
LBC fluid from the 3 anogenital compartments and oral rinses were 
tested using the LINEAR ARRAY test . Low risk 
Crude estimate only. High risk  
Somia, 2018 Prospective cohort study to assess anal hr-HPV infection and anal HSIL in MSM and TGW, with 
clinic sites in Jakarta and Bali (Indonesia), Bangkok (Thailand), and Kuala Lumpur (Malaysia). 
Between June 2013 and April 2015. MSM visiting 1 of the 4 clinics were invited to participate. 
Participants were eligible if they were Indonesian, Malaysian, or Thai citizens, at least 18 years of 
age, male at birth, and had a history of anal intercourse. They were not eligible for enrollment if 
they had prior treatment of anal cancer; anal cytology, high resolution anoscopy (HRA), or 
infrared coagulation within the previous 12 months; trichloroacetic acid/podophyllin application 
of the intraanal area in the previous month; or evidence of active concurrent intra- or peri-anal 
bacterial or herpes simplex infection. Low risk  
Anal swab collected by trained study physician/nurse. Linear Array . 
Low risk 
Crude estimate only. High risk  
(no associations found in univariate anlaysis) – 





Cross-sectional study based on baseline information from a cohort of HIV-positive MSM 
recruited at Condesa Clinic, which provides free HIV care in Mexico City. Men were eligible for 
participation if they were 18 years or older and had any type of sexual intercourse at least once 
with another male. Participants enrolled from December 2009 through October 2011 were 
included in the analysis. Medical personnel recruited subjects during their routine clinical visits.  
A total of 740 HIV+MSM were invited to participate in the study, of whom 82 declined, and 133 
did not return for the baseline visit, representing an acceptance rate of 70.9%. Low risk 
Linear Array. Low risk Crude estimate only. High risk A higher number of recent receptive 
sex partners, low CD4+ count were 
associated with prevalent 
HPV16/18 infection  
Van Aar, 
2013 
HIV negative and HIV-infected MSM were invited to participate in the H2M (HIV & HPV in 
MSM) study at three sites in Amsterdam, the Netherlands: the Amsterdam Cohort Study (ACS) 
among MSM (Public Health Service Amsterdam), a sexually transmitted infections clinic (Public 
Health Service Amsterdam), and an infectious disease outpatient clinic (Jan van Goyen Medical 
Center). Men were eligible for participation if they were aged 18 years or older and conversant in 
Dutch or English. Cohort of well controlled HIV and homogenous in terms of sexual behaviour 
risk (correlated) reducing power to detect any differences between exposure groups. Low-
medium risk 
Self collected anal samples using regular flocked swab with 1mul 
Universal Transport Medium (UTM). => interindividual variation in 
viability of samples. Low-Medium risk  
SPF10-PCR DEIA/LiPA25.  Quality Control for detection and typing 
performed by retesting 5% of all HPV-positive and HPV-negative DNA 
extracts in different laboratory using the same technique. Discordance 
was 10% among HPV-positive and 3% among HPV-negative samples.  
Low risk 
Adjusted for age, smoking, use of poppers, 
recent anal sex partners, RAI in past 6 months, 
fisting in last 6 months, number lifetime male 
sex partners, nadir CD4+ and HIV PVL. Low 
risk 
 
Anal HR-HPV associated with 
younger age, RAI in last 6 months, 
higher nadir CD4+ count and HIV 
PVL detection at enrolment.  
Van der 
Snoek, 2012 
Cross-sectional study; participants were included in a Rotterdam study on the screening of HPV 
related anal premalignancies in HIV-positive MSM. All patients were recruited from the 
outpatient clinics of 4 hospitals. No information on recruitment procedures. Medium risk  
Swabs collected swabbing perianal and intra-anal area. INNO-LiPA. 
Low risk 
Crude estimate only  
High risk 
ART associated with decreased risk 
of AIN and HR-HPV. No 
association with nadir CD4+ (few 
men with low nadir CD4+)  
Videla, 2013 The Can Ruti HIV+ Men cohort was a single-center, prospective cohort study, annually assessing 
HPV infection at anal, penile, and oral sites of HIV-positive men attending the Outpatient HIV 
Clinic of the Hospital Germans Trias i Pujol (Badalona, Spain). HIV-positive men were eligible 
for participation if they were older than 18 years and reported no previous diagnosis of HPV-
related pathology at anal, penile, and oral sites. Consecutive patients’ recruitment, based on 
outpatients who attended their AIDS routine clinic visit. The patients were informed of the study 
and invited to be seen in the Clinical Proctology HIV UnitY created ad hoc. Low risk  
IVD-CE F-HPV typing (13 HR types+ HPV6 and 11). Low risk Association of HR-HPV with ART and HIV 
PVL unadjusted for confounders (estimate in 
MVA not provided). Crude estimate combines 
MSM and MSW (no stratified analysis). High 
risk 
HR-HPV associated with sexual 
orientation, history of AGW, 




Case series study in HIV-seropositive sexually active women, aged 18 to 65 years old who 
attended a STI/AIDS Reference Clinic in Vitoria, southeastern Brazil, from August 2013 to 
December 2015. Unclear recruitment/selection method and sample. Medium-high risk 
PCR (PGMY09/11). Low risk Crude estimate only. High risk Anal HPV associated with younger 
age, CD4+ count <500 cells/mm3 
and HIV PVL >50 copies/ml.  
Wilkin, 2004 Clinicians referred men from the Columbia-Presbyterian Medical Center Infectious Diseases 
Clinic, an urban clinic that serves ∼1000 HIV-positive patients. Primary care providers from the 
referring clinic were asked to refer men without regard to the patient’s previous history of genital 
or perianal condyloma, other sexually transmitted diseases, or sexual behavior. Primary care 
providers were more likely to refer subjects who reported sex with other men and may have been 
more likely to refer subjects with a prior history of genital condyloma, which may limit the 
generalizability. Early ART period (2001-2002), 65% men started ART <200 cells/mm3. Mean 
nadir of men who started ART was 63 cells/mm3 vs. 290 cells/mm3 among ART naïve men; 
Small sample (not clear how many men refused). Medium risk  
HC-II and PCR. Low risk Associations of ART and HR-HPV not 
stratified by sexual orientation but adjusted for 
history of RAI. Low risk 
HR-HPV associated with history of 
RAI only in MVA (adjusted for 
ART use, age and nadir CD4+) 
Wiley et al, 
2013 
Men were invited by research personnel to participate in the AHS at the first MACS visit 
following the study’s opening in May 2010. anal Pap test and HPV genotyping was obtained and 






Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
study specimens were collected for 1,296 MSM at the first AHS study visit completed between 
May 2010 and February 2011. Low risk 
Yu et al, 
2013 
HIV-positive men attending the outpatient clinics of Infectious Diseases at the National Cheng 
Kung University Hospital for HIV care from August 2010-February 2011. Eligibility criteria 
included C20 years of age, no history of HPV vaccination, being able to provide informed consent 
and having no current symptomatic HPV-related anogenital lesions or diseases. Low risk 
 
PCR (34 types). Low risk Crude estimate for >500 vs. <500; high risk  
For >500 vs. <350, estimate adjusted for ime 
since HIV diagnosis, age, HIV exposure 
category, number recent sex partners, presence 
of STI, history of anal disease, RAI in past 
6mths, use of condoms in past 6 mths 
RAI in last 6 months and No. of sex 
partners  in the past 6 month 
associated with anal HR-HPV 
Anal lesions/anal cancer studies 
Abramowitz, 
2007 
Participants recruited during routine follow-up visit at the infectious diseases units of Bichat 
Claude Bernard University Hospital in Paris, France. The sample was composed of all consecutive 
patients consulting any of the medical doctors present during three randomly determined half-days 
per week. The three selected halfdays were modified three times during the study period to allow 
for the screening of a representative sample of patients. Anal exam proposed to 516 HIV positive 
patients, of whom 92% accepted. (Authors note potential referral bias of a large teriary care 
centre, cannot rule out geographical variation in characteristics of patients). Low risk 
Ocular inspection (with and without aceto-white test) of the anal and 
through anoscopy. An HPV intraepithelial lesion was suspected in the 
case of either an aceto-white area or a slightly elevated mucosa 
resembling tumours white to pink in color or of exophytic elevated 
lesions easily distinguishable from normal mucosa. A biopsy was 
systematically performed to confirm the diagnosis of HPV-related 
lesion.  Histological analysis: HPV intraepithelial lesions were 
diagnosed by two independent observers. Low risk  
Associations of AIN1+ and ART, PVL and 
CD4+ unadjusted for confounders.  
ART and PVL not included in MVA due to 
lack of association in univariate, CD4+ 
included in MVA but not stratified by sexual 
orientation or gender (although adjusted for 
RAI history). High risk (ART and PVL 
analysis)  
History of RAI and history of anal 





As above As above   
Aldersley et 
al, 2019 
Nested prospective cohort study in the MACS, an ongoing study established in 1984 that has 
enrolled 7343 HIV-positive and HIV-negative MSM. Clinical and laboratory data were collected 
at semiannual visits as described. Eligible participants were 5298 MSM 
aged 30–70 years with at least 5 years of follow-up during 1984–2014 and one or more visits with 
HBV laboratory test data. Baseline was first visit after age 30 years.Low risk  
Not reported. High risk  Adjusted for nadir CD4+. Low risk   
Baranoski, 
2012 
Prospective observational study conducted at Center for Infectious Diseases at Boston Medical 
Center, an inner city hospital. English speaking HIV positive women between 18-64 years  who 
had not had a cervical or anal cytology test, colpo or HRA in the 6 months prior to enrolment were 
eligible to participate. Exclusion criteria included: pregnancy, use of chronic anticoagulation 
medication and life expectancy less than one year. Study participants were recruited by nurse 
practitioner in CID from HIV positive women scheduled for gynecology care (including cervical 
cytology). Small sample size may not be representative of wider population of WLHIV: 10% of 
women had prior history of VIN and 27% had prior treatment for CIN (high risk population). 
Medium/high risk  
All women had HR-HPV (HC-II) and anal cytology performed. Women 
with any grade of anal cytology abnormality or anal HR-HPV were 
referred for HRA. Identified lesions were biopsied under direct 
visualization with biopsy forceps.  Medium risk 
Crude estimate only. High risk  
No risk factor analysis conducted using 
histology outcome- only available for cytology 
outcome  
.  
In MVA, ASCUS+ associated with 
current CD4+ <200 cells/mm3, anal 
HPV infection and history of other 
STI.  
Barnell et al, 
2019 
Using a cohort study design, changes in cancer incidence were evaluated from 1998 to 2012 
among 13,552 adult (≥18 years) KPNC members with HIV infection. Study subjects were 
identified from the KPNC HIV registry, which includes all known cases of HIV infection among 
KP members since the early 1980s and includes more than 25,000 cumulative patients. The 
registry maintains up-to-date lists of all HIV patients confirmed by medical chart review, and 
includes data on HIV transmission risk factors, dates of known HIV infection, clinical AIDS 
diagnoses, HIV-related lab and pharmacy data, and associated clinical data from the electronic 
health record (EHR). The study cohort was followed from 1998 through 2012, corresponding with 
10 years before and 5 years after the introduction of HRA capability at KPNC in 2008. The start 
of follow-up for each cohort member was assigned as the latest of: January 1, 1998; first KPNC 
membership; HIV diagnosis date; or the member’s 18th birthdate. Follow-up continued until 
earliest of: the outcome of interest (ie, anal cancer or advanced anal cancer); death; departure from 
the KPNC health plan (disenrollment or membership gap of 4 or more months); or December 31, 
2012. 
HRA was offered at 2 clinic locations—in San Francisco, as part of a 
screening program based in the HIV primary care clinic, and in 
Oakland, as a referral site for all other KPNC medical centers. 
 
Anal cancer diagnoses were identified from the KPNC cancer registry, a 
contributing site to the Surveillance, Epidemiology, and End Results 
Program. Participants with evidence of anal cancer diagnosed before 
January 1, 1998 were excluded. Anal cancer confirmed using tissue 
biopsy with pathologic diagnosis of invasive or superficially invasive 
squamous cell carcinoma of the anus 
 
Adjusted for year of HIV diagnosis, age at 
baseline, race, sexual risk group, ever smoked, 
baseline CD4+, baseline prior clinic AIDS 
Anal cancer decreased in later years 
(2011-2012) compare to 1998-
2007; was higher among those aged 
≥45 years, among MSM, smokers, 
those with baseline CD4+ <350 




Swiss HIV Cohort Study has enrolled people living with HIV since 1998 from 7 large hospitals in 
Switzerland representing 103,000 person years of follow-up until Dec 2011. A total of 68 anal 
cancer cases were identified in SHCS, 54 of these were identified from the SGCS database and 11 
through record linkage with 8 Swiss cantonal cancer registries. Six prevalent cancer cases before 
or within 1 month of enrolment in the SHCS and 3 diagnosed more than 6 months after the last 
SHCS FU data were excluded leaving 59 eligible incident cancer cases. For each anal cancer case, 
5 control subjects were matched at random using incidence density sampling from SHCS 
participants who were never diagnosed with anal cancer. Low risk 
Anal cancer cases identified from the SGCS database and through 
record linkage with 8 Swiss cantonal cancer registries. Low risk 
Odds Ratios conditioned on matching variables  
(SHCS centre, sex, HIV transmission category, 
age at enrolment, year at enrolment date). 
Association with ART adjusted for nadir CD4 .  
Analysis not stratified by sexual orientation 
 
Anal cancer associated with current 
smoking, antibodies against HPV16 
L1, low nadir CD4+ count, current 
CD4 at cancer diagnosis. Influence 
of CD4 was strongest 6-7 years 
prior to anal cancer diagnosis.  
Borghetti et 
al, 2015 
Longitudinal, observational study on a cohort of consecutively enrolled, HIV-seropositive patients 
followed at a single Italian center including HIV-1 infected patients aged 18 years or older. 
Recruitment procedure unclear. Medium risk  
Participants underwent anoscopy by a single specialist surgeon. 
Traditional pap and thin prep pap test o anal samples. Cytology results 
read by single reader according to Bethesda 2001, anal lesions classified 
as ASCUS+.  
Crude estimate only Anal warts and HPV DNA 






Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
Bruyand et 
al, 2015 
D:A:D study is a propsepctive study formed by the collaboration of 11 cohorts in Europe, 
Australia and the USA. Information on AIDS events, including ADC  have been provided 
prospectively on an annual basis since the start of the study in 1999, and on NADC since 2008.  
Information also collected retrospectively on events occurring between Jan 2004 to Jan 2008. 
Participants were followed from the latest of Jan 2004 (start of cancer data collection) or D:A:D 
study entry until the earliest of a first incident cancer diagnosis (any type, excluding precancer 
stages), Feb 2012, death or 6 months after the last visit. Low risk 
Detailed information on events collected on specific case report form. 
All reported events are validated centrally at the D:A:D coordinating 
centre with a proportion of events selected for discussion with an 
external consultant oncologist. All events are monitored for accuracy, 
and random monitoring is performed at participating centres to ensure 
complete ascertainment of events.  Low risk  
adjusted for age, gender, cohort, mode of HIV 
acquisition, ethnic group, calendar year, body 
mass index, any previous cancer, previous 
AIDS diagnosis, smoking status, and HCV and 
HBV status. Time updated covariates used.  
Medium risk 
Increasing time on PI associated 
with increase in anal cancer, no 
association with NNRTI 
Burgos et al, 
2015 
All MSM with HIV attending the HV unit at University Hospital Vall d’Hebron (Barcelona, 
Spain) and the University Hospital of Mar (Barcelona, Spain) were informed of the screening 
programme (The Screening and Treatment of Anal Dysplasia Unit), created in May 2009 in the) 
and participation was advised. Between 2009-2014, 47% of all MSM attending the HIV units of 
both hospitals agreed to participate. Not clear reasons for refusal or description of men refusing to 
participate. Medium risk (selection bias) 
 
Anal cytology followed by a digital anorectal examination (DARE) and 
HRA, including topical application of 3% acetic acid and lugol solution 
in the anal canal. Anal biopsy was performed from abnormal areas 
revealed by HRA. In cases with previous HSIL or ASCUS but with no 
visible lesions on HRA, a random biopsy of the squamocolumnar 
junction area was performed. Histology specimens were classified 
according to the Bethesda classification; 26% men had biopsy taken. 
Random biopsy included but no review of pathology indicated. Low 
risk 
adjusted for stable sexual partner, anal 
cytology result, abnormal HRA, HPV16/18 
infection High risk 
ART use, stable sexual partner, anal 
cytology result, abnormal HRA, 
HPV16/18 infection 
Burgos et al, 
2015 
MSM with HIV attending the HV unit at University Hospital Vall d’Hebron (Barcelona, Spain) 
and the University Hospital of Mar (Barcelona, Spain) were informed of the screening programme 
(The Screening and Treatment of Anal Dysplasia Unit), created in May 2009 in the) and 
participation was advised. Patients with previous intra-anal HGAIN who received treatment 
(electrocautery and ablation) and histological documented successes were included in this study. 
All patients have a biopsy-proven response obtained within 6-8 weeks after last treatment. Of 692 
MSM participating in screening programme, 185 (27%) presented with or developed intra-anal 
HGAIN. Of these, 141 accepted to be treated with electrocautery of which 100 achieved a 
successful treatment )complete or partial response confirmed based on post treatment biopsy) and 
were included in this analysis. Small samples (generalizable?). Medium risk  
Approx 6-8 weeks after treatment, men underwent another evaluation 
involving HRA and biopsy. Biopsies were taken from sites where 
HGAIN was previously reported to assess response to treatment. New 
anal biopsies were obtained from areas that were suspected for HGAIN 
recurrence (the same site or a different site from a previously high-grade 
lesion). If no changes suggestive of high-grade lesions were noted based 
on HRA, but ASC-H or HSIL cytology suggested presence of a lesion, a 
new HRA was conducted to perform random biopsies of the 
squamocolumnar junction. Recurrent HGAIN was defined as biopsy-
proven intraanal HGAIN diagnosed at follow-up subsequent to prior 
successful treatment. Complete response (CR)was defined as the 
resolution of AIN on the posttreatment biopsy, and partial response (PR) 
was defined as regression from highgrade to low-grade AIN. Low risk 
ART not associated with recurrence in 





HepC antibodies, nadir CD4+ <200 
and previous large HGAIN were 
associated with increased risk of 
recurrence. 
 
Cachey et al, 
2014 
Retrospective inception cohort analysis of HIV infected patients attending University of 
California, San Diego (UCSD) Owen Clinic between 2001 and 2012. Included patients had at 
least two cytology results without diagnosis of invasive anal cancer (IAC) or at least one cytology 
result if subsequently diagnosed with IAC. Patients diagnosed with IAC within 180 days of first 
anal cytology test were excluded to avoid prevalence bias. Overall, 71% patients attending the 
clinic were screened for anal cytology at least once. Inclusion of patients who underwent IRC 
ablation. Screening uptake differentially associated with being MSM, non-white and older. Low 
risk 
All participants underwent DRE and anal cytology collection at first 
clinical evaluation and annually thereafter. Patients with abnormal 
cytology (ASCUS+ ) were referred to HRA. Due to limited availability, 
those with HSIL lesions symptoms or DRE abnormalities were 
preferentially triaged to HRA. Cytology rather than histopathology used 
as outcome in order to avoid selection bias introduced by restricting 
analysis to patients who had undergone HRA procedures. Cytology 
smears reviewed at UCSD pathology laboratory. Anal cancer diagnosis 
ascertained by linking the clinic oncology database to UCSD Cancer 
registry and verified using UCSD histopathology reports. High risk   
ART as time dependent variable 
Low risk  
Anal cancer not found to be 
associated with any of the 
covariates (IRC ablation, ART, 




Cross-sectional analysis of participants enrolled in Wonen’s HIV cohort of the Evandro Chagas 
Clinical Research Instiute (IPEC) at Fiocruz, Rio de Janeiro. Participants in the IPEC women’s 
HIV cohort ≥18 years were invited by their gynaecologists to participate in the IPEC Women’s 
HIV anal HPV and Lesions Study.Swab specimens were collected by on site gynaecologists 
between Jan 2011 and Aug 2013.   
Women in this cohort regularly receive cervical pap smears (cervical lesions found to be 
associated with ASIL and so may not accurately reflect those of WLHIV in Brazil). Large sample. 
Low risk 
Anal cytology performed in Sao Paulo using Bethesda classification. 
High risk (no histology) 
Unadjusted for ART in MVA (lack of 
association in univariate). Associations of PVL 
and nadir CD4+ and ASCUS+ were adjusted 
age, cervical cytology abnormalty, anal HR-
HPV. No association with high risk sexual 
behaviour, including RAI. High risk 
ASCUS+ associated with cervical 
LSIL+, nadir CD4+, HIV PVL 
detection and anal HPV in MVA.  
Chao et al, 
2015 
Cohort study of adult HIV infected patients within Kaiser Permanente Northern California 
(KPNC) and Kaiser Permanente Southern California (KPSC) from 1996-2008. HIV infected 
persons were identified KP maintained HIV registries. Eligible participants included adults ≥18 
years HIV infected who were KP health plan members during the ART era, only participants for 
whom duration on ART was known were included. The baseline date for analysis was assigned as 
earliest date after 1996 for KPNC and 2000 for KPNC. Low risk 
Incident cancers were identified by record linkage with the KPNC and 
KPSC cancer registries, contributing sites to the Surveillance, 
Epidemiology and End Results (SEER) program. Cancer case 
ascertainment considered highly valid since reporting of cancers to the 
California Cancer Registry and National Cancer Institute SEER 
program mandated under state law. Low risk 
Adjusted for time updated CD4 and HIV PVL  
Adjusted for sexual orientation but no data on 
sexual behaviour and history of unprotected 
anal sex. Low risk  
 
Chaves et al, 
2012 
Anal smear screening was offered to all women infected with HIV seen at the outpatient sexually 
transmitted infections clinic of Hospital de Clınicas de Porto Alegre, Brazil, from March 2006 to 
March 2008. The test was performed only on patients who provided 
written consent. Low risk 
Anal cytology. No independent verification noted. High risk  
 
Crude estimate only. High risk   
Chiao et al, 
2013 
Veterans Administration (VA) Clinical Case Registry (CCR) is a nationwide registry for all 
known HIV infected persons utilising VA services established in 1992. Study population 
comprised of HIV infected male veterans entered into the registry between Jan 1985 and Jan 2009. 
Squamous cell cancer of the anus (SCCA) was defined as ICD-9 codes 
154.2 and 154.3. These codes were previously validated in the VA, with 
PPV of 88%. Low risk 
Age adjusted. CD4 and HIV PVL time 
dependent variables. Crude estimate given for 
ART. HIV VL estimate among ART users only 
History of drug use, race. Nadir 






Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
INnclusion criteria included well documented HIV diagnosis dates, patients over 18 years, 
confirmed HIV diagnosis, or at least one prescription for ART. Female veterans were excluded 
because they represented a small percentage of the population (2%). Patients with anal cancer 
diagnosis up to 90 days after HIV diagnosis were excluded, as were persons without CD4 count 
data over follow up. Only those patients with at least one HIV viral load were included. Low risk 
, generalizable to male veterans only.  
and adjusted for age at time of ART initiation, 
race, time from HIV diagnosis to ART 
initiation, illegal drug use, current CD4+ and 
duration of HIV viral undetection. No 
stratification by sexual orientation. Low risk 
undetection associated with anal 
cancer.  
Cheng, 2014 Cross sectional study among HIV positive men attending outpatient clinics of Taoyuan General 
Hospital, a regional hospital in northern Taiwan where 500 HIV infected patients receive regular 
follow up were invited to participate in the study. Participation rate was 52% and high proportion 
of injection drug users in the non-participants compared to final sample. Medium risk  
Anal swabs were self-collected after receiving instructions. Anal 
cytology using liquid based thin preparation Pap smears sent to certified 
laboratory where two cytopathology technicians and two blinded 
pathologists evaluated pap smears. Results classified according to 
Bethesda 2001 System. High risk  
Authors do not report proportion of ART users, 
although nadir CD4+ and HIV PVL given  
ASCUS+ associated with MSM, 
number HR-HPV types, after 
adjustment for age, experience of 
web sex, nadir CD4 and HIV PVL.  
Chikandiwa 
et al, 2017 
Baseline data from men living with HIV enrolled in a prospective cohort study to evaluate the 
natural history of HPV infection and disease in HIV-infected men in South Africa between 
October 2012 and August 2013, men in the community or attending HIV clinics were approached 
and asked to volunteer for the study. Potential participants were screened for eligibility and 
enrolled if they were willing to provide informed consent, 18 years or older, reported at least one 
episode of sexual intercourse in the past 3 months and were HIV positive on rapid testing. Low 
risk 
 
Anal smears were stained by the Papanicolaou stain before being 
analysed and classified according to the Bethesda System. Smears were 
read independently by a cytotechnologist and one cytopathologist at the 
NHLS in Johannesburg. If there was a discrepancy between these two 
readings, the smear was given to a second cytopathologist. Grade 
ASCUS or higher was considered abnormal. High risk   
Adjusted for age. Although duration ART, 
CD4+ count and virological control status not 
associated with ASCUS+. High risk   
Current ART use associated with 
increased risk of ASCUS+ 
Chuang et 
al,  
During a 12-month period, men and women, 18–65 years of age, were either self-referred or 
referred by community physicians for anal dysplasia/cancer screening in collaboration with the 
Hawaii Center for AIDS, University of Hawaii (UH), and UH Cancer Center. Subjects were 
included if HIV-positive regardless of previous history of HPV infection, anal dysplasia/cancer, or 
related treatment  
Small sample size and not stratified by gender or sexual orientation. Medium-high risk  
Two anal cytology specimens were collected with a Dacron swab and 
stored in ThinPrep. One anal specimen was processed by a CLIA-
certified clinical laboratory with cytopathology reviewed and reported 
by the same experienced cytopathologist according to the Bethesda 
system: anal cytology was evaluated, using criteria and terminology 
adapted from standardized cervical cytology screening. High risk  
Crude estimate only. Not possible to stratify by 
gender given small sample size. No data on 
sexual orientation or sexual behaviour.  
High risk 
ASCUS+ more likely among males 




As for Combes et, 2018 (HPV study).  
Study participants were HIV-positive MSM aged 35 years and older attending infectious disease 
units in six hospitals across France (Dijon, Lyon, Marseille, Montpellier, Paris, Rennes), recruited 
from December 2014 to June 2016. Ineligibility criteria included: history of anal cancer or of 
hHSIL treated during the last 12 months. Low risk 
Anal swabs taken for cytology and HR-HPV DNA. Participants 
received a proctologic examination including inspection, naked eye 
anoscopy, DARE, and HRA. Lesions identified by HRA were biopsied 
and processed for histological examination. Final histology diagnosis 
was established by a histopathology review panel: all slides 
concurrently read by pathologists from five of the six APACHES 
centres using a multihead microscope, blinded to HPV and cytology 
results. Low risk 
No adjustment for ART or CD4+ analysis. For 
PVL : adjusted for city, tobacco smoking and 
worst previous anal cytology/histology, High 
risk  
 
No adjustment for sexual behaviour |(but have 
adjusted for history of anal cyto/histo 
abnormalities). Medium risk  
HSIL-AIN2+ associated with city, 
smoking and history of anal lesions 
Conley et 
al,2010 
Prospective observational cohort (Study to Understand the Natural History of HIV/AIDS in the 
Era of Effective Therapy [SUN] study) of 700 HIV infected persons enrolled from 7 clinics in 
Denver, Colorado; Minneapolis, Minnesota; Providence, Rhode Island; St Louis, Missouri 
enrolled between 2004-2006. Approx 20% LTFU and 42% were ineligible for study on 
progression. Low risk 
 
Anal cytology (thinPrep) read by single cytopathologist, reported 
according to Bethesda. High risk 
Separate analyses for women, MSM and 
MSW. Associations of current and nadir CD4 
with ASCUS+ unadjusted among women and 
MSW, and adjusted for HPV genotypes among 
MSM. Adjustment for history of RAI and 
rectal STI for all groups, not included in MVA 
as no association, perhaps due to small 
numbers for individual groups. When women, 
MSM and MSW combined, history of RAI 
significantly associated with ASCUS+, as was 
nadir and current CD4+ and HPV genotypes. 
Low risk .  
Low nadir and current CD4 
associated with increased 
prevalence of ASCUS+ 
Conley et al, 
2016 
As for Conley, 2010. Of 700 participants enrolled in the SUN study, 297 (42%) had abnormal 
cytology at baseline, 50(7%) had unsatisfactory cytology or HPV specimen and 101 (14%) had no 
follow-up specimen.  Small sample. Medium risk  
As for Conley, 2010. High risk Separate estimates for women, MSM and 
MSW. Small numbers among individual 
population mean low power to detect different 
in associations. Low- Medium risk 
Among MSM, greater number of 
persistent HR types associated with 
progression. Among women and 
MSW, low CD4 count at follow-up 
visit and persistent HR types other 
than HPV16/18 were associated 
with progression.  
Cranston et 
al, 2014 
Retrospective chart review of patients attending University of Pittsburgh Anal Dysplasia Clinic 
(UPADC) with biopsy proven internal anal HSIL in a study to assess efficacy of topical 80% 
trichloroacetic acid (TCA) for treatment of biopsy proven internal anal HSIL, between July 2009 
and June 2012.  
The UPADC received referrals of HIV positive men and women with abnormal anal cytology. 
The UPADC database was searched using following criteria: male or female HIV positive patients 
with biopsy proven ain2+ who had TCA treatment only and had at least one follow up HRA visit 
at least 3 months after initial ablation procedure between July 2009 and June 2012. Low risk  
 
Initial assessment of participants included HRA (by two certified HRA 
providers) and biopsy of any suspicious lesion consistent with AIN2+.  
Images of lesions were captured using Second Opinion image capture 
software which allowed reidentification of index lesion during follow-
up. Low-Medium risk  
Analysis conducted on lesion-level data (98 
lesions among 72 men). Crude estimates 







Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
Cranston et 
al, 2018 
A multicenter, randomized, double-blinded, placebo controlled, phase III study was opened at 
selected ACTG sites (N = 24, 23 domestic US sites with 540 participants and one site in Brazil 
with 35 participants) with anal cancer screening programs that included capacity for anal 
cytology, HRA, and ready access to minimally invasive treatments for HSIL, such as topical 
application of trichloroaceticacid or infrared coagulation. At least 30% or 140 men were required 
to have bHSIL as were 50% or 50 of the women to ensure adequate power for the 
secondaryobjective ofthe studyassessing the effect of qHPV following treatment of bHSIL. 
Individuals with current invasive or microinvasive cancer were not eligible. Potential bias toward 
individuals with disease? Medium risk 
Participants had anal swabs taken for cytology. A certified HRA 
provider performed the screening HRA with biopsies of lesions 
suspicious for either HSIL, low-grade SIL(LSIL), or condyloma. All 
cytologies and anal pathologies were evaluated locally in College of 
American Pathologists accredited cytology/pathology laboratories in the 
United States, by local standard of care in Brazil. Low-medium risk 
 




Data from US Military Natural History Study (NHS) , a multicentre observational study which 
enrolled 5,042 HIV infected participants at 7 geographic locations in US between 1985-2008. 
Participants were military beneficiaries (active duty, retirees and dependents) evaluated on a 
biannual basis with medical histories and blood collection. Participants excluded from analysis 
were those without documented HIV positive test date, HIV infection diagnosed prior to 1985, age 
<18 years, with anal cancer prior to HIV seroconversion and females as they only accounted for 
8% of the study population. Low risk 
Anal cancer was histopathologically confirmed: types of cancer located 
in the anal area that were not confirmed to be squamous cell (e.g 
adenocarcinoma, carcinoid tumour, pre-invasive disease) were not 
included as anal cancer events but contributed to follow-up time in the 
models (n=4). Histopathologic specimens were not available for re-
confirmation or HPV testing. No data on staging and treatment 
information related to anal cancer. Low risk 
MVA adjusted for year of HIV diagnosis, time 
updated calendar year of event, age, variables 
that may change during follow-up (CD4+, HIV 
RNA, hep B infections, STI , AIDS events, and 
use of ART) were considered as time updated 
covariates. HIV RNA level (time updated) not 
associated with anal cancer). Low risk  
Nadir CD4 and AIDS event 
associated with anal cancer 
Dalla-Pria, 
2014 
Data collected from prospectively from HRA service available to PLHIV since 2000. Patients 
with anal symptoms routinely referred for HRA. Asymptomatic HIV positive MSM offered HRA 
on a voluntary basis. Authors suggest possibility of selection bias as high proportion of high risk 
men (32% with HSIL-AIN2+) who for reasons of lifestyle or past medical history were at higher 
risk of anal cancer. Patients attended on voluntary basis- potential for self/clinician selected bias. 
Medium risk  
Anal cytology and HRA exam with biopsies of viable anal lesions. 
Initial screening by HRA (and not cytology). Medium risk  
Crude estimates only. High risk  Higher grade histology associated 
with lower current CD4+ count (no 
estimate given). Progression from 
first HRA to anal cancer was 
associated with older age, and 
histopathological findings of AIN3 
(but not any HIV associated factors, 
although no estimates given).  
De 
Pokomandy 
et al, 2011 
Participants in the Human Immunodeficiency and Papilloma Virus Research Group (HIPVIRG) 
cohort were enrolled from January 2002 through January 2005. Men 18 to 65 years of age with a 
history 
of sexual intercourse with men who were receiving HAART (n= 221) or expected to be treated 
with HAART within the next 6 months (n = 26) were recruited.Of 172 paticipants without AIN2-3 
at baseline, 25 (15%) men were LTFU. Relatively small sample. Medium risk  
Anal cytology was conducted. High-resolution anoscopy (HRA) was 
performed at baseline and repeated yearly thereafter for those without 
AIN or with AIN-1 and was repeated every 6 months for individuals 
with AIN-2,3, if not treated. Aceto-white areas were biopsied and 
processed for routine histopathological examination. Histological slides 
were reviewed by 2 pathologists. Four participants with classical 
exophytic condylomas at the accrual HRA never had a biopsy of these 
condylomas during the study period and were considered to have AIN-
1. The outcome of interest was histological diagnosis of AIN2-3 on 
biopsy specimens obtained during HRA. Some cases of AIN2-3 may not 
have been detected on first HRA resulting in underestimation of the 
baseline prevalence and overestimation of incidence of AIN2-3. Low-
Medium risk of disease misclassification. 
adjusted for number visits,  age, CD4+ at time 
of ART initiation, have removed HPV type (on 
causal pathway) ; finding is significant when 
remove HPV from model. Low risk  
Age, CD4+ at time of ART 
initiation and duration of ART use 
Dona et al, 
2015 
Male attendees of the STI/HIV unit of the San Gallicano Dermatological Institute (Rome, Italy) 
between August 2009 and June 2017 who were 18 years old or older and had reported at least 1 
instance of sexual intercourse with a man in the preceding 6 months were offered an anal Pap test 
and an HPV-DNA test, included HIV-infected MSM attending  the center for the management of 
HIV-1 infection or for the anal Pap test only. Low risk  
Cytological slides, obtained with a ThinPrep 2000 processor (Hologic), 
were read by 2 expert cytopathologists. Findings were classified 
according to the Bethesda guidelines. Medium-high risk  
 
Crude estimate only, although data on sexual 
behaviour including RAI was presented. High 
risk  
No associations observed between 
HIV related factors and ASCUS+, 
marginally associated with lower 
nadir CD4+  
D´Souza et 
al, 2016  
Men enrolled in the Multicenter AIDS Cohort Study (MACS) , a prospective study of HIV-
infected and uninfected MSM, across four sites (Baltimore, Chicago, Pittsburgh, Los Angeles) 
over four enrollment periods (1984–85, 1987–1991, 2001–03, and 2010–12). All MACS 
participants who attended any MACS study visits between June 2010 and July 2011 were eligible 
to participate in the Anal Health Study (AHS) and were offered a free ACyt test by study staff. 
Men with an inadequate ACyt were offered another ACyt at their next study visit six months later. 
Low risk 
Liquid based cytology using Hologic T-2000 instrument. Specimens 
were initially screened for abnormalities by certified cytotechnologists 
and each was examined by a board certified cytopathologist.  Frequency 
of technically inadequate ACyt results was greater than expected from 
previous studies. High risk  
 
Crude estimate only (no MVA for prevalent 
ASCUS+). High risk 
ASCUS+ associated with 
decreasing CD4+ count  
D,Souza et 
al, 2008 
Men enrolled in the Multicenter AIDS Cohort Study (MACS) , a prospective study of HIV-infected 
and uninfected MSM, across four sites (Baltimore, Chicago, Pittsburgh, Los Angeles) over four 
enrollment periods (1984–85, 1987–1991, 2001–03, and 2010–12). Large proportion of men in 
the original MAC cohort died before HAART became available, many of these died before having 
the “opportunity” to develop cancer but still contributed to the longitudinal analysis competing 
risk could affect interpretation of longitudinal analysis. Medium-high risk  
 
 
Anal cancer cases included only men with T1 invasive cancer or rectal 
disease. Subjects self report of cancer was verified by histology report 
or cancer registry. When no medical documentation was available, self 
report of anal cancer by study subject was accepted (n=4). Histology 
reports and medical reports were collected, reviewed and summarised 
by trained abstractors and centrally re-reviewed for this paper. Tumor 
specimens were not available for histological review, testing or 
adjudication for these analyses. Incident anal, perianal and rectal ICD 
codes were classified together as anal cancer for these analyses. Low 
risk  
adjusted for number of unprotected anal 
receptive partners reported, smoking, nadir 







Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
Duncan et 
al, 2015 
A retrospective population-based cohort was created for this study from a linkage of health 
administrative data from two province-wide health databases: the British Columbia Cancer 
Registry (BCCR) and the HIV/ AIDS Drug Treatment Program (DTP) Registry. Data were 
obtained from the Anal Dysplasia Clinic database at St Paul’s Hospital. The linked cohort was 
further linked with the Anal Dysplasia Clinic database, established in 2003, to collect 
demographic, diagnostic, treatment and outcome data on individuals receiving screening or 
treatment for AIN at the Anal Dysplasia Clinic at St Paul’s Hospital. The population study 
cohortwas created by the BCCRand then populated by the DTP with ART-related information. 
The BCCR uses a probabilistic-match procedure on the basis of Personal Health Numbers, names 
and birth dates contained in the two registries to generate a province-wide listing of HIV-positive 
individuals in the DTP who were diagnosed with cancer or a precancerous malignancy. This 
cancer information was then augmented by the DTP with antiretroviral-related treatment 
information. Low risk  
The diagnosis of anal cancer was histopathologically confirmed and 
cancers located in the anus that were not confirmed to be invasive 
squamous cell carcinoma were excluded. Low risk 
Adjusted for nadir CD4+, ART starting prior to 
1995, percentage time CD4+ less than 100 




Women enrolled as part of the GRACE prospective cohort study, focussed on prevention of 
vaginal candidiasis infection and the natural history of anogenital HPV infection in HIV infected 
women. Study was conducted in  Connecticut and Massachusetts, USA from 1995-1998, women 
were recruited through a program of community outreach. Women were eligible if they were HIV 
infected, at least 18 years, English or Spanish speaking, not pregnant and not on long term 
antifungal medications.  
Women were seen for study procedures every 6 months. Of 225 enrolled in GRACE study, 73% 
returned for at least one follow-up visit., 100 of these women (61%) had satisfactory anal 
cytology. Small sample. Medium risk     
Aanl cytology smear taken, slides read by a pathologist using the 
Bethesda System (1996). Cytology specimens considered abnormal of 
result was ASCUS+. No review of cytology slides: 39% with 
unsatisfactory cytology smear at baseline and over follow-up. High risk  
 
HAART was examined as time dependent 
variable. -associated with reduction in 
incidence in univariate but not MVA following 
adjustment for CD4+, smoking and HPV type. 
No data on HIV PVL (HAART was introduced 
during course of study); Not adjusted for 
sexual behaviour (although no association 
found with anal HPV infection). Low-medium 
risk 
Incidence of ASCUS+ associated 
with low baseline CD4+ and 
smoking  
Frank et al, 
2018 
Retrospective chart review between December 1, 2013, and September 30, 2015 of patients at the 
Grady Ponce de Leon Center (Atlanta, GA). The Ryan White funded clinic provides 
comprehensive care for over 6,000 HIV infected patients annually,predominantly with advanced 
stages of HIV. Females were excluded from the chart review, Medium risk  
During the HRA visit, all patients underwent anal cytology collected in 
liquid media; HRA was performed by a single gynecologist. Abnormal 
lesions within the perianus and intraanal canal identified using 3% 
acetic acid or Lugol’s solution were biopsied.  
The majority of HRA patients, 143 (97%), had at least one biopsy; 2 
were unable to tolerate the procedure, 1 had no visible lesions, and in 1 
the practitioner was unable to adequately visualize the SCJ. Low risk 
Adjusted for number of biopsies taken, history 
of high-grade anal cytology, age and STI. 
High risk  
HSIL-AIN2+ associated with 
number of biopsies and history of 
high grade cytology  
Gaisa et al, 
2014 
Cohort study using data from treatment database of HIV infected outpatients engaged in care at 
three clinical sites. All HIV positive patients, irrespective of gender and sexual behaviour were 
offered anal cytology screening and referred for HRA if cytology was abnormal,  Patients with 
benign or inadequate anal cytology were not referred for HRA and not included in final analysis. 
Analysis includes only patients with abnormal anal cytology and HRA; bias towards individuals 
with disease (less likely to see difference in ART if fewer non diseased individuals?). 65% 
participants referred for HRA attended the HRA visit (similar among MSM, MSW and women). 
High risk  
Biopsy indicated if cytology ASCUS+ and HRA abnormal. HRA was 
performed among participants with ASCUS+ on cytology only after 
treatment with 3% acetic acid and Lugol’s iodine. Areas suspicious for 
HSIL or cancer were biopsied. If no lesion was seen, then no biopsy was 
taken and the patient was scored as having a ‘benign’ examination. 
Random biopsies of normal appearing tissue were not performed in this 
study. No review of pathology. Medium risk 
Estimate adjusted for age, sexual risk group, 
receptive anal intercourse (RAI), smoking, 
AGW and recent CD4+. Low risk 
HSIL-AIN2+ associated with RAI 
and lower CD4+ count 
Gaisa et al, 
2017 
Retrospective cohort study abstracted data from a longitudinal clinical database of HIV-infected 
women. Women were engaged in care at 1 of 3 clinical sites where they were offered anal 
cytology screening, and subsequently referred for HRA if anal cytology was abnormal. Women 
with benign or inadequate anal cytology were not routinely referred for HRA and were not 
included in the analysis of HRA results.  The primary analytic sample included 208 individual 
women with abnormal anal cytology who underwent HRA between April 2009 and July 2014. 
Analysis includes only patients with abnormal anal cytology and HRA; bias towards individuals 
with disease;  50% women referred for HRA attended the HRA visit. High risk 
As for Gaisa, 2014 
 
Crude estimate only. High risk   Smoking status associated with 
HSIL-AIN2+ (adjusted for RAI and 
current CD4+, age and years since 
HIV diagnosis)  
Gautam et 
al, 2018 
Cross-sectional exploratory study was conducted between 2014 and 2015 in HIV positive men 
attending the ART Center of Banaras Hindu University (BHU) with approximately 15,000 PLHIV 
registered in it. All HIV positive men above the age of 18, attending the ART centers were eligible 
for the study. Low risk 
Cytology smears were evaluated by a pathologist under light 
microscope and cytological changes were classified according to 
Bethesda system normal i.e. no cell changes; NILM (negative for 
intraepithelial lesions and malignancy) which includes inflammatory 
changes, organisms, atrophic changes and reactive changes; ASCUS 
(atypical squamous cells of undetermined significance) ; ASCH 
(atypical squamous cells cannot exclude a highgrade squamous 
intraepithelial lesion) ; LSIL (low-grade squamous intraepithelial 
lesions) and HSIL (high-grade squamous intraepithelial lesions) . Out of 
126 cases, 31 (25%) slides were broken, lost or found to be inadequate 
for result.  
Crude estimate only. High risk. history of anal intercourse (OR, 6.1; 
95% CI, 2.0– 18.7) p-value 0.00 
and WHO clinical stage (III+IV) 
(OR, 2.7; 95% CI, 1.1–7.5), p-value 
0.04) in univariate analysis 
Gimenez et 
al, 2011 
Cross sectional study conducted among 128 HIV-positive patients of both genders seen in the 
coloproctology outpatient clinic of the Tropical Medicine Foundation of Amazonas.  
Unclear on recruitment method. Participant demographics unclear, proportion female, sexual 
orientation and median age not given. High risk.  
Following anal canal cytological sampling, patients were submitted to 
HRA, by three colorectal surgeons after topical application of 3% acetic 
acid, in the anal canal, for 2 minutes. Biopsies of acetowhite lesions 
were performed. When no acetowhite lesion was observed, biopsies 
were performed in a standardized location (just above the pectinate line 






Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
at the 7 o’clock position, considering 12 o’clock the anterior 
commissure). Results (Table 2)do not clearly define outcome grade – 
understood to be AIN1+ .  Medium-high risk 
Gingelmaier 
et al, 2010 
Prospective study performed at a specialized gynaecological outpatient clinic for HIV-infected 
women at the University of Munich. Consecutive women with a known HIV infection who came 
for a gynaecological examination for different reasons between September 2007 and September 
2008 were included in the analysis. Small sample. Medium risk.  
 
Perianal cytology samples taken. Author do not specify how “abnormal” 
cytology is defined, but assumed to be ≥ASCUS (according to 
Bethesda). If the cytology was suspicious of a low-grade or high-grade 
lesion, high resolution anoscopy (HRA) and anal biopsy of visible 
lesions were undertaken. Medium-high risk  
Crude estimate only. High risk None 
Goeieman et 
al, 2017 
As per previous. Low risk  Participants with an abnormal anal cytology defined as 
atypical squamous cells (ASC) or greater, and 20% of those with a 
negative cytology were asked to return for HRA with biopsy of visible 
lesions.Authors suggest potential underestimation of the HSIL-AIN 
prevalence (60% of NILM on cyto were LSIL on HRA). Quality 
assurance activities included quarterly reviews of digital HRA 
photographs and periodic in-person observation and mentoring of HRA 
procedures. The pathologists were not masked to the cytology results 
but were masked to the HRHPV results. Histology specimens were 
interpreted by multiple pathologists from the South African National 
Health Laboratory Service in Johannesburg. Low risk 
Adjusted for HIV related factors where 
associations found in MVA. No data or 
adjustment for receptive anal intercourse. 
Medium risk  
No relationship between CD4+ and 
anal HSIL –possible ascertainment 
bias of HSIL.  
Goldstone et 
al, 2019 
a randomized, open-label trial in HIV-infected participants comparing the 1-year clearance of 
biopsy-proven intra-anal HSILs treated with IRC with regression of HSILs absent treatment at 7 
US AIDS Malignancy Consortium (AMC) trial sites (ClinicalTrials.gov No. NCT01164722). 
Participants were recruited between 2011 and 2014. All clinicians performing HRA and IRC were 
certified according to standards developed by the AMC HPV Working Group. Study participants 
were HIV-infected adults aged ≥27 years with 1–3 anal canal HSILs (index lesions). At 
enrollment HRA determined the presence of ≥1 previously identified, biopsy-proven index HSILs. 
Study participants were randomized 1:1 to HSIL ablation with IRC or active monitoring (AM) 
Treatment arm (TA) participants were seen every 3 months for digital 
anorectal examination, anal cytology, and HRA with biopsy of areas 
with suspected HSILs. After ablation, HSILs were characterized in 2 
ways: at the site of the original index lesion (recurrence) or at a new site 
(metachronous). Biopsy-proven recurrent or metachronous HSILs were 
treated with IRC within 4 weeks of diagnosis. Participants were 
followed up for 24 months after baseline treatment. At 12 and 
24 months, TA participants underwent biopsy at index lesion sites (even 
if no lesion was seen) and sites with lesions suspected of being new 
HSILs. 
Study participants in the AM arm were examined by means of digital 
anorectal examination, anal cytology, and HRA every 3 months. Anal 
biopsy specimens were obtained only for lesions suspected of possible 
progression to invasive cancer. At 12 months after enrollment, AM arm 
participants underwent biopsy at index lesion sites (even if no lesion 
was seen) and sites with lesions suspected of being new HSILs.  
Anal biopsy specimens were interpreted at local site laboratories. 
A single pathologist reviewed biopsy specimens centrally. Discordant 
interpretations were reviewed and adjudicated with a second central 
pathologist. The central pathology interpretation was used for analysis. 
If a biopsy specimen was not available for central review (for 4 follow-
up biopsy specimens through 12 months), the local histology result 
was used.  
The primary end point was complete index lesion clearance (CILC) at 
month 12. In the TA, CILC was defined as no biopsy-proven HSIL at 
the site of all index lesions from the time of the initial treatment through 
month 12. In the AM arm, CILC was defined as regression of all index 
HSILs to LSILs or normal findings at month 12. 
Association of ART and lesion clearance 
adjusted for treatment arm (infrared 
coagulation vs. no treatment but active 
monitoring) , clinic site of recruitment and 
number of index lesions 
Complete lesion clearance 
associated with IRC treatment, 
clinical trial site and smaller 
number of index lesions 
Gonzalez et 
al, 2013 
CoRIS-HPV is a cohort study within CoRIS, an open, prospective and multicenter cohort of adult 
patients with confirmed HIV infection and naïve to antiretroviral treatment at study entry, 
established in January 2004 in 30 sites from 13 of Spain’s 17AutonomousCommunities. CoRIS-
HPV was set up in 2007 with the objective to study the epidemiology of HR-HPV infection in 
MSM. Low risk  
Anal cytology samples were obtained in Thinprep. most of them 
(83.0%) were read by two independent cytologists, and those with 
discordant results were re-evaluated to achieve a consensus diagnosis.  
High risk (cytology only)  
Crude estimate only. High risk   
Goodall et 
al, 2012 
Case-notes of all (n= 287) HIV-positive MSM attending HIV clinic at Chalmers Sexual Health 
Centre over a 12-month period after implementation of protocol for anal cytology screening for 
HIV positive MSM on a yearly basis were reviewed. Of 285 HIV positive MSM seen during this 
period, 25% were not offered anal cytology screening. Of those that were offered, 38% declined 
(of 285 MSM, 47% men had a cytology result included in the final analysis). Patients not offered 
anal cytology screening were more recently diagnosed with HIV, were less likely to be on ART 
and have a higher nadir CD4+. High-medium risk  
LBC material was examined by a pathologist and graded as normal, 
insufficient sample, and abnormal ( mild dyskaryosis, moderate 
dyskaryosis or high-grade dyskaryosis.) High risk (cytology only) 
Crude estimate only. High risk ART status, previous AGW and CT 
infection (not evaluated in MVA) 
Guiguet et 
al, 2009 
Large prospective hospital cohort – French Hospital Database on HIV (FHDH-ANRS CO4). 
Patients infected with HIV-1 were eligible if they had never received ART before enrolment in the 
Clinical events were recorded with International Classification of 
Diseases (ICD) definitions (version 10). Disease misclassification could 
Adjustment for age, sex and HIV transmission 
group, and sub-Saharan origin. ART not 
Anal cancer associated with 






Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
FHDH cohort, had never been included in a double-blind clinical trial, and had not been diagnosed 
with cancer before 1998 (which could act as  competing risk).Patients were excluded if 
information about AIDS defining events was incomplete,  Patients were followed up until 
diagnosis of cancer, death, the end of follow-up, or Dec 31, 2006, whichever occurred first. Low 
risk 
have occurred; however, because of the magnitude of person-time in the 
cohort, the probability of being wrongly classified as having a 
malignancy will be negligible, limiting bias for the rate ratios. No 
histopathological diagnosis but ICD10 codes selected because they were 
validated and found to be highly sensitive to a diagnosis of invasive anal 
cancer. Low risk 
included in the model . Almost all anal cancer 
cases were receiving ART.  Low risk  
 
(>100,000 c/ml) HIV VL duration 
with low CD4+, HIV transmission 
group (IDI and women at lower 
risk). 
 
Heard et al, 
2015 
A cross-sectional and screening study nested within the VIHGY cohort, a multicenter study of 
HIV-infected women conducted in 5 sites within France. Women were recruited for this substudy 
during their first VIHGY visit in 2012 at 3 of the VIHGY hospital sites: Paris-Pitié-Salpétrière, 
Colombes-Louis-Mourier, and Marseille-Sainte Marguerite. Women were eligible if they had no 
history of anal cancer, and were invited to participate in a 2-step study: (1) anal HPV specimen 
collection during the gynecological visit and (2) to undergo an HRA at specialized anal dysplasia 
clinics. Of 171 women enrolled, 36% were from SSA. Contemporary cohort of WLHIV receiving 
effective ART and regular gynaecological follow-up. Of 352 women invited to participate, 91% 
accepted. Of these, 54% attended the HRA exam. These women were older with higher median 
CD4+, more received ART with undetectable PVL . Bias towards women with well controlled 
HIV (less likely to see impact of ART, PVL). Significant loss to follow-up (to HRA). 
Low/medium risk 
 
Anal swab specimens were collected for cytology before the physical 
examination, which included a DARE. HRA was performed by trained 
anoscopists without knowledge of the cytology and HPV results. 
Acetowhite areas were biopsied and processed for histological 
examination. Anal cytology and biopsies were read in local laboratories, 
blinded to the HPV result, and then reviewed centrally. If no biopsy was 
taken, histology was considered to be benign, provided that the HRA 
was normal. Composite endpoint of the most severe diagnosis on 
cytology or histology. In absence of histology, the grade was based on 
cytology alone. If the anal cytology was unsatisfactory, and the HRA 
was normal, those who were HPV negative were categorized as benign. 
Women with unsatisfactory cytology and no biopsy were excluded from 
the analyses if HR-HPV was positive. HG-AIN+ was defined as 
histological HG-AIN+ or HSIL on cytology, in the absence of biopsy. 
Low risk  
Unadjusted estimate (HIV related factors not 
significant in MVA; no data on sexual 
behaviour). High risk 
Strongest predictor was history of 
cervical lesions and concurrent 
HPV16 anal infection  
Hessol et al, 
2009 
Study nested within the Women’s Interagency HIV Study (WIHS), a prospective study of HIV-1 
infection in women, conducted in five locations within the United States. . Briefly, between 
October 1994 and November 1995, 2056 HIV-1 infected and 569 uninfected women were 
enrolled. A second enrollment, between October 2001 and September 2002, added 737 HIV-
infected and 406 HIV-uninfected women. Women were recruited in years 2001–2003 from the 
Brooklyn, Chicago, and San 
Francisco Bay Area WIHS sites. Women were eligible if they had no history of HGAIN or anal 
cancer. Low risk.  
 
Women with abnormal anal cytology were referred for HRA and biopsy 
of visible disease. Among the 148 women with abnormal anal 
cytology results, 50% had anoscopy and 41% had a biopsy for 
histological evaluation. Grade of the lesion defined as the more 
advanced diagnosis on cytology or histology when both were available. 
In the absence of histological data, grade was based on cytology alone.  
Medium risk  
Estimate adjusted for age, smoking, CD4+, 
PVL, anal HPV, cervical HPV, but not nadir 
CD4+ or duration on ART. Medium risk   
Anal HPV only significant factor 
associated with HSIL-AIN2+  
Hessol et al, 
2007 
All adult AIDS cases aged 16-86 years whose AIDS was initially diagnosed between 1990-2000 
were identified from the San Francisco, California AIDS surveillance registry. AIDS cancer 
patients were matched cancer cases diagnosed between 1985-2002 in the California Cancer 
Registry, a statewide population based registry. Of 17,709 adult AIDS cases initially identified, 
12% were excluded s they were non-San Francisco residents at the time of AIDS diagnosis, 8% 
were excluded as they had no information on HAART use or were lost to follow up. Low risk 
Each cancer was classified by using the SEER program site recoding 
which is based on ICD10 FOR Oncology. Low risk  
Adjusted models considered year and ART era 
(Jan 1996 or later) as time varying covariate, 
age at AIDS diagnosis, race, HIV transmission 
group and gender. Medium risk (no 





Cross-sectional study conducted between May 2010 and Sept.2013 in a cohort of 140 patients 
with HIV-MSM recruited consecutively into a program of screening, diagnosis, treatment and 
follow-up of dysplastic lesions of the anal mucosa. The HIVpositive patients were from among 
those receiving care in the Infectious Disease Unit of the Hospital Universitario Virgen de las 
Nieves (Granada, Spain) The inclusion criteria were: adult (≥18 years of age) MSM infected with 
HIV. The exclusion criteria were: females, heterosexual HIV-positive males, and history of anal 
canal neoplasia at the time of recruitment into the study. Low risk 
Cytology using the ThinPrep Pap Test; the same senior pathologist 
carried out the cytology evaluation, validation of the PCR, and histology 
analyses. Anoscopy was performed; samples were taken for histology 
examination not only from the lesions (color change with irrigation 
with 5% acetic acid), but also from other parts of the quadrant with 
ostensibly-normal mucosa. No pathology review. Medium risk.  
 
Estimate adjusted for perianal condylomas, 
HPV68, previous syphilis diagnosis 
No data on RAI. High risk  
AIN2+ associated with ART status, 
perianal condylomas, HPV68, 




As for Hidalgo-Tenorio et al, 2014 (cannot rule out the possibility this cohort may be the same as 
Hidalgo-Tenorio et al, 2014, or different individuals). Medium risk  
As for Hidalgo-Tenorio et al, 2014, Medium risk.  
 
Unadjusted estimate for ART. PVL estimate 
adjusted for HPV68, previous syphilis 
diagnosis. No data on RAI. High risk  
AIN2+ associated with HIV PVL 
detection, HPV68, previous syphilis 
diagnosis 
Holly et al, 
2001 
Participants recruited from November 1995 to January 1997 from women who were participating 
at the San Francisco Bay Area site of the multicenter Women’s Interagency HIV Study (WIHS); 
baseline visits (study entry) occurred from October 1993 through November 1994, with follow-up 
evaluations at 6-month intervals. A total of 251 HIV-positive and 68 HIV-negative women were 
enrolled. May include some women in the pre-HAART era. Medium risk  
Anal cytology was evaluated by an experienced pathologist who had no 
knowledge of the clinical status of the participants, their questionnaire 
responses, or other test results.  
HRA conducted if they had abnormal anal cytologic results. Women 
who consented underwent an anal biopsy if a lesion was present. If more 
than one lesion was seen, biopsy specimens were obtained from areas 
with different colposcopic appearances. Low-medium risk  
 
Estimates for PVL and CD4+ adjusted for anal 
HPV, history of anal intercourse and 
concurrent cervical cytology abnormalities. 
Low risk  
ASCUS+ associated with HIV PVL 
detection, anal HR-HPV detection, 
history of anal sex and concurrent 
cervical cytology abnormalities 
Lacey et al, 
1999 
In January 1994 HIV positive homosexual men were recruited for this study. Subjects were 
recruited from a larger cohort (300 patients, 33% CDC group C) attending North Manchester 
General Hospital for their HIV care. Medium risk (low number) 
Anal cytology and anoscopy conducted on all.  All cytology smears 
were examined by one observer who had knowledge of the previous 
results but not of the clinical findings at the time when the smear was 
taken. High risk  
Crude estimate only. High risk   
Libois et al, 
2017 
Since June 2011, a systematic anal cancer screening programme is offered to all HIV-positive 
MSM followed at the AIDS reference centre of Saint-Pierre University Hospital in Brussels, 
where 2950 patients who are HIV positive (33% MSM) are currently in care and included in the 
Anal swab for cytology was followed by HRA in case of any significant 
abnormalities at cytology. In case of abnormal cytology (including 
ASC-US), HRA with biopsies was performed by a single 
Adjusted estimate for ART status, adjusted for 
age only (though other HIV related factors not 
found to persist in MVA) Low risk.   







Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
Saint-Pierre HIV Cohort. Between June 2011 and February 2013, patients who performed this 
screening and had appropriate follow-up (normal swab or HRA with biopsies in case of abnormal 
cytology) were included in this cross-sectional study. Low risk 
gastroenterologist , specifically trained in HRA. Immunostaining for 
Ki67 and P16 was routinely carried out on all biopsies as help for 
histological grading of lesions. The same expert pathologist assessed all 
the samples. The first 250 anal cytology samples were blindly reviewed 
by another pathologist with international experience in quality control. 
Medium risk  
 
Li et al, 
2009 
Cross-sectional study of anal Pap smear results and linked clinical, sociodemographic and 
behavioural information collected at the TRC-ARC in Bangkok. The Thai Red Cross AIDS 
Research Centre (TRC-ARC) began offering anal Pap smear as part of an annual health 
examination programme to HIV positive and HIV negative MSM in January 2007. Participants 
were those receiving anal Pap smears between January 2007 and April 2008. Participants were 
part of a self-pay service cohort and may not be representative of all Thai MSM due to the cost of 
Pap smear screening. Our clients receiving anal Pap smears had on average twice the median 
household monthly income of all Thais surveyed at the TRC-ARC. This difference in 
socioeconomic status may result in lower ASIL prevalence due to better access to health care. 
Small sample size – unclear how the men were selected for inclusion. High risk 
Anal Pap smears were performed ; a cytotechnician screened all slides 
and positive slides were re-screened by the head cytotechnician. High 
risk  
Adjusted for age, CD4+ count, anal condyloma 
symptoms. Sexual behaviour not included in 
MVA model. Low risk  
ASCUS+ associated with anal 
conyloma only  
Limia et al, 
2017 
Cross-sectional study to detect ASIL and HPV infection. Study participants were outpatients 
of the sexually transmitted diseases (STD) clinic at the Institute of Tropical Medicine “Pedro 
Kourí” recruited between April and August 2012. Those eligible to participate were HIV-positive 
males with a history of a previous or current STD, willing to give informed consent to an 
interview and tests for anal HPV infection and anal cytology. Small sample. High risk  
Outcome is 6 high risk types only (16, 18, 31, 33, 45, 58). High risk  Crude estimate only. High risk   
Liu et al, 
2018 
The Mount Sinai high-resolution anoscopy (HRA) database was searched from 2009 to 2016 for 
patients diagnosed with anal LSIL by HRA-guided biopsy. Patients meeting the following criteria 
were included in the study: no prior history of HSIL, initial HRA and biopsy revealing 
LSIL without any concomitant HSIL, and surveillance HRA and biopsy of the index LSIL site 
having been performed within 2 years of initial diagnosis.  Individuals with risk factors for anal 
cancer were screened by either primary care physicians or infectious disease/HIV specialists using 
anorectal cytology (ARC). Patients were offered referral for HRA and biopsy of lesions suspicious 
for HSIL or cancer if ARC was abnormal (ASCUS+). Medium risk 
All patients underwent HRA examination and biopsy twice within 2 
years. On the basis of surveillance biopsy results, lesional outcomes 
were categorized as progression (if HSIL was detected at the prior LSIL 
site), persistence (if LSIL was detected) or regression (if benign mucosa 
was detected. Low risk  
Crude estimate only. High risk   
Machalek et 
al, 2016 
The Study of Prevention of Anal Cancer (SPANC) is a prospective study of HIV-positive and 
HIV-negative MSM,based in Sydney, Australia. Participants were recruited mainly from 
community based settings; about 35% of HIV positive and 5% HIV negative men were recruited 
through medical clinics.  
Eligible participants were men aged 35 years or older who reported sex with another man in their 
lifetime. Participants were excluded if they were unable to understand English, unable to attend 
scheduled visits, or were unwilling to undergo HRA, had bleeding disorder or were on anti-
coagulation medication. Men who previously received HRA or with a history of anal cancer were 
also excluded from the study. Low risk 
 
 
Anal swab collected for cytology analysis, followed by HRA with acetic 
acid and lugol´s iodine. Abnormalities suggestive of ASIL were 
biopsied for histological assessment. Men without visual abnormalities 
did not undergo biopsy. When a diagnosis of HSIL-AIN 2 was proposed 
based on histo-morphologic features on H&E stained slides, 
immunostaining for p16-INK4A was performed. Positivity of p16 
coupled with H&E features of AIN2 were both required for diagnosis of 
HSIL-AIN2. If p16 was negative, lesion was downgraded to LSIL or 
negative for SIL depending on other criteria. When multiple biopsies 
were taken, the result with the highest grade was used. ASIL disease 
classification based on composite endpoints of the most severe cytology 
or histology. Low risk 
                      
Adjusted for number HR-HPV types,and 
HPV16 positivity, age and smoking status.   
No associations observed with HIV related 
factors. Men with well controlled HIV may 
prevent observing any associations by HIV 
related factors (small number of men not on 
ART, with HIV PVL detection, low CD4+). 
Low-medium risk  
None observed for men with HIV 
Masia et al, 
2019 
A prospective study conducted in the HIV cohort from the Hospital General Universitario de 
Elche (Spain) between November 2013 and February 2017. Eligible participants were MSM 
≥18 years old, who were invited to be explored through high-resolution anoscopy (HRA) for 
screening of anal dysplasia and for anorectal secretion sampling for STIs investigation. Recent 
anorectal surgery was an exclusion criterion. Unclear recruitment method or number of refusals.  
Study participants underwent HRA, performed by a single, trained, 
infectious diseases specialist. The anal transformation zone and distal 
canal were afterwards explored using lugol solution. All suspicious 
areas were biopsied for a histopathological assessment. Lesions were 
classified by the Bethesda system into 3 categories: without dysplasia, 
low-grade dysplasia (AIN-I), and high-grade dysplasia (AIN-II/III). If 
multiple biopsy samples were taken at once, the sample with the highest 
AIN grade was considered. 
Crude estimate only   
Marra et al, 
2019 
HIV-positive MSM aged ≥18 years were recruited for a prospective cohort study in 2010–2011 at 
3 sites in Amsterdam, the Netherlands [19]. Participants were followed up approximately every 
6 months, up to 24 months. Independent of the H2M study, HIV-positive patients in regular care 
were offered HRA at 3 clinics in Amsterdam. Data of all HRAs of these clinics up to December 
2015 were extracted from patient records for research purposes and merged with the H2M data 
set. Only HIV-positive H2M participants who underwent a first HRA after their last H2M visit in 
1 of these 3 clinics were included in the present study. Only results of the first HRA of each 
participant were included. HIV-related data were obtained from the Dutch HIV Monitoring 
Foundation. Clinical information related to the HRA was obtained from the infectious diseases 
HRA consisted of a digital rectal examination, followed by intra- and 
perianal inspection with a high-resolution colposcope after repeatedly 
applying acetic acid (3–5% solution) and staining with Lugol’s iodine 
when indicated. Areas suspicious for squamous intraepithelial lesions 
were biopsied (151 or 78% men had at least one biopsy) The biopsied 
lesions were graded by specialized pathologists. In 2 out of 3 clinics, the 
pathologists used p16 staining for AIN2 grading of biopsies. The 
majority of AIN2 diagnoses were confirmed by p16 staining.The 
highest-grade biopsy defined the overall diagnosis.  
Crude estimate only  In a multivariable logistic 
regression, anal HPV16 and HPV35 
persistence remained significantly 
associated with anal HSIL (adjusted 
OR 2.41, 95% CI 1.09–5.35, and 







Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
physician or dermatologist. This is possibly the same cohort as that described by Siegenbeek et al 
(2017).  
Mbang et al, 
2015 
A retrospective cohort study of male US veterans with HIV who were diagnosed between 1985-
2010 using the Veterans Affairs HIV Clinical Case Registry (CCR) HIV-infected individuals were 
identified from the VA HIV clinical case registry (CCR). Established in 1992, the registry draws 
upon the electronic medical records of over 60,000 HIV infected patients diagnosed after1985 
who were ever cared for by the VA. The study population was restricted to HIV-infected veterans 
who were diagnosed between 1985–2010, were over the age of 18 with an identifiable HIV 
diagnosis date, or the earliest initiation of antiretroviral therapy. Individuals with only a single 
ICD-9 code for HIV and no lab or confirmatory pharmacy records were not included. Only men 
were included because of the small number of HIV-infected women veterans (<2%). Individuals 
excluded if date of death or censor was the same as their initial HIV diagnosis date. Only veterans 
ever receiving cART were included;  cART users with less than 90days of follow-up or without 
quantifiable CD4 or HIV RNA measurements within 90days of cART initiation were excluded. A 
total of 28,886 HIV-infected male veterans included in the registry (43%) met inclusion criteria. 
Low risk  
The primary endpoint was incident SCCA, identified from inpatient and 
outpatient ICD-9 codes154.2 and 154.3.These SCCA ICD-9  codes have 
been previously validated in the  VA and determined to have a positive 
predictive value of 88% . Prevalent SCCA cases (i.e., individuals 
diagnosed before or within 90days after the initial HIV diagnosis date) 
were excluded. The follow-up interval spanned from the index HIV 
diagnosis date to SCCA diagnosis, death, or  December 31, 2010(the 
final date of the current CCR iteration),whichever occurred first. Low 
risk  
adjusted for age at HIV diagnosis, 
race/ethnicity, illicit drug use, era of HIV 
diagnosis, Deyo comorbidity score, nadir and 
recent CD4, percent of time with undetectable 
HIV RNA, and number of HIV RNA 
measurements per year). No stratification by 
sexual orientation.  Low risk  
Protease Inhibitors associated with 
increased risk of anal cancer 
Time spent with HIV viral 





    
Palefsky et 
al, 2005 
MSM were recruited into this cohort study between February 1998 and January 2000 through 
newspaper advertisements and other community outreach at University of California, San 
Francisco (UCSF). Low risk  
Anal cytology (conventional, direct smears) was performed and 
interpreted using the Bethesda criteria. High-resolution anoscopy 
(HRA) after application of 3% acetic acid was completed with a biopsy 
of visible anal lesions unless there were medical contraindications. An 
anal biopsy was performed if one or more lesions were visualized. If 
more than one lesion was seen, biopsies were obtained from areas 
within the lesions that had different colposcopic appearances. A 
composite anal diagnosis based on cytology and histology was used in 
analysis. If both cytological and histological results were available, the 
diagnosis used for analyses was the more severe result. Participants 
were classified as normal if they had normal cytology and no lesions 
seen by anoscopy, or if both the cytology and histology results were 
normal. If a lesion was seen by anoscopy but not biopsied, the cytology 
result was used for diagnosis unless the cytology was normal. In that 
case, the diagnosis was considered indeterminate and the data were 
excluded from analysis. Medium risk.  
Adjusted for months of HIV positivity and age 
as a continuous variable; number of HPV 
types, CD4+ cell count, HIV viral load. No 
adjustment for sexual behaviour. Low risk  
HSIL-AIN2+ associated with 




Payam et al, 
2011 
Retrospective chart review evaluating the proportion of anal dysplasia among a multiethnic 
population from an ambulatory university-based HIV clinic in Hawaii. Unclear selection method 
and small sample.  
High risk 
Anal Pap specimens placed in a CytyoThinPrep medium and sent to a 
Clinical Laboratory Improvements Amendments (CLIA) certified 
laboratory for processing and diagnostic work up. If an anal Pap 
cytology result was abnormal, then the patient received 
recommendations for HRA. Biopsies obtained from the HRA procedure 
were sent to the same CLIA-certified laboratory for pathology 
diagnosis. An abnormal Pap smear was defined as anal dysplasia on 
routine Pap smear. Unclear outcome definition (ASCUS+?). No 
cytology review. Medium/high risk 
Crude estimate only. No data on sexual 
behaviour. High risk 
 
None reported in MVA 
Pereira et al, 
2008 
Descriptive study carried out in the Infectious and Parasitic Diseases Outpatient Clinic of the 
University Hospital of the Federal University of Pernambuco and in the Colposcopy and Lower 
Genital Tract Sector (SCTGI) of the same hospital from July to November 2006. Out of a total of 
118 male patients invited, a group of 60 agreed to take part in the study. Unclear selection criteria 
(eligibility) and reasons for refusal (49% refusals), small sample size. High risk 
Anal cytology performed; anoscopy was performed after cytology with 
acetic acid and lugol´s iodine and findings suggestive of anal lesion 
were biopsied (biopsy indicated by anoscopy only) Histological 
evaluation was carried out by a single pathologist. The outcome of 
interest was the presence of a perianal and an anal lesion characterized 
by the condyloma acuminata and intraepithelial neoplasia according to 
anuscopy under colposcopic vision summed to anal oncotic cytology 
and anal histology. Outcome in analysis assumed to be AIN1+.  
Medium-high risk  
Crude estimate only. No stratified analysis 
according to sexual behaviour/sexual 
orientation. High risk 
 
None reported in MVA 
 
Phanuphak 
et al, 2013 
Thai men aged ≥18 yrs with history of anal sex with men, with documented HIV positive status 
(within previous 30 days) and who visited Men’s Health Clinic at theThai Red Cross AIDS 
Research Centre in Bangkok, Thailand were consecutively enrolled over a 12 month period into 
this prospective study. MSM were excluded if they had prior treatment for anal cancer, anal 
cytology or HRA or infrared coagulation within 12 months prior to enrolment, trichloroacetic acid 
or podophyllin application to intra-anal area in past month, or evidence of active concurrent intra 
anal or perianal bacterial or HSV infection. Low risk 
Anal swab collected for cytology at baseline, month 6 and month 12 and 
added to liquid based medium. Anal cytology performed prior to HRA.  
All participants had HRA at baseline, month 6 and 12, regardless of anal 
cytology results by the same study physician. Abnormal anal tissue was 
biopsied. Histological diagnosis was made by three different 
pathologists; each pathologist was blinded to diagnosis of the other two 
pathologists. Discrepancies resolved through review and consensus. 
Crude estimates only (CD4 did not persist in 
MVA). High risk  
Persistent HPV16/18 associated 







Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
A composite anal diagnosis was used based on cytology and histology 
results. Cytology results were used for men with normal HRA findings 
and for men with abnormal cytology who refused a biopsy.  
Low risk .   
Piketty et al, 
2003 
Between June 1999 and October 2000, 120 HIV seropositive men attending the outpatient clinic 
of Hôpital Européen Georges Pompidou, Paris, France, were recruited in a cross-sectional study of 
anal HPV infection and anal SIL in HIV-seropositive men. Men were eligible for the study if they 
had acquired HIV through homosexual or bisexual contact or through injection drug use, were 
older than 18 years of age, and had absolute CD4+ cell counts less than 500 x 106 cells/L. 
Injection drug users who had sex with men were excluded from the study. The patients were 
recruited from a cohort of 1198 HIV-infected patients who were followed at the Clinical 
Immunology unit of Hôpital Européen Georges Pompidou. All patients were consecutively 
enrolled into the study. No eligible patient declined participation. Low risk  
When cytologic abnormalities were found (ThinPrep cytologic 
screening), consenting patients underwent anoscopic examination and 
biopsy with the use of a colposcope. If both cytologic and histologic 
results were available for analysis, a patient’s diagnosis was categorized 
as the more severe result. Definition of outcome is unclear but 
understood to be SIL-AIN1+ (composite cytology-histology endpoint) 
Medium-High risk 
Crude estimate only. High risk   Among IDU, low CD4+, HIV viral 
detection, AIDS defining illness 
and anal HPV. Among MSM, 
higher number sex partners and anal 
HPV.  
Piketty et al, 
2008 
Large prospective nationwide hospital cohort – French Hospital Database on HIV (FHDH-ANRS 
CO4) created in 1989. The only inclusion criteria are HIV-1 or HIV-2 infection and written 
informed consent. 
Patients were not eligible for this study of <13 years, not followed between Jan 1992 AND Dec 
2004, if they had less than 6 months follow up or if they had a history of anal cancer or ongoing 
anal cancer at FHDH enrolment, or if they were receiving ART in a double blind trial. Overall, 
86,332 were eligible for this study. Low risk 
ICD codes used by FHDH (ICD9 prior to 1997 and ICD10 thereafter). 
Available histological data was used to validate the diagnosis of 
invasive anal cancer and excluded all cases of carcinoma in situ. Eight 
cases were classified as presumptive anal cancer as no histological data 
was available. All cases of anal cancer were validated and 94% were 
histologically confirmed. Low risk 
Adjusted for age, HIV transmission route, 
nadir CD4+ , AIDS diagnosis before event, 
ART period. No data on HIV viral 
suppression. Low risk 
Anal cancer more likely among 
older participants, MSM, in patients 
with prior diagnosis of AIDS and in 
patients with lower nadir CD4+ 
Anla cancer more liely in recent 




HIV infected women who came for a routine visit at HIV clinic of Prapokklao Hospital, 
Chanthaburi, Thailand, between March 2013 and February 2014. Inclusion criteria were 
confirmed HIV infected women who visited Prapokklao Hospital HIV clinic during the study 
period. Exclusion criteria were if patients had active lower gastrointestinal bleeding, anal 
inflammation, acute anal fissure and those who declined to participate in the research. Unclear on 
recruitment method (number screening and enrolled) 
Medium risk 
Anal cytology using pap method and read according to Bethesda 2001 
System. Not clear if any review of cytology reading conducted. High  
risk 
Crude estimate only. High risk  In univariate analysis, duration 
since HIV diagnosis, duration on 
ART 
Powles et al, 
2008 
The Chelsea and Westminister cohort; people living with HIV seen at regular intervals for clinical 
assessment, attending since 1983.  Low risk  
The registration of cancers is checked by a dedicated HIV oncologist 
and also collected in a separate HIV cancer database. Observed numbers 
of anal cancer cases compared with expected numbers for the general 
population, derived from the Thames Cancer Registry. Low risk  
adjusted for age, sex, ethnic group, 
presence/absence of AIDS, nadir CD4 and 
duration of HIV infection. Low risk  
Low nadir CD4 associated with 
increased risk of anal cancer 
Richel et al, 
2013 
The study was performed at the HIV and dermatology outpatient clinics of the Academic Medical 
Center in Amsterdam, the Netherlands. All HIV+ MSM in care over 18 years of age were eligible 
if they did not have a history of anal cancer or current active inflammatory bowel disease. Of 656 
MSM invited for screening, 311 were eligible and consented (29% refused, 2% fulfilled exclusion 
criteria, 9% had significant comorbidity, 11% were excluded as they participate in co-existing 
study). Low risk  
Screening for AIN was performed by HRA by a single HRA 
experienced physician. Suspect lesions were biopsied for 
histopathological analysis, including Ki-67 and p16 immunostaining. A 
single pathologist evaluated all biopsies. If more than one biopsy was 
taken, the highest AIN grade was considered as outcome. 56% men had 
histologically confirmed AIN (AIN1+) ; remaining 44% did not have 
suspect lesions on HRA or AIN was ruled out in biopsies from suspect 
lesions. 305 men had HGAIN. Possibility too underestimate prevalence 
of disease using HRA as screen test. Medium risk.  
For ART status, HIV PVL and CD4+ count, 
crude estimate only (only duration ART, years 
since HIV diagnosis, anal ecstasy use, use of 
GHB and history of AGW associated with 
AIN1+ in univariate analysis). Separate MVA 
for HGAIN outcome did not find any 
association with HIV related factors (HIV 
PVL, nadir and current CD4+). Low risk  
 
Duration on ART (per year on 
ART) associated with AIN1+, 
adjusted for GHB use and anal 
ecstasy use. 




An open-labelled randomised trial to compare efficacy and side-effects of imiquimod, topical 
fluorouracil and electrocautery for the treatment of AIN. MSM with HIV aged ≥18 years visiting 
the HIV outpatient clinic of the Academic Medical Centre, Amsterdam, Netherlands were offered 
screening for AIN. Of 650 men screened for participation, 388 (60%) were eligible and consented 
to participate; of those 246 (63%) had AIN. Men with histologically confirmed AIN were 
randomly assigned to receive either 16 weeks of  imiquimod, 16 weeks of  fluorouracil, or 
monthly electrocautery for 4 months. Participants were assessed by HRA 4 weeks after treatment. 




At enrolment, all men underwent HRA. Suspect lesions were biopsied 
for histopathological analysis (assessed by a single histopathologist).  
Biopsy samples taken 4 weeks after last treatment date; samples were 
taken areas where AIN had been reported previously and if necessary 
from suspect lesions. Patients with persisting or progressing lesions 
were referred for further treatment and excluded from further study 
assessments. Complete response was defined as resolution of AIN and 
partial response defined as regression from HG to LG AIN. Low-
Medium risk  
Associations with duration on ART were 
conducted, irrespective of treatment used. 
Estimates were adjusted for type of treatment, 
years of HIV, current CD4+ and high grade 
AIN. Low risk  
Prolonged duration on ART was 
associated with complete or partial 
response to treatment.  
Richel et al, 
2015 
Data were selected from the ongoing AIDS Therapy Evaluation in the Netherlands (ATHENA) 
national observational HIV cohort, a nationwide data set, which includes anonymized data from 
all HIV-1–infected patients under care in the 26 HIV treatment centers in the Netherlands. 
Epidemiological, clinical, virological, and immunological data are collected retrospectively at 
entry in the cohort and prospectively thereafter 
cases of anal cancer were identified for the period 1995–2012 and 
incidence rates of anal cancer were calculated per 100,000 person-years 
of follow-up. Follow-up time was from the date of HIV diagnosis till the 
date of diagnosis of anal cancer, death, last clinical visit, lost to follow-
up, or closure of the database (February 1, 2013). Each treatment center 
was visited to verify the source documents and confirm pathological 
diagnoses. 
Association of nadir CD4 and anal cancer 
adjusted for alcohol abuse and smoking  
Anal cancer associated with a low 
nadir CD4 cell count, alcohol abuse 
and smoking (HR, 1.64; 95% CI: 
1.10 to 2.45 
Robbins et 
al, 2018 
Data from the MultiCenter AIDS Cohort Study (MACS), a cohort study of HIV positive and HIV 
negative MSM from 4 sites (Baltimore, Chicago, Pittsburgh and Los Angeles), visits occur every 
6 months. For this sub-study, all participants who attended any study visits between June 2010 and 
Cytology conducted; High number of inadequate cytology results. 
Outcome is abnormal cytology on first 3 consecutive abnormal cytology 
Adjusted for sexual behaviour.  High risk  Consistently abnormal cytology 
(ASCUS+) associated with current 






Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
July 2011 were offered a free anal cytology test. Men with unsatisfactory cytology result were 
offered another test at their next visit. HIV positive men were offered annual cytology up to 4 
cytologies in total. 
Men who had treatment of anal dysplasia between first and second cytology (n+38) were excluded 
from analysis. Of a total 709 HIV positive with baseline cytology test, 502 did not require 
treatment and had 2 valid cytology results, 328 had at least 3 valid cytology results and no 
treatment. Low risk  
smears compared to men with first 3 consecutive negative cytologies. 
High risk  
 
count , increased number of 
comdomless receptive anal sex acts, 
older age and race other than non-
Hispanic white.  
Rosa-Cunha 
et al, 2011 
From February to July 2006, patients 18 years and older with HIV infection attending routine 
clinic visits and two having no history of anal cancer or prior anal cytology screening were 
informed of the study. 
Of a total 160 HIV infected patients invited to participate, 131 (82%) agreed to participate; of 
those 98 (75%) had adequate cytology results and were included in final analysis. Small sample. 
Medium risk  
Anal cytology was performed and all samples were read by one 
pathologist. Patients with abnormal cytology classified as AS-CUS or 
greater referred for HRA with biopsy of visible lesions seen by addition 
of 3% acetic acid. HRAs were performed by proctology surgeons 
trained in HRA. Biopsy results were coded as the most severe category, 
if multiple biopsies were taken. Associations of ART and histologically 
confirmed AIN available for only 31 participants; results from 
cytology (outcome of cytology ASCUS+ presented in place).  High 
rate of inadequate cytology results 
High risk  
Crude estimate only (no MVA conducted) 
High risk 
None reported in MVA 
 
Rovelli et al, 
2017 
Retrospective observational study on HIV-infected male patients who were receiving primary 
inpatient or outpatient care for HIV infection at the Infectious Diseases Department of the San 
Raffaele Scientific Institute (Milan, Italy). Medium risk  
 
 
Cytology conducted using liquid based cytology preparation. Anal 
cytology findings were classified as normal if the finding was reported 
as negative and abnormal if reported as ASCUS or greater.  
Outcome in the risk factor analysis is LSIL/HSIL, High risk  
For CD4+ and ART, unadjusted estimates only 
(not found to be significant in univariate 
analysis). HIV PVL adjusted for age, HIV 
transmission route, yrs of HIV, HbsAg, 
previous AIDS diagnosis, previous syphilis 
diagnosis, CD4+/CD8+ ratio, number of HPV 
types and HPV16 infection. Medium risk  
Previous syphilis infection HIV 
PVL detection, HPV16+, number 
HPV types, 
Salit et al, 
2010 
Participants were part of the Toronto Research for Anal Cancer Evaluation (TRACE) anal cancer 
screening study and were enrolled between December 2001 and November 2005. All were HIV-
infected men aged 18 years or more with a history of anal receptive intercourse and who were 
attending tertiary care hospital HIV clinics or primary care clinics in Toronto, Canada. 
Participants were excluded if they had a history of anal cancer. At entry, none of the participants 
had known previous anal cytologic studies or anal biopsies, so no prior results were available. The 




Participants had concomitant anal cytology (Pap smears), HPV testing 
and HRA with directed biopsies. Evaluation of anal cytology  was 
performed on a specimen in liquid-based ThinPrep; HRA was done 
using a plastic anoscope with visualization of the anal squamocolumnar 
junction staining with 3% acetic and Lugol’s iodine. Biopsies were 
taken by endoscopic forceps from areas that appeared abnormal . Two 
anoscopists had received formal training in HRA and they examined all 
the participants. If anal canal at HRA appeared normal, no biopsy was 
taken and patient was designated as ´Normal´. Where multiple biopsies 
were taken, diagnosis of most severe histologic lesion was taken.  
Cytology and biopsy specimens were independently assessed by two 
experienced gynecologic pathologists using a multiheaded microscope 
and reached consensus on any specimen for which there had not been 
agreement in the independent review. Low risk 
Crude estimate only (not significant in 
univariate, no MVA). Medium risk  
 
 
AIDS-defining illness, low CD4+ 
and HPV types -16 and -31 
Sananpanich
kul et al, 
2015 
As for Pittyanont et al, 2014 Anal cytology using pap method and read according to Bethesda 2001 
System. Inadequacy of the collected specimen for evaluation was 34.4% 
(206/599). High risk  
Crude estimate only. High risk   
Scott et al, 
2008  
In November 2002, an anal cancer-screening program was implemented, using anal cytology, into 
HIV clinical care at Hospital of Saint Raphael (HSR) . All HIV infected patients seen at the HIV 
clinic at the HSR were offered anal cytology as part of routine clinical care. Outpatient charts 
were reviewed for all patients seen between November 2002 and November 2004 who had an anal 
cytology examination. 
Of 560 patients seen at HIV clinic, 276 (49%) had at least 1 pap smear and 265 (96%) had 
sufficient cytology results and were included in final analysis. Unclear selection criteria 
(significant proportion did not have anal cytology). High risk 
All samples were read by 1 pathologist at the HSR who was trained in 
interpreting anal cytology. Patients with insufficient cells on cytology 
slide or missing cytology results were excluded.  Patients with abnormal 
anal cytology findings, classified as ASCUS or greater, were referred 
for surgical evaluation and anoscopy. Anoscopy was preformed using a 
HRA with biopsy of any obvious lesions seen with addition of 3% 
acetic acid. Medium risk  
Results not stratified by risk group (gender or 
sexual orientation) nor adjusted for sex 
behaviour. Crude estimate for ART status and 
HIV PVL not significant in univariate analysis 
(HIV transmission route - MSM, IDU, 
heterosexual route - included in model). 
Medium risk  
ASCUS+ associated with low 
CD4+ , anal disease on physical 
exam, history of HSV, history of 
AGW, adjusted for age, race, sex, 
HIV risk factor (MSM, IDU, 





HIV-positive MSM visiting one of three outpatient HIV clinics in Amsterdam, the Netherlands, 
were offered AIN screening by their HIV-treating physician. The only exclusion criterion was a 
life expectancy of less than 12 months. Unlcear selection method – however large sample size 
recruited from three separate clinics. Low risk 
HRA was performed by individually trained anoscopists, did not include 
anal cytology, or human papillomavirus (HPV) testing and consisted of 
a DARE followed by intra- and perianal inspection with a 
colposcope after repeatedly applying acetic acid (3–5% solution) and 
staining with Lugol’s iodine when indicated. Lesions suspicious for SIL 
were biopsied and graded by pathologists specialized in SIL. In clinics 
A and C, pathologists used p16 staining for AIN2 graded biopsies.  The 
highest grade biopsy defined the overall diagnosis. Assessed outcome 
variables HSIL-AIN2+. Low –medium risk   
years living with HIV viral suppression 
adjusted for age, current and nadir CD4+, 
having an AIDS defining illness. ART, nadir 
CD4+ and HIV PVL suppression (one point in 
time) unadjusted as found to be not significant 
in univariate analysis. Low risk 
Only years living with HIV viral 
suppression associated with HSIL-
AIN2+ (considered to be equivalent 







Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
Schwartz, 
2013 
Using the Kaiser HIV registry at San Francisco KPNC anal cancer screening clinic, men aged ≥18 
years, not diagnose with anal cancer prior to enrolment were identified and enrolled between 
2009-2010.  
Anal swabs collected, after specimen collection, participants received a 
DARE followed by HRA. At most, 2 suspicious appearing lesions 
identified during HRA were biopsied and sent for routine 
histopathological evaluation. Combined endpoints based on cytology, 
histology, and HPV testing. Medium risk   
Crude estimates for ART and PVL. 
Associations with CD4 adjusted for age at 
enrolment, ethnicity, number lifetime male 
partners, chlamydia infection, smoking history. 




Data analysed from 13 cohort studies (10 from US and 3 from Canada), included in the North 
American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) between 1996-
2007. Eleven of the cohorts were clinic based and data obtained from medical records. The 
remaining 2 cohorts (Multicenter AIDS Cohort Study) and Women Interagency HIV Study were 
interval based and data obtained at 6 monthly study visits. Low risk  
Incident anal cancer diagnoses were ascertained separately by each 
cohort from medical records, patient interviews, or linkage with cancer 
registry. Cases comprised all anal cancer diagnoses, regardless of 
histology as histological information was not provided by all cohorts. 
Individuals with prevalent anal cancer at time of enrolment were 
excluded. Low risk  
Adjusted for gender, HIV transmission route, 
calendar era of diagnosis, ethnicity, age. 
Medium risk  
Low CD4 at time of enrolment 
associated with increased risk of 
anal cancer incidence  
Stier, 2019 The AIDS Malignancy Consortium (AMC) 084 study, “Screening HIV-Positive Women for Anal 
Cancer Precursors,” was a multicenter national trial to evaluate the prevalence, risk factors, and 
incidence of anal HSIL in a cohort of WLHIV in the United States; participants recruited between 
2014 and 2016. The clinicians responsible for performing HRA at each AMC clinical site were 
certified; the certification process included each clinician’s assembling a log of 50 HRA 
procedures with concurrent anal cytology and histology results as well as having a site visit by an 
expert HRA provider who observed the clinicians’ HRA skills. At baseline, all women were 
evaluated with collection of specimens for cervical/vaginal and anal assessments and by HRA 
with directed biopsies. If a study participant was diagnosed with anal hHSIL at any visit she was 
exited from the study. Eligible women were 18 years or older, with HIV infection, having no 
history of anal HSIL by cytology or histology, and having laboratory test results within the past 
120 days showing absolute neutrophil >750 cells/μL and platelet count ≥75 000 cells/μL. Women 
with a history of pelvic radiation, anal or perianal cancer, treatment for anal or perianal 
condyloma, or low-grade squamous intraepithelial lesion (hLSIL) within 4 months of study entry 
were ineligible. Women with previous hysterectomy were not excluded 
LBC required for local processing at each local institution (PreservCyt 
or SurePath. Site -specific pathology departments and cytopathologists 
processed the anal cytology specimens using the Bethesda classification 
system. Following anal cytology specimen collection, a digital anal/ 
rectal examination was performed followed by HRA. During the HRA, 
each study participant had at least 2 biopsies. Biopsies were taken of 
anal lesions most suspicious for anal hHSIL from 2 different quadrants 
of the anus. If <2 anal lesions were noted, 1–2 random biopsies were 
performed such that there were at least 2 anal biopsies from at least 2 
different quadrants of the anal canal. After evaluation of the anal canal, 
5% acetic acid was applied to the perianus, and the perianus was then 
examined under colposcopic guidance for any abnormalities. Biopsies 
were performed of any perianal  abnormalities. 
The study outcome of interest was anal hHSIL (vs less than hHSIL) as 
determined by consensus pathology review. Biopsy specimens were 
evaluated using terminology and classifications (including 
recommendations for p16 staining) from the Lower Anogenital 
Squamous Terminology Project . Central pathology review was 
submitted to a central pathologist. If there was a disagreement between 
the local and the central pathologist, then a third pathologist reviewed 
the slide and consensus for 2 of 3 pathologists was required. When 
several biopsies were taken from the same patient, the most severe 
histological grade was used for the analysis. In this study, anal hHSIL 
diagnosis refers to the consensus histologic diagnosis; a composite anal 
HSIL diagnosis of anal cytology and histology results was not used for 
this analysis. 
Crude estimate only  Women with current CD4+ ≤200 
cells/μL showed 10-fold higher 
odds of hHSIL (adjusted odds ratio 
[aOR],  10.34 [95% CI, 3.47–
30.87]) compared with the 
reference CD4 count category of 
>350 cells/μL,; and 1 or more 
lifetime anal sex partners was 
associated with anal hHSIL 
(aOR, 2.44 [95% CI, 1.22–4.76]) 
compared with those who never had 
an anal sex partner 
Tandon et al, 
2010 
Cross sectional study conducted at the Center for Infectious Diseases, primary site of HIV care at 
Boston Medical Center, an inner city hospital in Boston. English speaking, HIV infected women 
aged 18-64 years who had not had cervical or anal pap smear, colposcopy or HRA in previous 6 
months were eligible to participate. Exclusion criteria included pregnancy, use of chronic 
anticoagulation medication, and life expectancy of less than 1 year. Small sample size (based on 
sample size calculations for pilot study) 
Medium risk  
Anal smear collected with BD SurePath Papanicolaou Test. Follow up 
exam determined by anal cytology. Subjects with any grade of anal 
cytology abnormality (understood to be ASCUS+) were referred for 
HRA. 19 women were referred for HRA : 5 refused and anal 
histological abnormalities were found in 10/14 (3 HGAIN2+). High 
risk 
Unadjusted estimate (HIV related factors not 
associated in MVA). History of anal sex 
included in the model (no association).  
Low-Medium risk 
History of STI other than 
HIV/HPV, low current CD4+, 
concurrent cervical cytology 
abnormality 
Tong et la, 
2013 
Retrospective clinical audit of a cohort of men with untreated high-grade ASILs with at least one 
visit for anal Papanicolaou smear or HRA. Patients were referred from within the St Vincent’s 
Hospital HIV service and from local general practitioners specializing in HIV care. An anal cancer 
screening clinic was established at St Vincent’s Hospital in Sydney, Australia. High-grade ASILs 
diagnosed at this clinic were not routinely treated because there is no high-quality evidence to 
indicate current treatments prevent anal cancer. Maybe selection bias of men more likely to return 
for follow up (who may have more severe disease). Low risk 
Each patient had anal Papanicolaou smear or HRA. Biopsies were taken 
of abnormal areas. Liquid-based anal cytology and histology were 
reported by St Vincent’s Hospital’s diagnostic laboratory (SydPath) 
using standard laboratory protocols developed for cervical reporting. 
All anal cytology and intra-anal histology diagnoses (from HRA 
biopsies and anal surgery) were reviewed by one physician. The most 
abnormal result was used if histology results were available from more 
than one biopsy collected at any one HRA. A composite endpoint of 
histologically confirmed AIN2/3 and/or HSIL on anal cytology was 
defined as highgrade anal intraepithelial neoplasia (HGAIN). Low-
Medium risk 
Crude estimate only. No association with 
effective ART (as measured by detectable HIV 
PVL) but too few participants with detectable 
PVL – low power to detect a difference.  
Medium risk  
None observed for HGAIN 
progression  but progression to 
AIN3 more men with low nadir 
CD4+ 
No associations observed for 
regression  
Van der 
Snoek et al, 
2012 
Cross-sectional study; participants were included in a Rotterdam study on the screening of 
HPVrelated anal premalignancies in HIV-positive MSM. All patients were recruited from the 
outpatient clinics of 4 hospitals. No information on recruitment procedures or proportion men 
refused to participate. Medium risk 
 
Anal exam was performed by HRA; Biopsies were taken from the 
centre of suspicious lesions detected during examination. All biopsies 
were examined by the same pathologist. Medium risk 
adjusted for age, length of known HIV 
positivity. Sexual behaviour including RAI 
included in model. Low risk 






Participant selection HPV test method (HPV studies), or Endpoint 
determination and biopsy decision (lesion/cancer studies) 
Adjustment for confounding Summary findings 
Weis et al, 
2011 
prospective cohort of all patients receiving primary care services at the Preventive Medicine 
Clinic at Tarrant County Public Health from March 2006 to March 2008. The clinic provides 
medical and social services for HIV-infected patients living in North Texas who meet the Ryan 
White financial criteria; ie, uninsured or underinsured with income less than 3 times the federal 
poverty level. 
Cytology using the ThinPrep system (Cytyc Corporation). A 
conventional cytological assessment of stained cellular material was 
performed by experienced pathologists using Bethesda criteria. A 
second cytological assessment was made in patients for whom the 
results of the initial cytological assessment was normal., High-
resolution anoscopy (HRA) was recommended to patients with 
abnormal anal cytology on consenting patients (19% did not have 
HRA); the most abnormal acetowhite areas suspicious for AIN were 
biopsied. biopsies sent for routine histopathologic examination by 
university-associated pathologists 
Crude estimate only  Those reporting history of RAI, 
MSM and with history of HPV 
infection had higher risk of HSIL-
AIN2+ 
Wilkin et al, 
2004 
As for previous Wilkin, 2004  
 
Anal cytology conducted using two methods; pap (fixed on slide) and 
LBC; anal  colposcopy was performed using 3% acetic acid.  Any areas 
of acetowhitening or vascular changes suspicious for AIN were sampled 
by use of cervical biopsy forceps. If no visible lesions were seen, then 
no biopsy was done. Cytological specimens were initially screened by a 
cytotechnologist, with the final interpretation being made by a single 
pathologist who was blinded to all clinical information and other 
pathological results. A participant was classified as having normal 
results in the histology based analysis if no biopsy was performed 
because of a lack of visible lesions on anal colposcopy with normal 
cytological results or if there was no evidence of condyloma 
accuminata, AIN, or cancer on any of the biopsy specimens. Where a 
participant had abnormal cytology result but did not return for follow-
up, he was excluded form analysis. Medium risk  
Estimates adjusted for history of RAI, age, 
nadir CD4. Low risk  
History of RAI, ART use, younger 
age and lower nadir CD4+ 
Willeford et 
al, 2016 
Retrospective chart review of 348 male HIV positive patients from a North Carolina-based HIV 
clinic who were 18 years or older and had received at least 1 anal pap smear between January 1, 
2008, and August 31, 2013. Unclear selection criteria- mostly MSM (96%). High risk 
 
Yearly anal pap smear introduced for HIV positive MSM as part of 
routine HIV care. Results of ASCUS+ prompted referral to HRA. If 
HSIL+ was confirmed on biopsy, treatment was pursued. The HSIL 
biopsy was defined as any anal intraepithelial neoplasia (AIN2) or 
higher (regardless of P16 status). Outcome is HSIL on first HRA;  
28% men referred to HRA failed to attend visit. High risk 
adjusted for race, yrs since HIV,   current 
CD4+, nadir CD4+, smoking, PVL 
suppression). No adjustment for history of RAI 
, although number of lifetime partners included 
in the model.  Low risk  
Current CD4+ count 
Yaegashi et 
al, 2017 
Japanese HIV-infected MSM patients that visited the outpatient clinic of Kanazawa University 
Hospital, Ishikawa Prefectural Central Hospital, and the Shirakaba clinic recruited between April 
2013 and August 2014. There was a total of 148 patients enrolled - all participants were MSM; 
MSW, and bisexual men were excluded. Unclear recruitment procedures, small sample. High risk  
Liquid based cytology; 24/148 (16%) were classified as unsatisfactory. 
All slides assessed by two cytopathologists.  
High risk 
Adjusted for HR-HPV. High risk  Low nadir CD4+ and anal HR-HPV 
associated with ASC-H 
Yang et al, 
2012  
Study participants were outpatients of the Capital City Dermatology Hospital recruited through 
local MSM nongovernment organization (Beijing Rainbow Volunteers Workstation) between 
January and April 2011. To maximize outreach of study information to HIV-infected MSM 
community, multiple methods were used for recruitment including MSM website advertisement, 
distributing flyers with study-related information at MSM-frequented venues (e.g., MSM clubs, 
bars, parks and bathhouses), and participants were also encouraged to refer friends and 
acquaintances to attend the study. Those eligible to participate were males, 18 years or older, HIV 
positive, ever had homosexual behaviors, willing to take tests for anal HPV infection and anal 
cytology, and provision of written informed consent. The presence or absence of any symptoms, 
including anal symptoms, Medium risk (small sample)  
Anal cytology slides were read by a single cytologist. Smears were 
classified as unsatisfactory if no epithelial cells were present.  
3/98 were unsatisfactory. High risk 
 
Unadjusted estimates only. Data available on 
sexual behaviour (not included in MVA)  No 
data on HIV PVL. High risk 
No MVA conducted 
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